<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="pmc-domain-id">590</journal-id><journal-id journal-id-type="pmc-domain">mardrugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7699502</article-id><article-id pub-id-type="pmcid-ver">PMC7699502.1</article-id><article-id pub-id-type="pmcaid">7699502</article-id><article-id pub-id-type="pmcaiid">7699502</article-id><article-id pub-id-type="pmid">33228163</article-id><article-id pub-id-type="doi">10.3390/md18110570</article-id><article-id pub-id-type="publisher-id">marinedrugs-18-00570</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molluscan Compounds Provide Drug Leads for the Treatment and Prevention of Respiratory Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Summer</surname><given-names initials="K">Kate</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-18-00570">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Browne</surname><given-names initials="J">Jessica</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-18-00570">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3710-7042</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-18-00570">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4052-3888</contrib-id><name name-style="western"><surname>Benkendorff</surname><given-names initials="K">Kirsten</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-18-00570">4</xref><xref rid="c1-marinedrugs-18-00570" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-marinedrugs-18-00570"><label>1</label>Marine Ecology Research Centre, School of Environment, Science and Engineering, Southern Cross University, GPO Box 157, Lismore, NSW 2480, Australia; <email>kate.summer@scu.edu.au</email></aff><aff id="af2-marinedrugs-18-00570"><label>2</label>School of Health and Human Sciences, Southern Cross University, Terminal Drive, Bilinga, QLD 4225, Australia; <email>jessica.browne@scu.edu.au</email></aff><aff id="af3-marinedrugs-18-00570"><label>3</label>Southern Cross Plant Science, Southern Cross University, GPO Box 157, Lismore, NSW 2480, Australia; <email>ben.liu@scu.edu.au</email></aff><aff id="af4-marinedrugs-18-00570"><label>4</label>National Marine Science Centre, Southern Cross University, 2 Bay Drive, Coffs Harbour, NSW 2450, Australia</aff><author-notes><corresp id="c1-marinedrugs-18-00570"><label>*</label>Correspondence: <email>kirsten.benkendorff@scu.edu.au</email>; Tel.: +61-429-520-589</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2020</year></pub-date><volume>18</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">369590</issue-id><elocation-id>570</elocation-id><history><date date-type="received"><day>26</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>29</day><month>11</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-03 16:25:15.230"><day>03</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="marinedrugs-18-00570.pdf"/><abstract><p>Respiratory diseases place an immense burden on global health and there is a compelling need for the discovery of new compounds for therapeutic development. Here, we identify research priorities by critically reviewing pre-clinical and clinical studies using extracts and compounds derived from molluscs, as well as traditional molluscan medicines, used in the treatment of respiratory diseases. We reviewed 97 biomedical articles demonstrating the anti-inflammatory, antimicrobial, anticancer, and immunomodulatory properties of &gt;320 molluscan extracts/compounds with direct relevance to respiratory disease, in addition to others with promising bioactivities yet to be tested in the respiratory context. Of pertinent interest are compounds demonstrating biofilm inhibition/disruption and antiviral activity, as well as synergism with approved antimicrobial and chemotherapeutic agents. At least 100 traditional medicines, incorporating over 300 different mollusc species, have been used to treat respiratory-related illness in cultures worldwide for thousands of years. These medicines provide useful clues for the discovery of bioactive components that likely underpin their continued use. There is particular incentive for investigations into anti-inflammatory compounds, given the extensive application of molluscan traditional medicines for symptoms of inflammation, and shells, which are the principal molluscan product used in these preparations. Overall, there is a need to target research toward specific respiratory disease-related hypotheses, purify bioactive compounds and elucidate their chemical structures, and develop an evidence base for the integration of quality-controlled traditional medicines.</p></abstract><kwd-group><kwd>marine natural products</kwd><kwd>ethnomedicine</kwd><kwd>coronavirus</kwd><kwd>hemocyanin</kwd><kwd>Mollusca</kwd><kwd>pulmonary</kwd><kwd>lung</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-marinedrugs-18-00570"><title>1. Introduction</title><sec id="sec1dot1-marinedrugs-18-00570"><title>1.1. Respiratory Disease Pathology and Epidemiology</title><p>The role of the respiratory system is to allow continuous O<sub>2</sub> and CO<sub>2</sub> exchange with the environment [<xref rid="B1-marinedrugs-18-00570" ref-type="bibr">1</xref>]. In doing so, it incidentally permits exposure to airborne particles, chemicals, and infectious organisms with each breath [<xref rid="B1-marinedrugs-18-00570" ref-type="bibr">1</xref>,<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>]. As such, the nature and types of respiratory disease are many and physiological defense mechanisms must be well regulated. Also known as lung or pulmonary diseases, respiratory diseases are conditions affecting the lungs and other tissues of the respiratory system impairing normal gas exchange [<xref rid="B3-marinedrugs-18-00570" ref-type="bibr">3</xref>].</p><p>Respiratory diseases are among the leading causes of death and disability worldwide [<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>]. Asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and communicable infections impose a particularly immense burden on global health with staggering rates of morbidity and mortality [<xref rid="B4-marinedrugs-18-00570" ref-type="bibr">4</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). COPD affects over 200 million people at any one time, while lung cancer is the most common type of malignancy and responsible for the highest number (19%) of cancer-related deaths [<xref rid="B4-marinedrugs-18-00570" ref-type="bibr">4</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Around 340 million people are afflicted with asthma and 24 million disability-adjusted life years (DALYs) are lost to the condition each year [<xref rid="B5-marinedrugs-18-00570" ref-type="bibr">5</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Acute bacterial and viral respiratory infections are considered the greatest single contributor to the overall burden of disease worldwide; they are the leading cause of death in developing countries and in children under five [<xref rid="B4-marinedrugs-18-00570" ref-type="bibr">4</xref>,<xref rid="B6-marinedrugs-18-00570" ref-type="bibr">6</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>), and can also occur in epidemics and pandemics, as we were made poignantly aware by outbreaks of severe acute respiratory distress syndrome (SARS) in 2002 [<xref rid="B7-marinedrugs-18-00570" ref-type="bibr">7</xref>], Middle East respiratory syndrome (MERS) in 2012 [<xref rid="B8-marinedrugs-18-00570" ref-type="bibr">8</xref>], and the novel coronavirus in 2019 (COVID-19) [<xref rid="B9-marinedrugs-18-00570" ref-type="bibr">9</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>).</p><p>Acute respiratory conditions, such as acute respiratory distress syndrome (ARDS) and pneumonia, are typically sudden and severe and may be caused by infection, trauma, or hypersensitivity [<xref rid="B10-marinedrugs-18-00570" ref-type="bibr">10</xref>,<xref rid="B11-marinedrugs-18-00570" ref-type="bibr">11</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Conversely, chronic conditions, such as COPD, cystic fibrosis, and cancer, are ongoing, progressive, and generally attributed to lifestyle (e.g., air pollution and smoking) or genetic factors [<xref rid="B4-marinedrugs-18-00570" ref-type="bibr">4</xref>,<xref rid="B12-marinedrugs-18-00570" ref-type="bibr">12</xref>,<xref rid="B13-marinedrugs-18-00570" ref-type="bibr">13</xref>] (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). However, the distinction between acute and chronic is not always discrete. Chronic conditions may have acute episodes (e.g., asthma attacks) or be exacerbated by acute conditions (e.g., COPD with infection [<xref rid="B14-marinedrugs-18-00570" ref-type="bibr">14</xref>]), while acute conditions can progress into more chronic ones if persistent, recurrent, or severe (e.g., unresolving pneumonia [<xref rid="B15-marinedrugs-18-00570" ref-type="bibr">15</xref>]; ARDS causing pulmonary fibrosis [<xref rid="B11-marinedrugs-18-00570" ref-type="bibr">11</xref>]) (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Despite their varied aetiologies and symptoms, all respiratory diseases evoke a strong immune response characterized by inflammation.</p><p>The inflammatory pathway is the universal physiological basis underpinning immune responses to tissue damage, infection, and other insults [<xref rid="B16-marinedrugs-18-00570" ref-type="bibr">16</xref>] and is therefore a feature of every respiratory disease. A common spectrum of genes and endogenous mediators are involved, although the precise physiological and biochemical components that are induced vary in different conditions [<xref rid="B17-marinedrugs-18-00570" ref-type="bibr">17</xref>]. A typical response consists of stimulants (e.g., pathogenic microbial patterns, allergens, free radicals released from damaged cells, tumor antigens), the specialised cells that identify them (e.g., granulocytes, mast cells, macrophages, dendritic cells, memory lymphocytes), chemical mediators (e.g., complement, cytokines, chemokines, eicosanoids, amines, antibodies), and functional changes in target tissues and cells that enable elimination of the stimulant (e.g., vasodilation, neutrophil infiltration, phagocytosis, mucus secretion) [<xref rid="B16-marinedrugs-18-00570" ref-type="bibr">16</xref>]. This is a natural, and for the most part beneficial, response but tight regulation is critical [<xref rid="B10-marinedrugs-18-00570" ref-type="bibr">10</xref>]. A hyper-inflammatory response can be immediately life-threatening (e.g., [<xref rid="B18-marinedrugs-18-00570" ref-type="bibr">18</xref>,<xref rid="B19-marinedrugs-18-00570" ref-type="bibr">19</xref>]) and if the inducer is not quickly overcome or resolution is incomplete, cellular and tissue damage may ensue, leading to a chronic disease state (e.g., [<xref rid="B20-marinedrugs-18-00570" ref-type="bibr">20</xref>]). Respiratory disease pathogenesis and immune mechanisms are described elsewhere in detail [<xref rid="B10-marinedrugs-18-00570" ref-type="bibr">10</xref>,<xref rid="B21-marinedrugs-18-00570" ref-type="bibr">21</xref>,<xref rid="B22-marinedrugs-18-00570" ref-type="bibr">22</xref>,<xref rid="B23-marinedrugs-18-00570" ref-type="bibr">23</xref>,<xref rid="B24-marinedrugs-18-00570" ref-type="bibr">24</xref>,<xref rid="B25-marinedrugs-18-00570" ref-type="bibr">25</xref>] to assist in structure-target identification.</p><table-wrap id="marinedrugs-18-00570-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t001_Table 1</object-id><label>Table 1</label><caption><p>Epidemiological summary of respiratory diseases imposing a major burden on health worldwide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Respiratory Disease *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease Classification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Causative/Risk Factors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Predominant Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Estimated Worldwide Morbidity (Annual) (P: Prevalence, I: Incidence)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Estimated Worldwide Mortality (Annual)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional Treatments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trends</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infectious diseases (e.g., TB; NTM; influenza; pneumonia &#8224;; corona viruses)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Communicable &#8225;<break/>- Acute<break/>- May become chronic if unresolving or recurrent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Opportunistic bacterial; viral; fungal or parasitic invasion<break/>- Risk factors: low immunization rates; overpopulation; conditions of compromised immunity </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammation; cough; increased mucus; fever; dyspnea; tachypnea; malaise; muscle and join pain; sore throat; secondary infections </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- TB: 10 million (P)<break/>- NTM: 40 per 100,000 population (P)<break/>- Influenza: 5&#8211;15% of population; 3&#8211;5 million severe cases (I)<break/>- RSV: 34 million child episodes (I)<break/>- COVID-19: &gt;56 million <sup>&#167;</sup> (P)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- &gt;4 million total <sup>&#182;</sup><break/>- TB: 1.5 million<break/>- Pneumonia: &gt;1.3 million children &lt;5 y (15% of all deaths)<break/>- Seasonal influenza: 290,000&#8211;650,000<break/>- COVID-19: 1,500,000 <sup>&#167;</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Antibiotics (bacterial)<break/>- Neuraminidase inhibitors (viral)<break/>- Symptomatic treatment<break/>- Immunization </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Consistently within top 3 causes of death<break/>- TB incidence declining by 2%/y, NTM increasing 40%/y<break/>- Increasing epidemics and drug resistant strains<break/>- Highest impact in developing countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>,<xref rid="B26-marinedrugs-18-00570" ref-type="bibr">26</xref>,<xref rid="B27-marinedrugs-18-00570" ref-type="bibr">27</xref>,<xref rid="B28-marinedrugs-18-00570" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic obstructive pulmonary disease (COPD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Non-communicable &#8225;<break/>- Chronic with acute episodes<break/>- Progressive<break/>- Irreversible</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Tobacco smoke and other inhaled environmental pollutants<break/>- Frequent/chronic lower respiratory infections, asthma and abnormal lung development<break/>- Genetic factors </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic parenchymal and airway inflammation; persistent airflow restriction; dyspnea; wheeze; cough; decreased airway elasticity; airway remodeling; mucociliary dysfunction; co-morbidities </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- &gt;250 million (P)<break/>- Usually becomes apparent in people &gt;40 yes of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 3.2 million <break/>- Third leading cause of death </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Cessation of smoking<break/>- Symptomatic treatment<break/>- Inhaled corticosteroids; long-acting &#946; agonists; leukotriene modifiers<break/>- Immunization against infectious diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Increasing prevalence and mortality rates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>,<xref rid="B27-marinedrugs-18-00570" ref-type="bibr">27</xref>,<xref rid="B29-marinedrugs-18-00570" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Non-communicable <break/>- Chronic with acute episodes<break/>- Reversible</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Genetic factors <break/>- Environmental triggers <break/>- Airway hyperresponsiveness </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Airflow restriction; wheeze; dyspnea; cough; airway remodeling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- &gt;339 million (P)<break/>- 24.8 million DALYs lost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Relatively low mortality rate<break/>- 420,000 (2016) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Medications for: rescue (e.g., fast-acting &#946; agonists), maintenance (e.g., inhaled corticosteroids; long-acting &#946; agonists; leukotriene modifiers) and allergies <break/>- Avoidance of triggers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Increasing incidence<break/>- Highest mortality (80%) in developing countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>,<xref rid="B5-marinedrugs-18-00570" ref-type="bibr">5</xref>,<xref rid="B27-marinedrugs-18-00570" ref-type="bibr">27</xref>,<xref rid="B30-marinedrugs-18-00570" ref-type="bibr">30</xref>,<xref rid="B31-marinedrugs-18-00570" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung cancer </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Non-communicable <break/>- Chronic <break/>- Progressive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Tobacco smoke and other inhaled environmental pollutants<break/>- Physical carcinogens (e.g., ionizing radiation)<break/>- Other chronic respiratory diseases <break/>- Genetic factors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dyspnea; hoarseness; hemoptysis; pain; loss of appetite; weight loss; fatigue; persistent cough</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 2.09 million (P) <break/>- 1.8 million (I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 1.76 million</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Surgery<break/>- Radiation and chemotherapy<break/>- Palliative care and psycho-social support</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 15% of diagnosed cancers<break/>- Most fatal cancer<break/>- 19% of deaths</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>,<xref rid="B6-marinedrugs-18-00570" ref-type="bibr">6</xref>,<xref rid="B27-marinedrugs-18-00570" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute respiratory distress syndrome (ARDS)/acute lung injury (ALI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Non-communicable <break/>- Acute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Trauma <break/>- Pulmonary infection<break/>- Non-pulmonary sepsis <break/>- Certain medical procedures </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe dyspnea and tachypnea; pulmonary hemorrhage; edema; hypertension; hypoxemia; tissue damage; fibrosing alveolitis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- ARDS: 58.7&#8211;75 per 100,000 people (I)<break/>- ALI: 78.9 per 100,000 people (I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- In-hospital mortality 38% for ALI; up to 46.1% for ARDS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Corticosteroids and other anti-inflammatories; vasodilators <break/>- Mechanical ventilation<break/>- Hemodynamic management<break/>- Surfactant therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 10% of all patients in intensive care treated for ARDS <break/>- Survival rates improving </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-marinedrugs-18-00570" ref-type="bibr">11</xref>,<xref rid="B19-marinedrugs-18-00570" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cystic fibrosis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Non-communicable <break/>- Chronic with acute episodes<break/>- Progressive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Autosomal recessive genetic factors (CFTR mutation)<break/>- Exacerbated by environmental triggers and infection <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bronchiecstasis; persistent airway infection and inflammation; excessive, thick mucus and poor clearance; pneumothorax; hemoptysis; tissue damage; gastrointestinal, metabolic and reproductive manifestations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- 90,000 (P) (likely underestimated)<break/>- 1000 (I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- More than half of patients die before the age of 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Antibiotics <break/>- Immunisations<break/>- Nebulised hypertonic saline; dornase alfa; mannitol<break/>- CFTR modulators (e.g., Ivacaftor)<break/>- O<sub>2</sub> therapy; pulmonary rehab.<break/>- Management of co-morbidities and nutrition<break/>- Lung transplant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Survival rates improving</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-marinedrugs-18-00570" ref-type="bibr">32</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: DALYs: disability-adjusted life years- a metric that estimates the amount of active and productive life lost due to a condition; TB: tuberculosis; NTM: non-tuberculosis mycobacteria; RSV: respiratory syncytial virus; COVID-19: 2019 novel corona virus; CFTR: cystic fibrosis transmembrane conductance regulator; NO: nitric oxide. * Other important respiratory diseases not described in this table include sleep disordered breathing, pulmonary hypertension, and pulmonary embolism. &#8224; Typically caused by <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Haemophilus influenzae</italic> type b, respiratory syncytial virus; <italic toggle="yes">Pneumocystis jiroveci</italic> (in HIV infected). &#8225; Communicable refers to diseases caused by infectious agents that can be transmitted from one person (or animal) to another via. direct or indirect contact. Non-communicable diseases are not transmitted from one person (or animal) to another. <sup>&#167;</sup> From December 2019 to time of publication. <sup>&#182;</sup> The annual mortality rate from respiratory infection is difficult to quantify, particularly in developing countries, and estimates vary considerably e.g., van der Poll &amp; Opal (2009) estimate mortality rate of 4 million caused by pneumococcal pneumonia alone. <sup>#</sup> Particularly of <italic toggle="yes">Pseudemonas aeruginosa, Burkholdaria cepacia, Staphylococcus aureus,</italic> often multi-drug resistant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec1dot2-marinedrugs-18-00570"><title>1.2. Conventional Treatments and the Need for Alternatives</title><p>The discovery of antibiotics, vaccines, chemotherapeutic agents, and non-steroidal anti-inflammatory drugs (NSAIDs) revolutionised the treatment and prevention of respiratory diseases [<xref rid="B33-marinedrugs-18-00570" ref-type="bibr">33</xref>] and remarkably improved life expectancy from 30.9 years in 1900 to 46.7 years in 1940 and 61.1 years in 1980 [<xref rid="B34-marinedrugs-18-00570" ref-type="bibr">34</xref>]. These drugs are now the most consumed worldwide [<xref rid="B35-marinedrugs-18-00570" ref-type="bibr">35</xref>,<xref rid="B36-marinedrugs-18-00570" ref-type="bibr">36</xref>]. Nonetheless, they have not come without pitfalls, which now pose immense challenges to modern medicine, the most serious being the development of undesirable side-effects and drug resistance (e.g., [<xref rid="B37-marinedrugs-18-00570" ref-type="bibr">37</xref>,<xref rid="B38-marinedrugs-18-00570" ref-type="bibr">38</xref>,<xref rid="B39-marinedrugs-18-00570" ref-type="bibr">39</xref>,<xref rid="B40-marinedrugs-18-00570" ref-type="bibr">40</xref>]). These issues unfortunately decrease the arsenal of available therapeutic agents against an ever-increasing range of diseases, at a high social and economic cost [<xref rid="B41-marinedrugs-18-00570" ref-type="bibr">41</xref>]. Further, there are dire ecotoxicological consequences associated with the widespread use and distribution of synthetic pharmaceutical substances throughout the environment [<xref rid="B42-marinedrugs-18-00570" ref-type="bibr">42</xref>,<xref rid="B43-marinedrugs-18-00570" ref-type="bibr">43</xref>]. </p><p>In light of the ominous emergence of new and resistant pathogens, the rising incidence of respiratory diseases, and impacts of conventional drugs, there is an urgent need for the discovery of novel, ideally safer, compounds for therapeutic development. This need is widely acknowledged among the scientific community, health professionals, and policy makers alike (e.g., [<xref rid="B4-marinedrugs-18-00570" ref-type="bibr">4</xref>,<xref rid="B40-marinedrugs-18-00570" ref-type="bibr">40</xref>,<xref rid="B44-marinedrugs-18-00570" ref-type="bibr">44</xref>,<xref rid="B45-marinedrugs-18-00570" ref-type="bibr">45</xref>]). Natural products play a pivotal role in drug development and research programs considering their incomparable chemical diversity and novel mechanisms of action [<xref rid="B46-marinedrugs-18-00570" ref-type="bibr">46</xref>]. They also generally exhibit lower systemic and environmental toxicity than their synthetic pharmaceutical counterparts [<xref rid="B47-marinedrugs-18-00570" ref-type="bibr">47</xref>,<xref rid="B48-marinedrugs-18-00570" ref-type="bibr">48</xref>,<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>]. Marine organisms represent an especially rich source of structurally diverse natural products by virtue of their vast phylogenetic diversity and environmental conditions under which they have evolved [<xref rid="B50-marinedrugs-18-00570" ref-type="bibr">50</xref>]. These compounds are evidently valuable as drugs leads: to date, over 30 marine compounds have entered clinical trials for drug development, of which 12 have been approved for use by the Food and Drug Administration (FDA) and international counterparts [<xref rid="B51-marinedrugs-18-00570" ref-type="bibr">51</xref>,<xref rid="B52-marinedrugs-18-00570" ref-type="bibr">52</xref>]. </p></sec><sec id="sec1dot3-marinedrugs-18-00570"><title>1.3. Molluscs: A Wealth of Potential Therapeutic Compounds</title><p>Mollusca represents the second-most species-rich phylum with an estimated 150,000&#8211;200,000 extant species divided into eight classes [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B54-marinedrugs-18-00570" ref-type="bibr">54</xref>]. Molluscs have diversified to occupy almost every ecosystem on earth, from arid deserts to alpine regions, yet the majority occur in the sea where they account for around a quarter of all known species [<xref rid="B55-marinedrugs-18-00570" ref-type="bibr">55</xref>]. Such vast biological diversity affords Mollusca a rich chemical diversity [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>,<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B56-marinedrugs-18-00570" ref-type="bibr">56</xref>]. Irrespective of the presence of a shell, all molluscs are essentially soft-bodied and lack adaptive immune systems with antigen-specific cell-mediated mechanisms of protection [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>]. Many are also slow-moving or sessile and thus seemingly predisposed to biofilm formation [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B57-marinedrugs-18-00570" ref-type="bibr">57</xref>]. Molluscs could, therefore, be vulnerable to infection, yet reside in intimate coexistence with pathogenic microbes [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B57-marinedrugs-18-00570" ref-type="bibr">57</xref>]. Seawater is known to contain up to 10<sup>6</sup> bacteria and 10<sup>9</sup> virus per mL [<xref rid="B58-marinedrugs-18-00570" ref-type="bibr">58</xref>,<xref rid="B59-marinedrugs-18-00570" ref-type="bibr">59</xref>], and soil up to 10<sup>10</sup> bacteria and 10<sup>9</sup> virus per gram [<xref rid="B60-marinedrugs-18-00570" ref-type="bibr">60</xref>]. The survival and success of molluscs in microbially rich environments is attributed to robust chemical defenses and innate humoral immune components, including hemocyanins (Hcs) and antimicrobial peptides (AMPs) [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B57-marinedrugs-18-00570" ref-type="bibr">57</xref>,<xref rid="B61-marinedrugs-18-00570" ref-type="bibr">61</xref>]. Molluscs have also been shown to use chemical means of communication, predator-prey interaction and behavior [<xref rid="B62-marinedrugs-18-00570" ref-type="bibr">62</xref>,<xref rid="B63-marinedrugs-18-00570" ref-type="bibr">63</xref>,<xref rid="B64-marinedrugs-18-00570" ref-type="bibr">64</xref>,<xref rid="B65-marinedrugs-18-00570" ref-type="bibr">65</xref>], further demonstrating their diverse functional chemistry.</p><p>The chemical investigation of molluscs has led to the isolation of a wide variety of bioactive primary and secondary metabolites. These may be synthesized by the molluscs themselves, accumulated from dietary sources, or produced by symbionts [<xref rid="B66-marinedrugs-18-00570" ref-type="bibr">66</xref>]. Benkendorff [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B67-marinedrugs-18-00570" ref-type="bibr">67</xref>] established that, as of 2014, more than 1145 compounds had been isolated from marine molluscs, including peptides, sterols, terpenes, polyproprionates, macrolides, fatty acid derivatives, nitrogenous compounds, and alkaloids. An additional 145 molluscan compounds have since been documented in annual Marine Natural Product Reports covering years 2014&#8211;2018 [<xref rid="B68-marinedrugs-18-00570" ref-type="bibr">68</xref>,<xref rid="B69-marinedrugs-18-00570" ref-type="bibr">69</xref>,<xref rid="B70-marinedrugs-18-00570" ref-type="bibr">70</xref>,<xref rid="B71-marinedrugs-18-00570" ref-type="bibr">71</xref>,<xref rid="B72-marinedrugs-18-00570" ref-type="bibr">72</xref>]. </p><p>Bioassay-guided investigations and in vivo models have demonstrated the antimicrobial (e.g., [<xref rid="B45-marinedrugs-18-00570" ref-type="bibr">45</xref>,<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>,<xref rid="B74-marinedrugs-18-00570" ref-type="bibr">74</xref>]), anticancer [<xref rid="B48-marinedrugs-18-00570" ref-type="bibr">48</xref>,<xref rid="B75-marinedrugs-18-00570" ref-type="bibr">75</xref>,<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>], anti-inflammatory [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>,<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>,<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>], antispasmodic [<xref rid="B79-marinedrugs-18-00570" ref-type="bibr">79</xref>,<xref rid="B80-marinedrugs-18-00570" ref-type="bibr">80</xref>], neuromuscular blocking [<xref rid="B81-marinedrugs-18-00570" ref-type="bibr">81</xref>], wound-healing [<xref rid="B82-marinedrugs-18-00570" ref-type="bibr">82</xref>], and immunogenic [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>,<xref rid="B84-marinedrugs-18-00570" ref-type="bibr">84</xref>] properties of molluscan extracts and purified compounds. At least 19 compounds of molluscan origin are currently part of the global marine pharmaceutical clinical pipeline and four are now FDA approved [<xref rid="B51-marinedrugs-18-00570" ref-type="bibr">51</xref>,<xref rid="B85-marinedrugs-18-00570" ref-type="bibr">85</xref>], including the powerful analgesic Ziconotide derived from the venom of <italic toggle="yes">Conus magus</italic> [<xref rid="B86-marinedrugs-18-00570" ref-type="bibr">86</xref>], a carnivorous cone snail, and three dolastatin derivatives originally sourced from the tissue of the sea hare <italic toggle="yes">Dolabella auricularia</italic>: Brentuximab vedotin [<xref rid="B87-marinedrugs-18-00570" ref-type="bibr">87</xref>] and Polatuzumab vedotin [<xref rid="B88-marinedrugs-18-00570" ref-type="bibr">88</xref>] for the treatment of hematologic cancers (e.g., Hodgkins lymphoma) and Enfortumab vedotin for urotherial cancer [<xref rid="B89-marinedrugs-18-00570" ref-type="bibr">89</xref>]. Nonetheless, more than half of the known molluscan secondary metabolites have never been screened for potential bioactivity, let alone entered in vivo studies or clinical trials, and &lt;1% of molluscan species have been investigated [<xref rid="B67-marinedrugs-18-00570" ref-type="bibr">67</xref>]. Indeed, the therapeutic potential of natural products derived from this phylum is enormous.</p><p>A surprisingly large number of traditional medicines incorporating molluscs have been used to treat respiratory-related illness in cultures worldwide from antiquity to present [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>,<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>] (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). In most cases, there is little data to support the application of traditional medicines [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>,<xref rid="B92-marinedrugs-18-00570" ref-type="bibr">92</xref>]. However, they provide useful clues for the discovery of novel compounds that may underpin some claims [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>] and adequate testing could see their integration into mainstream healthcare in a complementary capacity at least. To illustrate this point, the isolation of ephidrine from <italic toggle="yes">Ephedra sinica</italic> (Ma Huang), a plant used in Traditional Chinese Medicine (TCM) for over 2000 years to treat asthma, cough and respiratory congestion, led to the synthesis of salbutamol (Ventolin) in 1969, a fast acting &#946;2-adrenergic receptor agonist now considered the first-line clinical intervention for acute asthma and COPD [<xref rid="B93-marinedrugs-18-00570" ref-type="bibr">93</xref>,<xref rid="B94-marinedrugs-18-00570" ref-type="bibr">94</xref>]. Moreover, molluscs are rich in essential nutrients and polyunsaturated fatty acids (PUFAs) [<xref rid="B95-marinedrugs-18-00570" ref-type="bibr">95</xref>] and high dietary intake of shellfish and PUFAs has been associated with lower risk of chronic respiratory conditions and improved health outcomes [<xref rid="B96-marinedrugs-18-00570" ref-type="bibr">96</xref>,<xref rid="B97-marinedrugs-18-00570" ref-type="bibr">97</xref>,<xref rid="B98-marinedrugs-18-00570" ref-type="bibr">98</xref>,<xref rid="B99-marinedrugs-18-00570" ref-type="bibr">99</xref>,<xref rid="B100-marinedrugs-18-00570" ref-type="bibr">100</xref>,<xref rid="B101-marinedrugs-18-00570" ref-type="bibr">101</xref>].</p><p>There is mounting evidence that molluscs comprise of pharmacologically active compounds that could be optimized for the treatment and prevention of respiratory disease. The aim of this review was to critically analyse in vitro and in vivo studies, human clinical trials, and approved therapies using molluscan extracts/compounds, as well as reports on the traditional medicinal uses of molluscs, used in the treatment of respiratory diseases or symptoms thereof. This pertinent review may help to identify research needs and priorities for the future development of therapeutic agents and approaches used to address respiratory diseases mediated by pathogenic infection, inflammation, malignancy, and hypersensitivity.</p></sec></sec><sec id="sec2-marinedrugs-18-00570"><title>2. Literature Search Methods and Evaluation</title><p>We undertook an extensive scoping review of published biomedical and ethnomedical literature using scientific databases Scopus, Web of Science, and PubMed. Databases were searched by article title, abstract, and keywords without date limits (as of October 2020). Full search criteria are provided as <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Information</xref>. All records were screened by title and abstract before full-text articles were assessed.</p><p>Over 900 biomedical articles were screened based on their relevance to respiratory disease and focus on bioactivity of the molluscan extract or compound/s. In vitro studies were accepted if the test suite included at least one respiratory pathogenic microorganism or cell line of respiratory origin. Other non-respiratory microorganisms, cell types, and models that may also have been tested are not described herein, unless results were useful for comparison to respiratory microorganisms, cell types, or models. In vivo animal models and human clinical trials were accepted if the disease was specific to the respiratory system (e.g., asthma, infection, COPD, lung cancer) and the bioactivity of the molluscan extract/compound was evident in the results. Search results returned copious studies using Hc as a vaccine adjuvant or conjugate which were only accepted if treatments (or controls) used Hc alone or the antigen both with and without Hc. In vivo immunological studies using Hc as a model antigen were separated from those using Hc as a treatment or treatment component and accepted if the investigation was respiratory related. Key review articles [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>,<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B56-marinedrugs-18-00570" ref-type="bibr">56</xref>,<xref rid="B66-marinedrugs-18-00570" ref-type="bibr">66</xref>,<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>,<xref rid="B102-marinedrugs-18-00570" ref-type="bibr">102</xref>,<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>] were searched for relevant references therein, which were then screened by abstract. Many of the studies included in previous reviews provide further insight into the bioactivity and immunogenicity of molluscan extracts/compounds and their potential to treat respiratory diseases, however are not specific to these diseases and therefore not included herein. In total, 97 peer-reviewed biomedical articles are included in this review. Those with substantial in vivo and in vitro components were regarded as separate studies in tables and analyses (total: 54 in vitro studies, 25 in vivo studies, 11 human clinical trials and 16 in vivo human/animal studies in which Hc was used as a model antigen).</p><p>For literature regarding traditional medicinal applications, database searches returned 113 results, minus duplicates. Key review papers by Ahmad et al. [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>] and Benkendorff et al. [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>] provided important references to books and monographs not recorded in databases. The Chinese <italic toggle="yes">Marine Materia Medica</italic> [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] was translated by the third author of this review. All texts (published in English or otherwise translated) were screened for mollusc-derived remedies relating to the treatment of respiratory disease or symptoms, and appear directly as translated with contemporary revisions provided in footnotes. In total, 22 traditional medicine studies/texts are included in this review. The phrase &#8220;other traditional medicines&#8221; used throughout refers to traditional medicines other than TCMs. We use the term traditional or molluscan &#8220;medicine&#8221; to refer to any concoction traditionally used to treat human ailments that contain molluscan products functioning as potential active pharmaceutical ingredients (APIs).</p><p>Data were collated and descriptive statistics calculated in Excel. Summary tables are provided throughout the review and as <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Files</xref>. <xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref> summarises the number of different remedies and species traditionally used to treat specific symptoms of respiratory disease; full details of traditional medicines, including species, preparations, and indications are provided in <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Tables S1 and S2</xref>. <xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref> provides a taxonomic breakdown of the number of species in each molluscan class as well as their division by terrestrial, freshwater, and marine habitat, that are used in traditional medicines and compares these to biomedical studies, whereas <xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref> provides the number of studies and species tested for different bioactivities. In both cases, the species, extract or compound, experimental design, effective concentrations and outcomes are detailed in <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref> to inform research direction and provide evidence that molluscan compounds could be the APIs in traditional medicines. Studies using molluscan Hcs as vaccine conjugates or model antigens are included in summary <xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref> and <xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref> and detailed in <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Tables S3 and S4</xref>. Selected patents and purified compounds that have been tested with relevance to respiratory disease are provided in <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Tables S5 and S6</xref>, respectively. Taxonomic nomenclature of the mollusc species used throughout this review is corrected according to the World Register of Marine Species [<xref rid="B105-marinedrugs-18-00570" ref-type="bibr">105</xref>]. Where corrected, reference to species names used in the cited publications is provided in footnotes.</p></sec><sec id="sec3-marinedrugs-18-00570"><title>3. Uses of Molluscs in Traditional Medicines for Respiratory Disease</title><sec id="sec3dot1-marinedrugs-18-00570"><title>3.1. Traditional Molluscan Respiratory Medicines</title><p>Molluscs are a valued resource providing food, dye, shells, forming currencies and medicines, as well as being of symbolic and ritualistic importance to many historical and contemporary cultures around the world [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>,<xref rid="B106-marinedrugs-18-00570" ref-type="bibr">106</xref>,<xref rid="B107-marinedrugs-18-00570" ref-type="bibr">107</xref>,<xref rid="B108-marinedrugs-18-00570" ref-type="bibr">108</xref>]. Respiratory diseases have always concerned human health and sophisticated traditional medicine systems formed the basis of care long before the advent of modern pharmaceuticals. Many traditional respiratory medicines feature diverse preparations of the flesh, shell, opercula, eggs and secretions of different mollusc species, mostly sourced from local marine environments (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref> and <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>). Records of molluscan respiratory medicines date back at least as far as Ancient Greece (800 BC), when the boiled flesh of <italic toggle="yes">Octopus vulgaris</italic> was used to relieve heavy nasal congestion with fever, treat infectious diseases, and strengthen the body&#8217;s immune system [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). During the Middle Eastern Medieval Period (500&#8211;1500 AD), the sea hare <italic toggle="yes">Aplysia depilans</italic> was used in traditional Arabic medicine to alleviate dyspnea (difficult or labored breathing), dry cough, and hemoptysis (coughing up blood) (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Traditional Chinese Medicine (TCM) is considered one of the oldest (&gt;3500 years old) and most well-documented systems of traditional medicine in the world [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>]. Most TCMs are derived from plant/terrestrial natural products, although marine species are important with an entire volume dedicated to marine-derived remedies [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>]. Of the marine TCMs, 111 are derived from molluscs and 61 of these are used to treat various respiratory ailments [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>). References to two additional molluscan (1 marine, 1 terrestrial) TCMs that are not listed in the <italic toggle="yes">Marine Materia Medica</italic> [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] but are used for respiratory disease were found [<xref rid="B110-marinedrugs-18-00570" ref-type="bibr">110</xref>,<xref rid="B111-marinedrugs-18-00570" ref-type="bibr">111</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>).</p><p>Several recurrent themes emerge regarding the application of molluscan traditional medicines for certain respiratory diseases (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>). Many are indicated for the treatment of tuberculosis (TB), both pulmonary and extrapulmonary (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). The disease has been a permanent challenge over the course of human history, given the primordial origins of <italic toggle="yes">Mycobacterium tuberculosis</italic> [<xref rid="B112-marinedrugs-18-00570" ref-type="bibr">112</xref>] and it stands to reason that traditional treatments for TB infection (and the cough and inflammatory symptoms it causes) are ubiquitous. Alves et al. [<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>] documented the use of bivalve mollusc flesh and shells used to treat TB throughout South America; in India, the flesh of marine <italic toggle="yes">Turbinella</italic> sp. and freshwater <italic toggle="yes">Plia globosa</italic> is cooked and eaten [<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B115-marinedrugs-18-00570" ref-type="bibr">115</xref>]; &#8220;snail water&#8221; and &#8220;snail syrup&#8221; prepared from terrestrial <italic toggle="yes">Helix</italic> sp. were prescribed in Europe since the 1700s (Lemery, 1738 in [<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>]) and decoctions of numerous marine mollusc species occur in TCM (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Traditional molluscan medicines are also indicated for other infectious respiratory diseases, including influenza, pneumonia, bronchitis, measles, otitis media, and general respiratory tract infections (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>) and biomedical studies have targeted responsible pathogens (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref>, <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref> and <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>). Two biomedical studies have shown good in vitro activity of molluscan compounds against <italic toggle="yes">M. tuberculosis</italic>&#8211; analogues of kahalalide F [<xref rid="B116-marinedrugs-18-00570" ref-type="bibr">116</xref>] from a tropical sea slug, and lobophorins from <italic toggle="yes">Streptomyces</italic> sp. associated with a gastropod from the Philippines [<xref rid="B117-marinedrugs-18-00570" ref-type="bibr">117</xref>]. However, in both cases, effective concentrations exceed toxicity estimates, rendering these compounds unsuitable as therapeutic candidates against <italic toggle="yes">M. tuberculosis</italic> without modification to reduce toxic side effects (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Non-tuberculosis mycobacteria (NTM) infection (arising from mycobacteria other than <italic toggle="yes">M. tuberculosis</italic>) is a clinically severe and rapidly increasing problem worldwide (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>) [<xref rid="B28-marinedrugs-18-00570" ref-type="bibr">28</xref>]. No reference to this disease was found in traditional or contemporary literature and it should be a subject of further investigation.</p><table-wrap id="marinedrugs-18-00570-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of traditional molluscan medicines used to treat respiratory diseases or symptoms. Details available in <xref ref-type="app" rid="app1-marinedrugs-18-00570">Supplementary Tables S1 and S2</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Respiratory Disease or Symptom</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Words/Phrases Used in the Literature to Describe Symptom or Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Remedies *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mollusc Parts Used</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cultures/Traditional Medicine Systems</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergy; hypersensitivity; ENT or pulmonary allergies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egg masses; flesh; whole animal; ink; shell </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Europe; China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>,<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma; shortness of breath; dyspnea; wheeze; asthmatic cough; dyspnea with cough</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body; foot; shell; pearl; eggs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; India; South America; Middle East</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>,<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B110-marinedrugs-18-00570" ref-type="bibr">110</xref>,<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B115-marinedrugs-18-00570" ref-type="bibr">115</xref>,<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>,<xref rid="B121-marinedrugs-18-00570" ref-type="bibr">121</xref>,<xref rid="B122-marinedrugs-18-00570" ref-type="bibr">122</xref>,<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>,<xref rid="B124-marinedrugs-18-00570" ref-type="bibr">124</xref>,<xref rid="B125-marinedrugs-18-00570" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer; tumor; neoadjuvant treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; shell; operculum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India; South America; Egypt; China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>,<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>,<xref rid="B127-marinedrugs-18-00570" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cough; chesty cough; croup; hemoptysis; laryngismus; whooping cough; cough associated with infection or fever; cough associated with inflammatory conditions; nervous cough; cough with chest stuffiness and dyspnea; xeropulmonary cough; cough and regurgitation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adductor muscle; egg masses; flesh; mucus; pearl; shell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India; South America; Middle East; Nigeria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>,<xref rid="B124-marinedrugs-18-00570" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ear problems</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ear problems; ear pain; ear inflammation; ear ache; ottorhoea; otitis media; parotid gland swelling and hearing loss; ear and eye diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; mucus; shell; operculum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India; Egypt; Nigeria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>,<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>,<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>,<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>,<xref rid="B127-marinedrugs-18-00570" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fever</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fever; high fever; low fever; fever in children; fever and convulsion in children; high fever; feverish sensation in chest; night sweating; heat; heat toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adductor muscle; flesh; pearl; shell; whole animal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India; Korea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>,<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B128-marinedrugs-18-00570" ref-type="bibr">128</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strengthens immune system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; shell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Europe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection; pneumonia; measles; flu; bronchitis; anthrax; upper respiratory tract infections in children; infectious diseases; bronchitis; measles; conjunctive congestion with swelling and pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; shell; mucus; whole animal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; South America; India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>,<xref rid="B129-marinedrugs-18-00570" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory inflammation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammation; sinus inflammation; inflammatory conditions; parotid gland swelling; acute and chronic chest ailments; edema; swelling and pain; acute and chronic sinusitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; shell; mucus; whole animal; operculum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus; excessive mucus; phlegm; congestion; nasal congestion; used as expectorant; retention of phlegm and fluid; phlegmatic heat; retention of fluid in chest</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adductor muscle; flesh; operculum; pearl; shell </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sore throat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sore throat; pharyngitis; hoarseness; tonsillitis; tracheitis; pharynalgia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; mucus; shell; whole animal; pearl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; South America; India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B130-marinedrugs-18-00570" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tuberculosis &#8225;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tuberculosis; pthisis; scrofula; pulmonary tuberculosis; tuberculosis of lymph nodes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adductor muscle; egg masses; flesh; shell; mucus; whole animal; pearl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China; Europe; India; South America</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>,<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>,<xref rid="B115-marinedrugs-18-00570" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chest and abdomen heat and pain; pain in sternum; bleeding from five aperture or subcutaneous tissue (e.g., eye; ear; nose; teeth; tongue) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flesh; shell; pearl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* Containing at least one, usually several different, mollusc species; one remedy may be used to treat various conditions in which case it has been counted more than once; a remedy is included once if various words/phrases were used in the cited text relating to the same condition. &#8224; Not including tuberculosis. &#8225; Pulmonary and extrapulmonary. &#167; Included if remedy used for at least one specified respiratory condition.</p></fn></table-wrap-foot></table-wrap><p>Asthma represents another universal respiratory disease, albeit of a completely different nature to TB, being non-communicable and a function of inherent immune dysregulation, with both genetic and environmental factors (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Records of eight TCMs and 19 other traditional molluscan medicines refer to the treatment of asthma (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Notable ones include tea of toasted cuttlefish bones or octopus arms taken among traditional Brazilian communities [<xref rid="B122-marinedrugs-18-00570" ref-type="bibr">122</xref>], soup prepared from the foot of freshwater snail <italic toggle="yes">Filopaludina</italic> sp. in India, and preparations of mollusc flesh eaten in China [<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>], India [<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>], and South America [<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). </p><p>Most TCMs and other traditional medicines are applied for multiple, possibly related, respiratory conditions (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). For example, the TCM &#8220;Yan Qiu Bei&#8221; derived from the decocted shell of the cowrie <italic toggle="yes">Naria erosa</italic> (Cypraeidae) is used for extrapulmonary TB, shortness of breath, excessive mucus, and conjunctive congestion [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>), while Indian remedies using <italic toggle="yes">Turbinella</italic> sp. are not only used for TB, but for cough, excessive mucus, sore throat, fever, earache, and asthma as well [<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). It must be noted that most of the TCMs and other traditional medicines used for respiratory diseases (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>) are commonly used for other, non-respiratory conditions (e.g., gynecological problems, gastrointestinal disorders and cardiovascular diseases), which may reflect general anti-inflammatory and anti-angiotensin properties. </p><p>There are few references to cancer in general, or respiratory cancer specifically, among traditional molluscan medicines (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Those in this review were included because they are/were also used for at least one other definitively respiratory condition: <italic toggle="yes">Crassostrea rhizophorae</italic> flesh and shell used in South America [<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>] for cancer, TB, flu and pneumonia, opercula of the <italic toggle="yes">Muricid</italic> mollusc <italic toggle="yes">Chicoreus virgineus</italic> used in Medieval Egypt for tumor and eye/ear diseases [<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>,<xref rid="B131-marinedrugs-18-00570" ref-type="bibr">131</xref>], and the TCM &#8220;Mu Li&#8221; comprising the flesh and shell of 12 Ostreidae/Grypaeidae sp. for cancer and TB [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Descriptions of the preparation and application of each of these medicines is unavailable or ambiguous (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>), in alignment with Cragg et al. [<xref rid="B93-marinedrugs-18-00570" ref-type="bibr">93</xref>,<xref rid="B132-marinedrugs-18-00570" ref-type="bibr">132</xref>] who advises that claims for cancer treatments should be viewed with some skepticism because the disease is likely to be poorly defined in traditional medicine. Respiratory cancer, insidious and inconspicuous by nature, may be masked by other symptoms described in the literature (e.g., pneumonia, hemoptysis, shortness of breath, tightness or fullness in chest; <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Nonetheless, there exists plenty of biomedical evidence regarding the anticancer activity of molluscan extracts and compounds, some with specificity to respiratory cancers, discussed later in this review (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>).</p><p>Among different traditional medicine systems, certain molluscan families, species and body parts are commonly used suggesting shared properties. For example, mucus of terrestrial snails has been widely consumed as a cough remedy with records of use in Africa (<italic toggle="yes">Limicolaria aurora</italic>, <italic toggle="yes">Lanistes ovum</italic>) [<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>], China (<italic toggle="yes">Limax</italic> sp.) [<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>], and throughout European history (reviewed by Bonnemain [<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>]) (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Intertidal periwinkles (Littorinidae) are used in South America [<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>] and Africa [<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>] for symptoms of respiratory inflammation (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Different parts of the cuttlefish <italic toggle="yes">Sepia officinalis</italic> were used in Ancient Greece [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>] and more recently in India [<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>] and Europe [<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>], while the remedy &#8220;Sepia&#8221;, manufactured from <italic toggle="yes">S. officianalis</italic> ink [<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>] has been part of the <italic toggle="yes">Homeopathic Materia Medica</italic> since the 1800s [<xref rid="B133-marinedrugs-18-00570" ref-type="bibr">133</xref>]. However, this and other homeopathic remedies are typically prescribed at dilutions of 6C or 30C (equivalent to 10<sup>&#8722;12</sup> or 10<sup>&#8722;60</sup>, respectively). At such high dilutions the presence and bioactivity of the original compounds is conceivably negligible [<xref rid="B90-marinedrugs-18-00570" ref-type="bibr">90</xref>]. </p><p>The shell (and whole body, including shells) is the molluscan part most frequently used in traditional medicines for respiratory diseases (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>; <xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>). In TCM, shells are ground into powder or decocted (heated to extract essence) and ingested (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>). Ashes of burned mollusc shells or cuttlefish bones, prepared into pills, pastes, and solutions, feature in several traditional respiratory medicines originating in India [<xref rid="B114-marinedrugs-18-00570" ref-type="bibr">114</xref>] and Ancient Greece [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>]; shells are also used in South American medicine [<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>,<xref rid="B121-marinedrugs-18-00570" ref-type="bibr">121</xref>] and homeopathy [<xref rid="B118-marinedrugs-18-00570" ref-type="bibr">118</xref>,<xref rid="B119-marinedrugs-18-00570" ref-type="bibr">119</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>]. Only three biomedical studies have investigated shell extracts with relevance to respiratory disease: powdered cowry (<italic toggle="yes">Monetaria moneta</italic>) shell [<xref rid="B134-marinedrugs-18-00570" ref-type="bibr">134</xref>] and chitosan from cuttlefish (<italic toggle="yes">S. officianalis</italic>) bone [<xref rid="B135-marinedrugs-18-00570" ref-type="bibr">135</xref>,<xref rid="B136-marinedrugs-18-00570" ref-type="bibr">136</xref>], both which show antimicrobial properties in vitro (<xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>; <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). </p><p>The shell-less body (or &#8220;flesh&#8221;, and &#8220;whole animal&#8221; including the body) is the second most utilized molluscan part in traditional medicines for respiratory diseases of every nature (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>; <xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>). Flesh may be cooked and eaten [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B115-marinedrugs-18-00570" ref-type="bibr">115</xref>] or applied externally [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>,<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). In Ancient Greece, flesh of cephalopods (<italic toggle="yes">O. vulgaris, S. officianalis</italic>) and the giant trumpet shell (<italic toggle="yes">Charonia tritonis</italic>) were eaten for conditions of low immunity in addition to infectious or inflammatory respiratory diseases [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Among Nigerian tribes, the flesh is &#8220;punctured to obtain the fluid&#8221; ([<xref rid="B123-marinedrugs-18-00570" ref-type="bibr">123</xref>] p. 491). These accounts could be related to circulating hemolymph (equivalent to blood), which represents at least 20% of molluscan body weight [<xref rid="B137-marinedrugs-18-00570" ref-type="bibr">137</xref>]. Hemolymph is composed largely of hemocyanin (Hc), which has a range of bioactivities and is among the most potent of immunogens used in respiratory disease-related studies, as discussed later in this review (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S3 and S4</xref>). Many other bioactive compounds (e.g., AMPs, proteins, peptides, and polyketides) have been derived from molluscan body tissue (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref> and <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S6</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f002">Figure 2</xref> and <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>).</p></sec><sec id="sec3dot2-marinedrugs-18-00570"><title>3.2. Supporting Evidence for the Bioactivity of Traditional Molluscan Respiratory Medicines</title><p>The bioactivity and therapeutic value of traditional molluscan medicines is for the most part speculative. However, there are growing bodies of substantiating evidence by virtue of biomedical studies using derivatives of hemolymph, mucus, body extracts, and specialized glands (<xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>, <xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref>, <xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref>, <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). European 18&#8211;19th century physicians and pharmaceutical texts proclaimed the unsurpassed benefits of helicidine (mucus of the terrestrial snail <italic toggle="yes">H. pomatia</italic>) for alleviating various respiratory conditions such as whooping cough, TB, influenza, pneumonia, chronic bronchitis, and asthma [<xref rid="B91-marinedrugs-18-00570" ref-type="bibr">91</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). In 1953, Quevauviller [<xref rid="B138-marinedrugs-18-00570" ref-type="bibr">138</xref>] reviewed the pharmacology of helicidine relating its effectiveness to demonstrated sedative, mucolytic and bacteriolytic activities, and in 1999, Pons et al. [<xref rid="B79-marinedrugs-18-00570" ref-type="bibr">79</xref>] established that the broncho-relaxant effect of helicidine in vitro was mediated by the release of prostaglandin E<sub>2</sub> and inhibited by pre-treatment with a cyclooxygenase (COX) inhibitor, indomethacine (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>). A double-blind, placebo controlled clinical trial followed in 2001 [<xref rid="B80-marinedrugs-18-00570" ref-type="bibr">80</xref>] whereby 30 patients with COPD were treated with daily doses of helicidine (10%) over five days, resulting in a significant reduction in nightly coughing episodes (4.7&#8211;5.1 pre-treatment, 2.7&#8211;4.9 placebo, 1.3 helicidine group) and duration of coughing periods (<xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). </p><p>Other terrestrial land snails, of the <italic toggle="yes">Limax</italic> genus, originally appeared in the Chinese <italic toggle="yes">Compendium of Materia Medica</italic> in 1578 and continue to be used in TCM for respiratory wheeze, phlegm, and pharyngitis [<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>). In a recent robust murine model of cigarette-smoke induced COPD undertaken by Liang et al. [<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>], aqueous body extract of <italic toggle="yes">Limax</italic> sp. significantly improved pulmonary function and reduced key inflammatory mediators (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). The effect is attributable to enhancement of peroxisome proliferator-activated receptor-&#947; (PPAR-&#947;), which acts to downregulate pro-inflammatory transcription factors and mucin synthesis, and suppression of p38 and ERK1/2 mitogen-activated protein kinase (MAPK) pathways, which activate the production of pro-inflammatory mediators [<xref rid="B17-marinedrugs-18-00570" ref-type="bibr">17</xref>], and also play a role in malignant transformation [<xref rid="B139-marinedrugs-18-00570" ref-type="bibr">139</xref>], in structural and immune cells of the lung. In other models, systemically administered <italic toggle="yes">Limax</italic> sp. powder-water suspensions have been shown to inhibit Lewis lung carcinoma growth in mice [<xref rid="B111-marinedrugs-18-00570" ref-type="bibr">111</xref>], and reduce the onset of asthma symptoms and production of inflammatory markers in guinea pigs more effectively than the clinical bronchodilator Aminophylline [<xref rid="B140-marinedrugs-18-00570" ref-type="bibr">140</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>).</p><p>The flesh and shell of Muricidae sp. occur in eight TCMs [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] and their operculum were ingested as a medicinal oils in Ancient Greece [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>], Ancient India [<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>,<xref rid="B131-marinedrugs-18-00570" ref-type="bibr">131</xref>], and Medieval Egypt [<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>,<xref rid="B127-marinedrugs-18-00570" ref-type="bibr">127</xref>] for various infectious and inflammatory respiratory diseases, and cancer (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Considerable attention has been devoted to Tyrian purple (6,6&#8242;dibromoindigo and related compounds), a historically important textile dye obtained from the Muricidae family, which was first described in the <italic toggle="yes">Historia Naturalis</italic> (1669) [<xref rid="B141-marinedrugs-18-00570" ref-type="bibr">141</xref>,<xref rid="B142-marinedrugs-18-00570" ref-type="bibr">142</xref>,<xref rid="B143-marinedrugs-18-00570" ref-type="bibr">143</xref>,<xref rid="B144-marinedrugs-18-00570" ref-type="bibr">144</xref>,<xref rid="B145-marinedrugs-18-00570" ref-type="bibr">145</xref>]. Natural product research has since ascertained the broad spectrum antibacterial, anti-inflammatory, and anticancer activity of Tyrian purple precursor compounds, minor pigments, and modified derivatives [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>,<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>,<xref rid="B75-marinedrugs-18-00570" ref-type="bibr">75</xref>,<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>,<xref rid="B141-marinedrugs-18-00570" ref-type="bibr">141</xref>,<xref rid="B146-marinedrugs-18-00570" ref-type="bibr">146</xref>,<xref rid="B147-marinedrugs-18-00570" ref-type="bibr">147</xref>,<xref rid="B148-marinedrugs-18-00570" ref-type="bibr">148</xref>]. Extracts of an Australian whelk <italic toggle="yes">Dicathais orbita</italic> containing these bioactive compounds have shown preliminary antimicrobial activity against respiratory pathogens in vitro [<xref rid="B149-marinedrugs-18-00570" ref-type="bibr">149</xref>] and anti-inflammatory activity in a murine model of acute lung inflammation [<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). Some bioactive compounds are also detectable in lipophilic extracts of <italic toggle="yes">D. orbita</italic> operculum [<xref rid="B126-marinedrugs-18-00570" ref-type="bibr">126</xref>], with relevance to ancient medicinal oil preparations [<xref rid="B127-marinedrugs-18-00570" ref-type="bibr">127</xref>,<xref rid="B131-marinedrugs-18-00570" ref-type="bibr">131</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Nonetheless, the only Muricidae sp. that have been the focus of investigations pertaining directly to respiratory disease are <italic toggle="yes">D. orbita</italic> (brominated compounds) [<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>] and <italic toggle="yes">Rapana venosa</italic> (Hcs) [<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>,<xref rid="B150-marinedrugs-18-00570" ref-type="bibr">150</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref> and <xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>), while at least 30 different Muricidae sp. are used in traditional respiratory medicines (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>).</p></sec><sec id="sec3dot3-marinedrugs-18-00570"><title>3.3. Taxonomic and Geographic Trends</title><p>The majority of traditional medicines and biomedical studies are based on extracts and compounds from the Gastropoda and Bivalvia (<xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref>), which is unsurprising given that these classes comprise the majority (&gt;90%) of molluscan biodiversity [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>]. There are 21 families of Bivalvia used in traditional medicines that have not yet been investigated scientifically. Only one study has investigated the anti-inflammatory activity of Cephalopoda extracts [<xref rid="B151-marinedrugs-18-00570" ref-type="bibr">151</xref>], despite their widespread traditional use as anti-inflammatory medicines [<xref rid="B109-marinedrugs-18-00570" ref-type="bibr">109</xref>,<xref rid="B120-marinedrugs-18-00570" ref-type="bibr">120</xref>,<xref rid="B121-marinedrugs-18-00570" ref-type="bibr">121</xref>,<xref rid="B122-marinedrugs-18-00570" ref-type="bibr">122</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). The remaining four classes are all marine and relatively minor in terms of their ecological diversity and representation in both biomedical and ethnomedical literature (<xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref>) [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>]. However, the Polyplacophora (chitons) are of research interest, also noted by Benkendorff [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>], given their ecological abundance and use in TCM for asthma, TB, and bronchitis (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>). Chitons also form important South African traditional medicines, but not for respiratory disease [<xref rid="B108-marinedrugs-18-00570" ref-type="bibr">108</xref>]. The Scaphopoda (tusk shells) represent a unique evolutionary avenue within the Mollusca [<xref rid="B152-marinedrugs-18-00570" ref-type="bibr">152</xref>]; they are the only class of exclusively infaunal molluscs and could yield interesting chemistries but remain poorly examined to date (<xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref>) [<xref rid="B152-marinedrugs-18-00570" ref-type="bibr">152</xref>]. The Aplacophora and Monoplacophora mostly occupy the deep-sea making for challenging access and limited utility, although such extreme adaptive radiation in their biology suggests that they are also likely to be chemically unique [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>]. </p><table-wrap id="marinedrugs-18-00570-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t003_Table 3</object-id><label>Table 3</label><caption><p>Number of different mollusc families by taxonomic class and habitat represented in traditional medicines (Traditional Chinese Medicines [TCMs]; other traditional medicines [OTMs]) and biomedical studies in which molluscan extracts/compounds have been used for the treatment or investigation of respiratory disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Number of Different Mollusc Families Represented in Each Literature Type</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Traditional Medicines</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Biomedical Studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCMs *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OTMs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model Antigen &#8224;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mollusc class</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gastropoda</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bivalvia</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cephalopoda</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polyplacophora</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aplacophora</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monoplacophora</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scaphopoda</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Habitat type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Marine</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Freshwater</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terrestrial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>* Literature based on marine sp. only [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>]. &#8224; Hc used as a model antigen in in vivo models and clinical trials.</p></fn></table-wrap-foot></table-wrap><p>Regional environmental factors have important bearings on the chemical and biological diversity of mollusc species used as traditional medicines in different cultures. A large proportion of traditional medicines included in this review represent Asian (52%), European (24%), and South American (5%) cultures and species endemic to these regions. By comparison, biomedical research efforts have been focused in Europe (34%), North America (28%), and Asia (China and India, 27%). Only one South American species has been studied [<xref rid="B153-marinedrugs-18-00570" ref-type="bibr">153</xref>,<xref rid="B154-marinedrugs-18-00570" ref-type="bibr">154</xref>] and Australian species are also underrepresented (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Numerous sources attest to the importance of molluscs as traditional food sources as opposed to traditional medicines in Australia and throughout the Indo-pacific [<xref rid="B155-marinedrugs-18-00570" ref-type="bibr">155</xref>,<xref rid="B156-marinedrugs-18-00570" ref-type="bibr">156</xref>]. It is possible that molluscs are also used for medicinal purposes but the knowledge has been retained by Indigenous communities or otherwise lost. Accordingly, species from these regions do not appear in our review of traditional medicines, but are nevertheless likely to have some nutraceutical qualities equivalent to molluscs found elsewhere.</p><p>Respiratory diseases have changed over time and modern society now faces pathogens and environmental hazards once unimagined [<xref rid="B33-marinedrugs-18-00570" ref-type="bibr">33</xref>]. Nonetheless, traditional medicines have not lost their place and continue to provide stimulus for research. Those included in this review incorporate over 300 different mollusc species (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>), while only 93 species have been investigated in biomedical studies to date (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S3&#8211;S8</xref>). It is estimated that 80% of people in developing countries still rely on traditional medicines as a primary source of healthcare [<xref rid="B157-marinedrugs-18-00570" ref-type="bibr">157</xref>] and well-known systems, including TCM, Indian Ayurveda and homeopathy, are expanding in global popularity throughout the developed world, despite a lack of robust evidence for their safety and efficacy [<xref rid="B157-marinedrugs-18-00570" ref-type="bibr">157</xref>,<xref rid="B158-marinedrugs-18-00570" ref-type="bibr">158</xref>,<xref rid="B159-marinedrugs-18-00570" ref-type="bibr">159</xref>]. Further testing is needed to substantiate the use of traditional molluscan medicines and identify bioactive compounds that could serve as APIs and novel drug leads for respiratory disease.</p></sec></sec><sec id="sec4-marinedrugs-18-00570"><title>4. Chemistry, Bioactivity and Biomedical Applications of Molluscan Extracts and Compounds Relevant to Respiratory Disease</title><sec id="sec4dot1-marinedrugs-18-00570"><title>4.1. Overview</title><p>At least 97 peer-reviewed biomedical articles published mostly within the past two decades investigate the bioactivity of molluscan extracts and compounds with direct relevance to the treatment, prevention or understanding of respiratory disease (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref>). A small proportion (less than 2%) of the 327 individual extracts/compounds tested in vitro have progressed though in vivo models of respiratory disease to clinical trials (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref>). Only two have been approved for use although at least 12 have been patented for development toward respiratory disease (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S5</xref>). Fewer than half of studies have used purified compounds (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S6</xref>). Those compounds that have been purified include polyketides (e.g., <xref ref-type="fig" rid="marinedrugs-18-00570-f002">Figure 2</xref>), proteins, glycoproteins (e.g., <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>), PUFAs, and brominated indole/isatin derivatives (e.g., <xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>) (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S6</xref>).</p><p>The in vitro studies included in this review are focused on antimicrobial properties, usually expressed as a minimum inhibitory or bactericidal concentration (MIC or MBC, respectively), representing the minimum concentration of an extract/compound required to inhibit the growth of microbial cells or kill them entirely; and, anticancer properties whereby the indexes IC<sub>50</sub>, EC<sub>50</sub>, GI<sub>50</sub> or CC<sub>50</sub> (50% inhibitory concentration, effective concentration, growth inhibition or cytotoxic concentration, respectively) are used often and interchangeably, representing the concentration of an extract/compound that reduces cell growth in vitro by 50% compared to the untreated control. In vitro studies have used extracts/compounds derived from the hemolymph, sperm, tissue associated with symbiotic bacteria, shell, salivary gland, digestive gland, egg mass, body, and mucus of different mollusc species (representing 56 families) (<xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>, <xref rid="marinedrugs-18-00570-t003" ref-type="table">Table 3</xref>). Further testing and characterization of crude extracts used in many of these studies may lead to the identification of novel bioactive lead compounds, which could become productive drug leads (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref> and <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>).</p><p>In vivo studies are based on mouse models of respiratory disease (COPD, allergic and acute inflammatory airway disease, lung cancer and respiratory infection) treated with molluscan extracts/compounds. More than half (13) of these models use Hc for its immunogenic properties in vaccine preparations targeting respiratory pathogens (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>). Another three extracts and 10 compounds are derived from the body, hemolymph, or hypobranchial gland of different mollusc species with a focus on their anti-inflammatory and anticancer properties (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref> and <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). A separate body of research uses molluscan Hcs as a model antigen in respiratory disease-related immunological studies (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). The focus of these studies is not on the therapeutic value of Hc, rather they provide insight into the bioactivity, safety, and biomedical applications of Hc and functional units.</p><p>We identified 11 human clinical trials using purified molluscan compounds as treatments for respiratory disease (<xref rid="marinedrugs-18-00570-t004" ref-type="table">Table 4</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). These trials have used keyhole limpet hemocyanin (KLH) as a vaccine adjuvant/conjugate (n = 4) (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>), kahalalide F (and derivatives) for lung cancer (n = 3), helicidine for COPD (n = 1), and Lyprinol for asthma (n = 3) (<xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). Lyprinol is now FDA approved for use as an alternative anti-inflammatory agent, and helicidine-containing cough medicines have been available over-the-counter in European pharmacies for over 50 years [<xref rid="B160-marinedrugs-18-00570" ref-type="bibr">160</xref>]. The overall benefits of other clinically tested molluscan compounds have been marginal (<xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>) such that they are being further developed with structural modifications (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S5</xref>).</p><table-wrap id="marinedrugs-18-00570-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t004_Table 4</object-id><label>Table 4</label><caption><p>Activity of molluscan extracts and compounds with relevance to respiratory disease reviewed across 97 biomedical publications.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In Vitro</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In Vivo Models</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Antigen *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total Studies</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% of Studies</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">No. of studies</td><td align="center" valign="middle" rowspan="1" colspan="1">54</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">106 &#8224;</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No. of compounds/extracts &#8225;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">327</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="7" align="center" valign="middle" rowspan="1">No. of studies reporting bioactivity <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Antiviral</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anti-inflammatory <sup>&#8214;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Antitussive</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunogenic <sup>&#182;</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td></tr></tbody></table><table-wrap-foot><fn><p>* Includes both in vivo animal models and human studies using molluscan hemocyanin as a model antigen as opposed to treatment. &#8224; Of the 97 biomedical articles, nine in vivo animal models include substantial in vitro components which are presented separately in this table, hence 105 total studies. &#8225; Experimentally purified and laboratory grade hemocyanin considered different; some compounds represented in in vivo studies and clinical trials may not be represented in in vitro studies in this table as assays may have been less specific to respiratory disease. <sup>&#167;</sup> Number of studies reporting bioactivity may exceed the total number of studies as some report &gt;1 type of bioactivity. <sup>&#8214;</sup> General anti-inflammatory activity in vitro is underrepresented in this table as assays are less specific to respiratory disease, but still relevant; see Ahmad et al. [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>]. <sup>&#182;</sup> Vaccine conjugate/adjuvant or immune stimulant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4dot2-marinedrugs-18-00570"><title>4.2. Antimicrobial Activity</title><p>Research on molluscan antimicrobial chemistry and immunology has been driven mainly by development of the commercial aquaculture industry and microbial disease outbreaks among major cultured mollusc species (e.g., oysters, abalone and mussels [<xref rid="B161-marinedrugs-18-00570" ref-type="bibr">161</xref>,<xref rid="B162-marinedrugs-18-00570" ref-type="bibr">162</xref>,<xref rid="B163-marinedrugs-18-00570" ref-type="bibr">163</xref>,<xref rid="B164-marinedrugs-18-00570" ref-type="bibr">164</xref>]). However, the bioactivity of molluscan extracts and compounds is not strictly limited to molluscs and the pathogens that affect them. Antimicrobial susceptibility test suites often include bacterial, viral, and fungal pathogens responsible for common respiratory infections in humans (e.g., [<xref rid="B65-marinedrugs-18-00570" ref-type="bibr">65</xref>,<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>,<xref rid="B136-marinedrugs-18-00570" ref-type="bibr">136</xref>], <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). The prevalence, intrinsic virulence, and progressive antimicrobial resistance of respiratory pathogens continues to drive research interest and some novel molluscan compounds show promising bioactivity. Even so, most antimicrobial work has only been performed in vitro, and to describe a compound or effect as &#8220;promising&#8221; based on this data alone is to forget that a disease in a living organism is much more complex; hence, the need for in vivo testing. <italic toggle="yes">Pseudomonas aeruginosa</italic> is particularly associated with chronic bacterial infections in COPD, cystic fibrosis, and conditions of compromised immunity (<xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>) and its treatment is complex because of recurrence and multi-drug resistance [<xref rid="B165-marinedrugs-18-00570" ref-type="bibr">165</xref>,<xref rid="B166-marinedrugs-18-00570" ref-type="bibr">166</xref>]. Given the clinical need, <italic toggle="yes">P. aeruginosa</italic> is commonly included in antibacterial assays (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>; 23 studies), although activity against it is generally weak due to the protective lipopolysaccharide outer cell membrane characteristic of this and other Gram-negative bacteria [<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>,<xref rid="B167-marinedrugs-18-00570" ref-type="bibr">167</xref>,<xref rid="B168-marinedrugs-18-00570" ref-type="bibr">168</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Reasonable antibacterial activity against <italic toggle="yes">P. aeruginosa</italic> has been observed using some molluscan extracts and compounds (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Examples include: tyriverdin (MIC 0.005 mg/mL) sourced from egg masses of <italic toggle="yes">D. orbita</italic> [<xref rid="B149-marinedrugs-18-00570" ref-type="bibr">149</xref>]; tartrolon E (MIC 0.31 mg/mL) a polyketide isolated from a molluscan gill symbiont [<xref rid="B169-marinedrugs-18-00570" ref-type="bibr">169</xref>]; peptides from <italic toggle="yes">O. vulgaris</italic> (MIC 50&#8211;300 &#956;g/mL) [<xref rid="B170-marinedrugs-18-00570" ref-type="bibr">170</xref>]; Scutinin A isolated from Australian limpet <italic toggle="yes">Scutus antipodes</italic> (MIC 33 &#956;M) [<xref rid="B171-marinedrugs-18-00570" ref-type="bibr">171</xref>]; 5&#8217;-deoxy-5&#8217;-methylthio-adenosine (MTA) from a dorid nudibranch [<xref rid="B172-marinedrugs-18-00570" ref-type="bibr">172</xref>]; and body extract of <italic toggle="yes">Drupella margariticola</italic> (MIC 0.07 mg/mL) [<xref rid="B173-marinedrugs-18-00570" ref-type="bibr">173</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f002">Figure 2</xref> and <xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>). Preliminary assays using mucus of <italic toggle="yes">H. aspera</italic> [<xref rid="B174-marinedrugs-18-00570" ref-type="bibr">174</xref>] and crude extract of <italic toggle="yes">Babylonia spirata</italic> [<xref rid="B175-marinedrugs-18-00570" ref-type="bibr">175</xref>], show antimicrobial activity although weaker than antibiotic controls (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Notwithstanding, crude extracts would sensibly become more effective if the active compound/s were concentrated by purification. Hence, extracts that show weak activity should not necessarily be overlooked in case the active factor is a minor component.</p><fig id="marinedrugs-18-00570-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Examples of molluscan compounds with defined chemical structures showing antimicrobial activity against respiratory bacteria. Produced with information in [<xref rid="B169-marinedrugs-18-00570" ref-type="bibr">169</xref>,<xref rid="B171-marinedrugs-18-00570" ref-type="bibr">171</xref>,<xref rid="B172-marinedrugs-18-00570" ref-type="bibr">172</xref>,<xref rid="B176-marinedrugs-18-00570" ref-type="bibr">176</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="marinedrugs-18-00570-g002.jpg"/></fig><p>The capacity to form biofilms (structured communities of bacteria encapsulated within an extracellular polymeric matrix) confers some bacteria, including <italic toggle="yes">P. aeruginosa</italic>, an enormous advantage in establishing and maintaining infections in the respiratory tract [<xref rid="B177-marinedrugs-18-00570" ref-type="bibr">177</xref>]. Of interest therefore are studies by Gasu et al. [<xref rid="B178-marinedrugs-18-00570" ref-type="bibr">178</xref>,<xref rid="B179-marinedrugs-18-00570" ref-type="bibr">179</xref>] using peptide extract of <italic toggle="yes">Olivancillaria hiatula</italic> establishing a relatively low MIC of 0.039 mg/mL against <italic toggle="yes">P. aeruginosa</italic> and 50% inhibition of biofilm formation at the same concentration, though 2.5 mg/mL was required to degrade pre-formed biofilm (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Further, the peptide extract reduced the expression of virulence factors (pyocyanin, pyoverdine, and protease) by &gt;50% at 0.0195 mg/mL and acted synergistically with standard antibiotics ciprofloxacin and cefotaxime (up to 100% reduction in MICs) (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). As well, Maselli et al. [<xref rid="B170-marinedrugs-18-00570" ref-type="bibr">170</xref>] recently reported antibiofilm activity (60% eradication at 80 &#956;M) among peptides derived from the suckers of <italic toggle="yes">O vulgaris</italic>. Preliminary evidence indicates that Hcs from marine crustaceans can also inhibit biofilm formation (at 0.1 mg/mL) [<xref rid="B180-marinedrugs-18-00570" ref-type="bibr">180</xref>,<xref rid="B181-marinedrugs-18-00570" ref-type="bibr">181</xref>,<xref rid="B182-marinedrugs-18-00570" ref-type="bibr">182</xref>] and molluscan Hcs could function similarly.</p><p>Community-acquired pneumonia is the leading cause of death from infection worldwide, particularly in infants, and is typically caused by <italic toggle="yes">Streptococcus pneumoniae</italic> [<xref rid="B2-marinedrugs-18-00570" ref-type="bibr">2</xref>,<xref rid="B183-marinedrugs-18-00570" ref-type="bibr">183</xref>]. Bacteriostatic activity against <italic toggle="yes">S. pneumoniae</italic> has been observed using crude body extracts of <italic toggle="yes">D. margariticola</italic> (MIC 0.07 mg/mL) [<xref rid="B184-marinedrugs-18-00570" ref-type="bibr">184</xref>], <italic toggle="yes">Babylonia spirata</italic> [<xref rid="B175-marinedrugs-18-00570" ref-type="bibr">175</xref>], and several Cephalopods at high concentrations [<xref rid="B185-marinedrugs-18-00570" ref-type="bibr">185</xref>]. Other molluscan extracts/compounds (e.g., Helicidae sp. Hcs [<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>] and Muricidae sp. brominated compounds [<xref rid="B149-marinedrugs-18-00570" ref-type="bibr">149</xref>]) showing activity against Gram-positive bacteria could be investigated targeting this pathogen.</p><p>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) is a common cause of troublesome healthcare-acquired infections, including pneumonia [<xref rid="B186-marinedrugs-18-00570" ref-type="bibr">186</xref>]. Bacteriostatic effects on MRSA have been observed using compounds isolated from molluscan bacterial symbionts [<xref rid="B169-marinedrugs-18-00570" ref-type="bibr">169</xref>]. The recent work of Miller et al. [<xref rid="B176-marinedrugs-18-00570" ref-type="bibr">176</xref>] using 7,8-dideoxygriseorhodin C (DC) is notable: MIC values for DC (0.08&#8211;0.12 &#181;g/mL) were lower than the control antibiotic oxacillin (1.59&#8211;6.24 &#181;g/mL), and both the number of colony-forming units and MICs for DC and oxacillin were reduced &gt;100 fold (i.e., synergistic effects) when present in combination (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f002">Figure 2</xref>). Extracts from the sperm of the Mediterranean mussel (<italic toggle="yes">Mytilus galloprovincialis</italic>) have displayed bactericidal activity against clinical <italic toggle="yes">S. aureus</italic> strains, as well as negligible toxicity and resistance to acid digestion (i.e., suitable for oral administration) [<xref rid="B187-marinedrugs-18-00570" ref-type="bibr">187</xref>]. Wei et al. [<xref rid="B188-marinedrugs-18-00570" ref-type="bibr">188</xref>] prepared two recombinant proteins (rSgSABL-1 and -2) from lectins of the razor clam <italic toggle="yes">Solen grandis,</italic> which exhibited strong binding affinity to <italic toggle="yes">S. aureus</italic> peptidoglycan, increased phagocytic and encapsulation activity in vitro, and generated reactive antibodies in vivo (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref> and <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). Aside from Wei et al. [<xref rid="B188-marinedrugs-18-00570" ref-type="bibr">188</xref>], the antimicrobial activity of molluscan extracts/compounds against respiratory pathogens has not been tested in animals or humans aside from the inclusion of Hcs in vaccine preparations (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>).</p><p>Terrestrial mollusc mucus is a mixture of proteoglycans, glycoprotein enzymes, AMPs, and other minor constituents in ~90% water [<xref rid="B189-marinedrugs-18-00570" ref-type="bibr">189</xref>]. Preliminary antibacterial results from disc diffusion assays using some respiratory pathogens are presented by Cilia and Fratini [<xref rid="B189-marinedrugs-18-00570" ref-type="bibr">189</xref>], but statistically meaningful data are yet to be derived. de Toledo-Piza et al. (2016) demonstrated impressive anti-viral activity with concentrated mucus from the terrestrial shell-less mollusc <italic toggle="yes">Phyllocaulis boraceiensis</italic> whereby host cell pre-treatment reduced Influenza A (H1N1) and measles virus-induced cytopathic effects by up to 80% with no host cell cytotoxicity [<xref rid="B153-marinedrugs-18-00570" ref-type="bibr">153</xref>,<xref rid="B154-marinedrugs-18-00570" ref-type="bibr">154</xref>]. Further studies should incorporate bioassay guided fractionation of concentrated mucus extracts to isolate and identify the active factors.</p><p>Numerous published reviews discuss Hcs and AMPs as effectors of invertebrate immunity and their potential as antibiotic leads [<xref rid="B102-marinedrugs-18-00570" ref-type="bibr">102</xref>,<xref rid="B190-marinedrugs-18-00570" ref-type="bibr">190</xref>,<xref rid="B191-marinedrugs-18-00570" ref-type="bibr">191</xref>,<xref rid="B192-marinedrugs-18-00570" ref-type="bibr">192</xref>,<xref rid="B193-marinedrugs-18-00570" ref-type="bibr">193</xref>,<xref rid="B194-marinedrugs-18-00570" ref-type="bibr">194</xref>,<xref rid="B195-marinedrugs-18-00570" ref-type="bibr">195</xref>]. Regardless of their biological origin, all AMPs are small in size, often cleaved from Hcs, with either a cyclic (encompassing amphipathic surfaces) or linear (containing di-sulfide bridges) structure and broad-spectrum antimicrobial activity [<xref rid="B164-marinedrugs-18-00570" ref-type="bibr">164</xref>,<xref rid="B193-marinedrugs-18-00570" ref-type="bibr">193</xref>] (<xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>). Molluscan Hcs and AMPs show some inhibition of respiratory bacteria (mostly Gram-positive) and fungi [<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>,<xref rid="B167-marinedrugs-18-00570" ref-type="bibr">167</xref>,<xref rid="B168-marinedrugs-18-00570" ref-type="bibr">168</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>). Although, they may hold even greater potential as antivirals. The review by Dang at al. [<xref rid="B56-marinedrugs-18-00570" ref-type="bibr">56</xref>] presents evidence for antiviral effects of molluscan Hcs and AMPs against a range of human viruses including herpes simplex virus, Epstein-Barr virus (double-strand, lipid-enveloped DNA), simian rotavirus (double-strand, non-enveloped RNA) and poliovirus (single-strand, non-enveloped RNA) [<xref rid="B56-marinedrugs-18-00570" ref-type="bibr">56</xref>]. Regarding respiratory disease, virucidal activity has been shown using oyster hemolymph tested against human adenovirus (AdV-5) (EC<sub>50</sub> 0.05&#8211;0.09 mg/mL, cytotoxic at 0.19&#8211;0.36 mg/mL) [<xref rid="B196-marinedrugs-18-00570" ref-type="bibr">196</xref>] and with Hc subunit c (RvH-c) from <italic toggle="yes">R. venosa,</italic> which inhibited the cytopathic effects of respiratory syncytial virus (by 71.4% at 1 mg/mL) and indicated that some Hc structural units may be more bioactive than others [<xref rid="B197-marinedrugs-18-00570" ref-type="bibr">197</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>). Nonetheless, negligible toxicity toward healthy eukaryotic cells and low potential for the development of resistance [<xref rid="B164-marinedrugs-18-00570" ref-type="bibr">164</xref>,<xref rid="B198-marinedrugs-18-00570" ref-type="bibr">198</xref>] are clear advantages for the inclusion of Hcs and AMPs in various antimicrobial and anticancer preparations.</p><fig id="marinedrugs-18-00570-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>General structural levels of molluscan hemocyanins and two functional units (c and e) of deoxygenated hemocyanin from <italic toggle="yes">Rapana venosa</italic> (RvH) (Mollusca: Muricidae; originally listed as <italic toggle="yes">R. thomasiana</italic>) with bioactivities (antiviral, anticancer, immunomodulatory) relevant to respiratory disease. Adapted from [<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>,<xref rid="B197-marinedrugs-18-00570" ref-type="bibr">197</xref>,<xref rid="B199-marinedrugs-18-00570" ref-type="bibr">199</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="marinedrugs-18-00570-g003.jpg"/></fig><p>Molluscs provide good bioavailable sources of elemental zinc [<xref rid="B200-marinedrugs-18-00570" ref-type="bibr">200</xref>]. Zinc was recently shown to inhibit the replication of respiratory viruses (including influenza and COVID-19), reduce host cell infection, improve immune function, and act synergistically with standard antiviral therapies [<xref rid="B201-marinedrugs-18-00570" ref-type="bibr">201</xref>,<xref rid="B202-marinedrugs-18-00570" ref-type="bibr">202</xref>,<xref rid="B203-marinedrugs-18-00570" ref-type="bibr">203</xref>]. Antiviral factors isolated from molluscs could therefore be combined with zinc for improved activity. As well, extracts from whole molluscs, bodies, and shells used in traditional medicines likely contain zinc, which may be in part responsible for some derived benefits (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>).</p></sec><sec id="sec4dot3-marinedrugs-18-00570"><title>4.3. Anti-Inflammatory Activity</title><p>Scientific and epidemiological evidence suggest a beneficial relationship between dietary PUFA consumption and prevention or alleviation of chronic diseases including asthma, allergic airway disease, cardiovascular disease, and cancer [<xref rid="B204-marinedrugs-18-00570" ref-type="bibr">204</xref>,<xref rid="B205-marinedrugs-18-00570" ref-type="bibr">205</xref>,<xref rid="B206-marinedrugs-18-00570" ref-type="bibr">206</xref>]. Lyprinol&#8482; is a patented extract of the New Zealand green lipped mussel (<italic toggle="yes">Perna canaliculus</italic>) known to inhibit 5&#8242;-lipoxygenase and COX pathways responsible for the production of inflammatory eicosanoids, among other less well-characterised involvement in the production of resolvins and protectins [<xref rid="B207-marinedrugs-18-00570" ref-type="bibr">207</xref>]. In a murine model of allergic airway disease, Wood et al. [<xref rid="B208-marinedrugs-18-00570" ref-type="bibr">208</xref>] found that daily gavage with 100 &#181;L Lyprinol&#8482; significantly reduced eosinophil influx, mucus hypersecretion, and airway hyperresponsiveness (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). Indeed, different forms of marine oils have different bioactivities since they contain different types and amounts of PUFAs as well as a variety of lipid mediators [<xref rid="B207-marinedrugs-18-00570" ref-type="bibr">207</xref>]. Lyprinol&#8482; contains a mixture of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA] and other n-3 PUFAs), triglycerides, sterol esters, sterols, and polar lipids combined with olive oil and vitamin E, and these multiple nutritional components may contribute to the superior effectiveness of the supplement over fish oil in animal models [<xref rid="B208-marinedrugs-18-00570" ref-type="bibr">208</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>) and clinical trials (e.g., [<xref rid="B209-marinedrugs-18-00570" ref-type="bibr">209</xref>,<xref rid="B210-marinedrugs-18-00570" ref-type="bibr">210</xref>] [<xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>] compared with [<xref rid="B211-marinedrugs-18-00570" ref-type="bibr">211</xref>]).</p><p>Ahmad et al. [<xref rid="B212-marinedrugs-18-00570" ref-type="bibr">212</xref>] first established evidence for the anti-inflammatory activity of hypobranchial gland (HBG) extract and 6-bromoisatin (among other related compounds) from <italic toggle="yes">D. orbita</italic> based on the in vitro inhibition of pro-inflammatory mediators (NO, TNF-&#945; and NF&#954;B) in mouse cell lines (<xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>). In this study, effective, non-toxic concentrations were &lt;50 &#181;g/mL and the purified mono-brominated indole and isatin compounds (i.e., 6-bromoisatin) were more bioactive than their non-brominated counterparts and crude HBG extract [<xref rid="B212-marinedrugs-18-00570" ref-type="bibr">212</xref>]. Ahmad et al. [<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>] was led to investigate whether these anti-inflammatory effects could be replicated in a model of acute lung inflammation, in which HBG extract and 6-bromoisatin significantly inhibited the inflammatory pathway (TNF-&#945; and IL-1&#946;, and neutrophil infiltration) and prevented associated lung tissue damage (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>). No mortality, ill-health, liver toxicity, or gastro-intestinal damage was observed in this model, nor others (non-respiratory) using the same extracts/compounds administered over 2&#8211;14 weeks (0.05&#8211;0.1 mg/g) [<xref rid="B48-marinedrugs-18-00570" ref-type="bibr">48</xref>,<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>,<xref rid="B213-marinedrugs-18-00570" ref-type="bibr">213</xref>,<xref rid="B214-marinedrugs-18-00570" ref-type="bibr">214</xref>,<xref rid="B215-marinedrugs-18-00570" ref-type="bibr">215</xref>]. Evidently, brominated compounds from <italic toggle="yes">D. orbita</italic>, and other Muricidae sp., could prove especially valuable for their anti-inflammatory activity and other properties relevant to respiratory disease.</p><fig id="marinedrugs-18-00570-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Examples of brominated indole/isatin derivatives showing anti-inflammatory, anticancer, and antimicrobial activity relevant to respiratory disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="marinedrugs-18-00570-g004.jpg"/></fig><p>Very few investigations of molluscan extracts and compounds are specific to inflammatory respiratory diseases, regardless of all the traditional uses of molluscs relevant to symptoms of inflammation (<xref rid="marinedrugs-18-00570-t002" ref-type="table">Table 2</xref>, <xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>; [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>]) and the prevalence of these conditions (e.g., COPD, asthma, ARDS; <xref rid="marinedrugs-18-00570-t001" ref-type="table">Table 1</xref>). Those extracts/compounds that have been tested specifically for inflammatory respiratory conditions include: helicidine, studied in vitro with relevance to asthma [<xref rid="B79-marinedrugs-18-00570" ref-type="bibr">79</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>) and in a clinical trial for COPD [<xref rid="B80-marinedrugs-18-00570" ref-type="bibr">80</xref>]; <italic toggle="yes">Limax</italic> sp. extract, studied twice in vivo for COPD [<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>] and asthma [<xref rid="B140-marinedrugs-18-00570" ref-type="bibr">140</xref>]; <italic toggle="yes">muricid</italic> sp. brominated compounds, studied in vivo for acute lung inflammation [<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>]; and Lyprinol<sup>TM</sup>, used in three clinical trials for asthma [<xref rid="B207-marinedrugs-18-00570" ref-type="bibr">207</xref>,<xref rid="B209-marinedrugs-18-00570" ref-type="bibr">209</xref>,<xref rid="B210-marinedrugs-18-00570" ref-type="bibr">210</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). Notwithstanding, there is significant work dedicated to the general anti-inflammatory activity of molluscan compounds(recently reviewed by Ahmad et al. [<xref rid="B49-marinedrugs-18-00570" ref-type="bibr">49</xref>]).</p><p>Molluscan compounds displaying potent anti-inflammatory activity in vitro, but not appearing in studies specific to respiratory disease (and therefore not included in <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref> and <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>), include: abalone (<italic toggle="yes">Haliotis</italic> sp.) body [<xref rid="B216-marinedrugs-18-00570" ref-type="bibr">216</xref>,<xref rid="B217-marinedrugs-18-00570" ref-type="bibr">217</xref>] and shell [<xref rid="B218-marinedrugs-18-00570" ref-type="bibr">218</xref>] extracts; lipid extracts of the freshwater snail <italic toggle="yes">Filopaludina bengalensis</italic> [<xref rid="B219-marinedrugs-18-00570" ref-type="bibr">219</xref>], the Humboldt squid [<xref rid="B220-marinedrugs-18-00570" ref-type="bibr">220</xref>], Australian cephalopods [<xref rid="B151-marinedrugs-18-00570" ref-type="bibr">151</xref>], and Aplysiidae sp. [<xref rid="B221-marinedrugs-18-00570" ref-type="bibr">221</xref>]; and isolated compounds derived from Muricidae sp. [<xref rid="B222-marinedrugs-18-00570" ref-type="bibr">222</xref>,<xref rid="B223-marinedrugs-18-00570" ref-type="bibr">223</xref>,<xref rid="B224-marinedrugs-18-00570" ref-type="bibr">224</xref>,<xref rid="B225-marinedrugs-18-00570" ref-type="bibr">225</xref>,<xref rid="B226-marinedrugs-18-00570" ref-type="bibr">226</xref>,<xref rid="B227-marinedrugs-18-00570" ref-type="bibr">227</xref>] and four Asian marine bivalves (<italic toggle="yes">Magallana bilineata</italic> [originally <italic toggle="yes">Crassostrea madrasensis</italic>, Preston, 1916] [<xref rid="B228-marinedrugs-18-00570" ref-type="bibr">228</xref>,<xref rid="B229-marinedrugs-18-00570" ref-type="bibr">229</xref>], <italic toggle="yes">Perna viridis</italic> [<xref rid="B230-marinedrugs-18-00570" ref-type="bibr">230</xref>], <italic toggle="yes">Anadara kagoshimensis</italic> [originally <italic toggle="yes">Arca subcrenata</italic>, Lischke, 1869] [<xref rid="B231-marinedrugs-18-00570" ref-type="bibr">231</xref>], and <italic toggle="yes">Villorita cyprinoides</italic> [<xref rid="B232-marinedrugs-18-00570" ref-type="bibr">232</xref>]). Additionally, molluscan compounds displaying potent anti-inflammatory activity in vivo, but not appearing in studies specific to respiratory disease, include: different extracts (foot lipid, extra-pallial fluid, flesh homogenate and purified proteins) of Indian freshwater snail <italic toggle="yes">F. bengalensis</italic> [<xref rid="B219-marinedrugs-18-00570" ref-type="bibr">219</xref>,<xref rid="B233-marinedrugs-18-00570" ref-type="bibr">233</xref>,<xref rid="B234-marinedrugs-18-00570" ref-type="bibr">234</xref>,<xref rid="B235-marinedrugs-18-00570" ref-type="bibr">235</xref>]; various extracts of Indian marine gastropods [<xref rid="B173-marinedrugs-18-00570" ref-type="bibr">173</xref>,<xref rid="B184-marinedrugs-18-00570" ref-type="bibr">184</xref>,<xref rid="B236-marinedrugs-18-00570" ref-type="bibr">236</xref>,<xref rid="B237-marinedrugs-18-00570" ref-type="bibr">237</xref>,<xref rid="B238-marinedrugs-18-00570" ref-type="bibr">238</xref>,<xref rid="B239-marinedrugs-18-00570" ref-type="bibr">239</xref>,<xref rid="B240-marinedrugs-18-00570" ref-type="bibr">240</xref>] and Sepiidae sp. [<xref rid="B241-marinedrugs-18-00570" ref-type="bibr">241</xref>,<xref rid="B242-marinedrugs-18-00570" ref-type="bibr">242</xref>]; lipid extracts of three mussel species [<xref rid="B243-marinedrugs-18-00570" ref-type="bibr">243</xref>,<xref rid="B244-marinedrugs-18-00570" ref-type="bibr">244</xref>,<xref rid="B245-marinedrugs-18-00570" ref-type="bibr">245</xref>]; a preparation of the pearl of <italic toggle="yes">Pinctada imbricata</italic> [<xref rid="B242-marinedrugs-18-00570" ref-type="bibr">242</xref>]; and melanoprotein from the neon flying squid <italic toggle="yes">Ommastrephes bartramii</italic> [<xref rid="B246-marinedrugs-18-00570" ref-type="bibr">246</xref>]. These and other molluscan extracts and compounds clearly need to be studied for respiratory-associated anti-inflammatory activity given the significance of the pathway in respiratory disease, differences in presentation from other sites of inflammation, and the need for alternatives (e.g., COX-2 specific inhibitors) to available anti-inflammatory medications.</p></sec><sec id="sec4dot4-marinedrugs-18-00570"><title>4.4. Anticancer Activity</title><p>The A549 (human alveolar carcinoma) lung cancer cell line is often used to investigate anticancer activity in vitro, enabling comparison between studies (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>). Significant inhibition of A549 proliferation has been shown using a recombinant tumor necrosis factor from the Pacific oyster (200 ng/mL) [<xref rid="B247-marinedrugs-18-00570" ref-type="bibr">247</xref>], crude methanol extracts of an intertidal snail <italic toggle="yes">Euchelus asper</italic> (40% inhibition at 10 &#181;g/mL) [<xref rid="B248-marinedrugs-18-00570" ref-type="bibr">248</xref>], and lipid extract from a squid digestive gland (CC<sub>50</sub> 260 &#181;g/mL) [<xref rid="B249-marinedrugs-18-00570" ref-type="bibr">249</xref>] (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>). Liu et al. [<xref rid="B250-marinedrugs-18-00570" ref-type="bibr">250</xref>] tested extracts of Ampullarriidae, a family of freshwater snails used in TCM for epilepsy and stomach ache, reporting 31-57% inhibition of A549 between 20&#8211;200 &#181;g/mL, and Zhang et al. [<xref rid="B251-marinedrugs-18-00570" ref-type="bibr">251</xref>] reports 73-96% inhibition using ethanol extracts of eight Chinese mollusc species, some of which are used in TCM [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>]. However, these studies are less robust than others; only three studies included in <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref> report cytotoxicity against human/animal-derived healthy cell lines, which is critical to ensure specificity [<xref rid="B249-marinedrugs-18-00570" ref-type="bibr">249</xref>,<xref rid="B252-marinedrugs-18-00570" ref-type="bibr">252</xref>,<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>] (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>).</p><p>In assays using a novel peptide (termed Mere15) from the Asiatic clam <italic toggle="yes">Meretrix meretrix</italic> (Veneridae), Wang et al. [<xref rid="B252-marinedrugs-18-00570" ref-type="bibr">252</xref>] found that A549 was more susceptible (IC<sub>50</sub> 31.80 &#181;g/mL) than other cancer (breast, colorectal, liver, pancreas; IC<sub>50</sub> 43.5&#8211;57.4 &#181;g/mL) and healthy (IC<sub>50</sub> 123.1&#8211;149.5 &#181;g/mL) cell lines (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>). These results prompted the use of A549 in a mouse xenograft model, whereby 50 mg/kg Mere15 administered by subcutaneous injection inhibited tumor growth by 69%, an effect greater than (although statistically indifferent to) the control chemotherapeutic cyclophosphamide (53% inhibition at the same concentration) [<xref rid="B252-marinedrugs-18-00570" ref-type="bibr">252</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). The Veneridae are valued in TCM with 42 different species used in 11 remedies for inflammatory respiratory diseases (e.g., asthma, cough, tuberculosis, tracheitis), but not cancer [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>); Veneridae sp. are also used as medicines in South America for asthma and influenza [<xref rid="B113-marinedrugs-18-00570" ref-type="bibr">113</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>). Anti-inflammatory activity of extracts and compounds from this family is a topic certainly worth pursuing, in conjunction with anticancer work.</p><p>The best available evidence for molluscan anticancer compounds to date comes from kahalalide F (KF) (a cyclic depsipeptide), dolastatin-10 (a linear pentamer with four unique amino acids), and structurally related analogues, which have progressed from in vitro through in vivo studies into Phase I and II clinical trials for respiratory, and other, cancers (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f005">Figure 5</xref>). The strong activity of dolastatin 10 is illustrated by Kalemkerian et al. [<xref rid="B254-marinedrugs-18-00570" ref-type="bibr">254</xref>], who report low IC<sub>50</sub>s (0.03&#8211;0.184 nM) against a panel of lung cancer cell lines (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>) and found that two doses of 4.5 mg/kg dolastatin 10 could completely inhibited tumor formation, or significantly reduce the size of established tumors (1635 mg control vs. 44 mg dolastatin-10) and improve survival in a H446 (small cell lung cancer) xenograft model (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). Once a lead compound is identified, a research team may synthetically explore and alter the structure in order to maintain its favourable properties while improving on deficiencies, as did Kobayashi et al. [<xref rid="B255-marinedrugs-18-00570" ref-type="bibr">255</xref>] who found that TZT-1027, a synthetically modified dolastatin-10 derivative designed for enhanced bioactivity and lower toxicity, resulted in 84&#8211;98% regression of pre-established lung cancer xenograft tumors with just one or two treatments at 1&#8211;2 mg/kg (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f005">Figure 5</xref>).</p><p>GI<sub>50</sub>/IC<sub>50</sub> values for KF against A549 range from 0.135&#8211;1 &#181;M (0.20&#8211;1.48 &#181;g/mL) [<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>,<xref rid="B256-marinedrugs-18-00570" ref-type="bibr">256</xref>,<xref rid="B257-marinedrugs-18-00570" ref-type="bibr">257</xref>], which are far lower than cytotoxic concentrations (&gt;4.76 &#181;g/mL [<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>]) (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>). A549 appears more sensitive to KF than other cancer types in vitro (e.g., colon, leukemia, melanoma, ovarian, prostate; [<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>,<xref rid="B257-marinedrugs-18-00570" ref-type="bibr">257</xref>]), although other respiratory cell lines are more resistant (e.g., H460 [<xref rid="B256-marinedrugs-18-00570" ref-type="bibr">256</xref>], HOP62 [<xref rid="B258-marinedrugs-18-00570" ref-type="bibr">258</xref>]). Three clinical trials involving KF and elisidepsin (a KF derivative; <xref ref-type="fig" rid="marinedrugs-18-00570-f005">Figure 5</xref>) have shown their capacity to stabilize lung cancer (by induction of apoptosis, inhibition of microtubule formation and blockade of cellular growth pathways, as opposed to immunomodulatory mechanisms) at maximum tolerable doses of around 6.5 mg/m<sup>2</sup> [<xref rid="B259-marinedrugs-18-00570" ref-type="bibr">259</xref>,<xref rid="B260-marinedrugs-18-00570" ref-type="bibr">260</xref>,<xref rid="B261-marinedrugs-18-00570" ref-type="bibr">261</xref>,<xref rid="B262-marinedrugs-18-00570" ref-type="bibr">262</xref>] (<xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). Interestingly, elisidepsin has been shown to act synergistically with paclitaxel, cisplatin, and gemcitabine against lung cancer cell lines in vitro [<xref rid="B258-marinedrugs-18-00570" ref-type="bibr">258</xref>] and with Erlotinib in vivo, significantly enhancing the survival of mice with A549 tumors (elisidepsin 54 d, erlotinib 39 d, combination &gt;150 d, control 23 d) [<xref rid="B263-marinedrugs-18-00570" ref-type="bibr">263</xref>] (<xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>). Such combinations of molluscan compounds with approved drugs may help to overcome chemotherapy resistance. Myelosuppression and elevated transaminase levels are dose-limiting drawbacks of KF and dolastatin compounds in vivo, as per many chemotherapeutic agents [<xref rid="B254-marinedrugs-18-00570" ref-type="bibr">254</xref>,<xref rid="B260-marinedrugs-18-00570" ref-type="bibr">260</xref>,<xref rid="B264-marinedrugs-18-00570" ref-type="bibr">264</xref>,<xref rid="B265-marinedrugs-18-00570" ref-type="bibr">265</xref>].</p><p>Original sources of KF and dolastatin-10, the tropical ornate leaf sea slug, <italic toggle="yes">Elisia ornata</italic> (Plakobranchidae) and the sea hare, <italic toggle="yes">Dolabella auricularia</italic> (Aplysiidae) respectively, are rarely used in traditional medicine, with the exception of an unknown Aplysiidae sp. body part used in Middle Eastern medicine (for cough, dyspnea, and hemoptysis) and egg masses used in one TCM (for cough, TB and dyspnea) (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>). Aplysiidae sp. egg masses contain a range of bioactive compounds, but not dolastatins, [<xref rid="B266-marinedrugs-18-00570" ref-type="bibr">266</xref>] and there is evidence for acute liver damage upon ingestion [<xref rid="B267-marinedrugs-18-00570" ref-type="bibr">267</xref>]. The bias of natural product cancer research toward heterobranch gastropods, in which the shell is often reduced or entirely absent, is not justified by the potential for toxic (anti-predatory) compounds and the fact that traditional molluscan medicines are largely derived from shelled species (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S1 and S2</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f001">Figure 1</xref>) [<xref rid="B53-marinedrugs-18-00570" ref-type="bibr">53</xref>].</p><p>The lung is the preferred site for metastases of common cancers originating elsewhere (e.g., breast, colon, prostate and bladder) in up to 52% of cases [<xref rid="B268-marinedrugs-18-00570" ref-type="bibr">268</xref>] and such metastases are the single most negative factor in the cancer prognosis [<xref rid="B269-marinedrugs-18-00570" ref-type="bibr">269</xref>,<xref rid="B270-marinedrugs-18-00570" ref-type="bibr">270</xref>]. Gesheva et al. [<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>] measured lung metastases in a murine model of colon cancer, whereby direct solid C-26 (colon) tumor injection with Hcs from <italic toggle="yes">R. venosa</italic> (RvH; <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>) or <italic toggle="yes">Helix pomatia</italic> (HpH) resulted in significant reductions in tumor size, high anti-C-26 antibody levels, marked reductions in surface lung metastases and up to 30% increased survival after &gt;13 weeks (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). The effectiveness of RvH was dependent on priming before tumor inoculation, yet HpH was effective even without it [<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>], suggesting that the mechanism of action is related to modulation of cellular immunity (i.e., natural killer cells, antigen presenting cells, and specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells) by Hc and subsequently, better recognition and elimination of abnormal cells [<xref rid="B271-marinedrugs-18-00570" ref-type="bibr">271</xref>,<xref rid="B272-marinedrugs-18-00570" ref-type="bibr">272</xref>].</p><p>Synergeneic (or allograft) models involve the transplant of immunologically compatible cancer cells into immunocompetent mice [<xref rid="B273-marinedrugs-18-00570" ref-type="bibr">273</xref>]. Because of these qualities, these models are useful to study interactions between tumors, functional host immune systems and treatments, and eliminate the potential for tumor rejection that exists in xenograft models unless mice are first immune compromised. The only reproducible syngeneic model for lung cancer to date is the Lewis lung carcinoma model [<xref rid="B273-marinedrugs-18-00570" ref-type="bibr">273</xref>], as used by Gomes et al. [<xref rid="B274-marinedrugs-18-00570" ref-type="bibr">274</xref>], who measured the formation of lung metastases in mice treated with a heparin-like glycan from <italic toggle="yes">Nodipecten nodusus</italic>, a bivalve mollusc found along the north Atlantic coast of America. In this study, the size and number of metastatic lung foci were significantly reduced, from ten to one per lung (PBS control and molluscan heparin treatment groups, respectively) [<xref rid="B274-marinedrugs-18-00570" ref-type="bibr">274</xref>] (<xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref>). The in vivo and in vitro components of the study by Gomes et al. [<xref rid="B274-marinedrugs-18-00570" ref-type="bibr">274</xref>] demonstrated that molluscan heparin inhibits P-selectin interaction with colon carcinoma (LS180) and reduces inflammatory cell recruitment, platelet-tumor cell complex formation, and heparinase enzymatic activity, thereby attenuating metastases, although not to an extent beyond its mammalian counterpart. Heparin analogues from other mollusc species that possess strong anticoagulant activity [<xref rid="B275-marinedrugs-18-00570" ref-type="bibr">275</xref>,<xref rid="B276-marinedrugs-18-00570" ref-type="bibr">276</xref>,<xref rid="B277-marinedrugs-18-00570" ref-type="bibr">277</xref>,<xref rid="B278-marinedrugs-18-00570" ref-type="bibr">278</xref>] are yet to be tested as chemotherapeutics.</p><p>Abundant literature has been published on the anticancer activity of brominated indole and isatin derivatives from muricid molluscs in vitro [<xref rid="B75-marinedrugs-18-00570" ref-type="bibr">75</xref>,<xref rid="B147-marinedrugs-18-00570" ref-type="bibr">147</xref>,<xref rid="B251-marinedrugs-18-00570" ref-type="bibr">251</xref>,<xref rid="B279-marinedrugs-18-00570" ref-type="bibr">279</xref>,<xref rid="B280-marinedrugs-18-00570" ref-type="bibr">280</xref>,<xref rid="B281-marinedrugs-18-00570" ref-type="bibr">281</xref>,<xref rid="B282-marinedrugs-18-00570" ref-type="bibr">282</xref>,<xref rid="B283-marinedrugs-18-00570" ref-type="bibr">283</xref>,<xref rid="B284-marinedrugs-18-00570" ref-type="bibr">284</xref>,<xref rid="B285-marinedrugs-18-00570" ref-type="bibr">285</xref>] and in in vivo models of cancer treatment [<xref rid="B285-marinedrugs-18-00570" ref-type="bibr">285</xref>,<xref rid="B286-marinedrugs-18-00570" ref-type="bibr">286</xref>] and prevention [<xref rid="B48-marinedrugs-18-00570" ref-type="bibr">48</xref>,<xref rid="B214-marinedrugs-18-00570" ref-type="bibr">214</xref>,<xref rid="B287-marinedrugs-18-00570" ref-type="bibr">287</xref>,<xref rid="B288-marinedrugs-18-00570" ref-type="bibr">288</xref>] (<xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref>). Zhang et al. [<xref rid="B251-marinedrugs-18-00570" ref-type="bibr">251</xref>] present the only evidence for Muricidae sp. extracts against respiratory cancer, indicating that they can inhibit A549 proliferation and regulate adaptive immunity in vitro, but further analysis is required to determine significance and identify which, if any, extracts are productive to pursue. The recent review by Ciavatta et al. [<xref rid="B66-marinedrugs-18-00570" ref-type="bibr">66</xref>] covers other potentially promising mollusc-derived anticancer agents, including terpenes, steroids, peptides, polyketides, and nitrogenous compounds, currently untested against respiratory cancers.</p><p>Depending on the specific mode of action, certain compounds can exhibit multiple related activities with multiple potential therapeutic benefits in the context of respiratory disease. For example, 6-bromoisatin has anticancer [<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>,<xref rid="B212-marinedrugs-18-00570" ref-type="bibr">212</xref>,<xref rid="B279-marinedrugs-18-00570" ref-type="bibr">279</xref>,<xref rid="B289-marinedrugs-18-00570" ref-type="bibr">289</xref>] as well as anti-inflammatory [<xref rid="B84-marinedrugs-18-00570" ref-type="bibr">84</xref>,<xref rid="B213-marinedrugs-18-00570" ref-type="bibr">213</xref>] and antibacterial activity [<xref rid="B149-marinedrugs-18-00570" ref-type="bibr">149</xref>]; helicidine has both anti-spasmodic and anti-inflammatory properties [<xref rid="B79-marinedrugs-18-00570" ref-type="bibr">79</xref>], while KF possesses antimicrobial as well as anticancer activity [<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>] (<xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f004">Figure 4</xref> and <xref ref-type="fig" rid="marinedrugs-18-00570-f005">Figure 5</xref>). This highlights the importance of comprehensive in vitro screening and structure-target identification, and suggests that the full range of activities are yet to be elucidated for many compounds included in this review.</p><table-wrap id="marinedrugs-18-00570-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t005_Table 5</object-id><label>Table 5</label><caption><p>Antimicrobial (antiviral, antibacterial, antifungal) activity of molluscan extracts and compounds tested in vitro.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mollusc Class<break/>Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Derivative Part</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specific Extract/<break/>Compound </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microbial or Cellular Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effective Concentrations *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Other Important Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bivalvia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mytilidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sperm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude perchloric acid extract (CE) and 3 isolated protamine-like (PL) proteins </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical and lab strains: <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>; human lymphocytes and red blood cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs 7.8&#8211;250 &#956;g/mL; MBCs (&#956;g/mL): CE: 15.7&#8211;125, PL-II 15.7&#8211;125, PL-III 62.5&#8211;250, PIV 62.5&#8211;250 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Digested and non-digested PL-proteins had same effect; low toxicity to lymphocytes (80&#8211;90% viability), no sig. hemolysis; effect re protein membrane binding, cytosolic intrusion and nucleotide leakage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B187-marinedrugs-18-00570" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph (hemocytes)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myticin C and 9 peptide fragments </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa, S. aureus, Micrococcus lysodeikticus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs &gt;64 &#956;M for <italic toggle="yes">P. aeruginosa</italic>; MIC 32 &#956;M of 3 peptide fragments for <italic toggle="yes">S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-marinedrugs-18-00570" ref-type="bibr">168</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph (hemocytes, plasma)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myticin A and B peptides </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. luteus, Bacillus megaterium, S. aureus</italic> (clinical strain)<italic toggle="yes">, Listeria monocytogenes</italic> (G+); <italic toggle="yes">P. aeruginosa</italic> (clinical strain)<italic toggle="yes">, Brucella suis</italic> (G&#8722;); Fungi: <italic toggle="yes">Fusarium oxysporum</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBCs (&#956;M): G+ 2.25- &gt;20 Myt A, 1- &gt;20 Myt B; G&#8722; &gt;20 Myt A and B; fungi &gt;20 Myt A, 5&#8211;10 Myt B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-marinedrugs-18-00570" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ostreidae </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cellular (c) and acellular (a) hemolymph fractions (0.2 &#956;m filtration) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human adenovirus (respiratory strain AdV-5) cultured in Vero and HEp-2 cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CC<sub>50</sub> 0.19&#8211;0.36 mg/mL; EC<sub>50</sub> 0.05&#8211;0.16 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Crassostrea rhizophorae</italic> cellular fraction showed best (64%) viral inhibition, particularly w post-infection treatment; virus preincubation w both fractions protected &gt;90% of cells indicating virucidal activity at non-cytotoxic concs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B196-marinedrugs-18-00570" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teredinidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gill (symbiotic <italic toggle="yes">Teredinibacter turnerae</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tartrolon E </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. aeruginosa</italic>, methicillin-sensitive and methicillin resistant <italic toggle="yes">S. aureus</italic> (MSSa, MRSa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs (mg/mL): 0.31 for <italic toggle="yes">P. aeruginosa</italic>, 0.08 for MSSa, 1.25 for MRSa </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-marinedrugs-18-00570" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Cephalopoda</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Octopodidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suckers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide (OctoPartenopin) (crude + 6 HPLC fractions + 5 synthetized fractions)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC80 (&#956;g/mL) 50&#8211;200 <italic toggle="yes">S. aureus</italic>, 50- &gt;300 <italic toggle="yes">P. aeruginosa</italic>; 80 &#956;M peptides inhibit and eradicate up to 60% biofilm formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Also antifungal activity; improved activity with synthetized peptides </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-marinedrugs-18-00570" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sepiidae &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria: <italic toggle="yes">K. pneumoniae, Bacillus cereus</italic> (G+), <italic toggle="yes">S. aureus, M. luteus</italic> (G&#8722;); Fungi: <italic toggle="yes">Aspergillus niger, Fusarium</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mg/mL (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. officinalis</italic> chitosan stronger activity than shrimp and crab chitosan; ZIs similar to gentamycine for G&#8722;, &gt; cyclohemimide for fungi</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-marinedrugs-18-00570" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptococcus pneumoniae, S. aureus</italic> (G+)<italic toggle="yes">, P. aeruginosa, K. pneumoniae</italic> (G&#8722;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC (&#956;g/mL): 60&#8211;100 (G&#8722;), 100 (G+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher MICs for phosphorylated chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-marinedrugs-18-00570" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salivary glands</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSG toxin (glycopeptide) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">K. pnemoniae, Streptococcus pyogenes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;50 &#956;M (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Little difference between 1&#8211;50 &#956;M concs; low toxicity to zebrafish embryo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B290-marinedrugs-18-00570" ref-type="bibr">290</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSG toxin (glycopeptide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">K. pnemoniae, S. aureus, P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25&#8211;100% (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Susceptibility: <italic toggle="yes">S. aureus</italic> &gt; <italic toggle="yes">K. pneumonia &gt; P. aeruginosa</italic>; ZIs comparable to Ciprofloxacin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B291-marinedrugs-18-00570" ref-type="bibr">291</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sepiidae, Octopodidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude CH<sub>3</sub>OH extracts </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical bacterial strains: <italic toggle="yes">P. aeruginosa, K. pnemoniae, S. aureus, S. pneumoniae, Streptococcus</italic> sp., <italic toggle="yes">Vibrio alginolyticus</italic>; Fungi: <italic toggle="yes">Pencillium italicum, Alternaria alternata</italic> (allergen), <italic toggle="yes">Fusarium equisetii</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC range 60&#8211;100 mg/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extract from <italic toggle="yes">S. kobiensis</italic> showed the best/broadest spectrum activity; no positive control or toxicity data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B185-marinedrugs-18-00570" ref-type="bibr">185</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Gastropoda</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Achatinidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mytimycin-AF (antimicrobial peptide) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, B. megaterium, K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC (&#956;g/mL) <italic toggle="yes">S. aureus</italic> 1.9, <italic toggle="yes">B. megaterium</italic> 15<italic toggle="yes">, K. pneumoniae</italic> 30 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Better activity than human AMP control for <italic toggle="yes">S. aureus</italic>; minimal hemolysis (max 3.9% at 329 &#956;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B292-marinedrugs-18-00570" ref-type="bibr">292</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Achatinidae, Helicidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude mucus and 4 size-separated fractions </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K. pneumoniae, P. aeruginosa</italic> (3 strains), <italic toggle="yes">S. aureus, S. pyogenes, Acinetobacter sp.</italic> (clinical), <italic toggle="yes">Serratia marcescens</italic> (clinical)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:3 crude mucus:PBS (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude <italic toggle="yes">H. aspera</italic> mucus inhibited <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. aeruginosa</italic>; <italic toggle="yes">A. fulica</italic> mucus inhibited <italic toggle="yes">S. aureus</italic>; other microorganisms unsusceptible</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-marinedrugs-18-00570" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Babyloniidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extracts &#8225; </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. aeruginosa, K. pneumoniae, S. aureus, S. pneumoniae</italic>; Fungi: <italic toggle="yes">A. flavus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extract (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol extract had highest antimicrobial activity; most effective against <italic toggle="yes">P. aeruginosa</italic>, least effective against <italic toggle="yes">S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-marinedrugs-18-00570" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clathurellidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatopancreas (symbiotic <italic toggle="yes">Streptomyces</italic> sp.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>3</sub>OH extract (lobophorin compounds) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Mycobacterium tuberculosis, P. aeruginosa, Burkholderia cepacia;</italic> CEM-TART cell line </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC<sub>90</sub>: 1.3&#8211;24 &#956;M for <italic toggle="yes">M. tuberculosis</italic>, &gt;100 for <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">B. cepacia</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong cytotoxicity at similar MIC concentrations (0.3&#8211;100 &#956;M) therefore not a suitable therapeutic candidate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-marinedrugs-18-00570" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conotoxin MVIIA and 9 analogues </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs: &gt;500 &#956;M MVIIA, 7&#8211;78 &#956;M analogues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVIIA considered inactive, different activity among analogues re. cyclic structure and side chain modification </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B293-marinedrugs-18-00570" ref-type="bibr">293</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cypraeidae <sup>&#8214;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Powder </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Micrococcus</italic> sp. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4&#8211;5% w/v shell powder in distilled water (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose-dependent antipyretic effect in vivo (not sig)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-marinedrugs-18-00570" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dorididae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sperm (also in egg masses)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8217;-deoxy-5&#8217;-methylthio-adenosine (MTA) and two natural analogues (xylo-MTA and xylo-A) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus, Corynebacterium diphtheriae;</italic> Vero and C8166 cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs: MTA 33 &#956;M, xylo-MTA 200 &#956;M, xylo-A 18 &#956;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs always higher than minimum non-toxic concentrations; xylo-A most toxic, xylo-MTA least toxic; no positive control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-marinedrugs-18-00570" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fissurellidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scutinin A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC: 30 &#956;g/mL scutinin A, 100 &#956;g/mL scutinin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-marinedrugs-18-00570" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicidae, Muricidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimentally purified Hc (&#946;c-HaH subunit + 8 FUs, RvH1 + 4 FUs) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, S. pyogenes, P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC: 6.5 &#956;M &#946;c-HaH; MIC not calculated for RvH1 (1.25&#8211;10 &#956;M range) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HaH more effective than RvH; native Hc more effective than subunits from both species; &#946;c-HaH <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">S. pyogenes</italic> 60 and 51% inhibition respectively, RvH1 35% inhibition, relative to control; limited activity against <italic toggle="yes">P. aeruginosa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-marinedrugs-18-00570" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Muricidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimentally purified Hc (RvH), glycosylated (RvH-c) and non-glycosylated (RvH-b) subunits </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory synctial virus (RSV), cultured in Hep-2 cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RvH-c 1 mg/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RvH-c effective against replication of RSV (71.4% inhibition at 1 mg/mL), no effect on other tested viruses (poliovirus, cocksackie virus); native RvH and RvH-b no antiviral activity; no cytotoxic effect at highest concs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B197-marinedrugs-18-00570" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egg masses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extracts (de, eth, CHCl<sub>3</sub>, CH<sub>3</sub>OH-H<sub>2</sub>O) <sup>#</sup> and isolated ty, tv, Tp, 6-b <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. aeruginosa</italic> (G&#8722;), <italic toggle="yes">S.aureus</italic> (G+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs (mg/mL): 0.0005 tv, 0.5&#8211;1.0 ty, 0.1&#8211;1.0 6-b, &gt;1 Tp, 1.0&#8211;10 CHCl<sub>3</sub>, 0.1 de, 10 eth, &gt;50 CH<sub>3</sub>OH-H<sub>2</sub>O </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipophilic extracts had better activity; tv bacteriostatic, ty bactericidal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-marinedrugs-18-00570" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimentally purified Hc (11 protein fractions) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113&#8211;598 &#956;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides 8, 9, 10 and 11 showed &gt;90% inhibition; <italic toggle="yes">S. aureus</italic> more susceptible; different proteins more/less active against different bacteria; longer protein chains more effective </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B294-marinedrugs-18-00570" ref-type="bibr">294</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extracts ** </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">K. pneumoniae, P. aeruginosa, S. pneumoniae, Citrobacter sp., B. cereus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs 0.05&#8211;0.12 mg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetone extract most effective; similar effectiveness against other (non-resp) pathogens </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B184-marinedrugs-18-00570" ref-type="bibr">184</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Olividae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acid-acetone peptide extract </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, P. aeruginosa, K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC (mg/mL): 2.5 <italic toggle="yes">S. aureus</italic>, 0.039 <italic toggle="yes">P. aeruginosa</italic>, 1.25 <italic toggle="yes">K. pneumoniae</italic>; MBC (mg/mL): 2.5 <italic toggle="yes">S. aureus</italic>, 1.25 <italic toggle="yes">P. aeruginosa</italic>, &gt;2.5 <italic toggle="yes">K. pneumoniae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein ZIs comparable to control antibiotics; ciprofloxacin and cefotaxime MICs reduced by &gt;100% w protein extract, metronidazole and erythromycin MICs increased; effects re changes in membrane porosity/permeability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-marinedrugs-18-00570" ref-type="bibr">179</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acid-acetone peptide extract </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC: 39.06 ug/mL (Gentamycin MIC 1.95 ug/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteriostatic; dose dependent reduction in virulence factors (pyoverdine, pyocyanin, protease)- peptide mix (69%) similar to gentamycin (72%) at 1/2 MIC; 50% reduction in biofilm formation at 39 ug/mL, 2.5 mg/mL required to degrade pre-formed biofilm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-marinedrugs-18-00570" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onchidiidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dolabellanin B2 (AMP)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, P. aeruginosa, K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs: 10&#8211;25 ug/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Structure-function characterization; better activity against G+; compound identified as one previously isolated from <italic toggle="yes">Dolabella auricularia</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B295-marinedrugs-18-00570" ref-type="bibr">295</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patellidae, Donacidae &#8224;&#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acid-acetone extract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, S. pneumoniae, K. pneumoniae, P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs 17&#8211;20 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZI&#8217;s similar to ciprofloxacin; <italic toggle="yes">Galeta paradoxa</italic> extract stronger antibacterial than <italic toggle="yes">Patella rustica</italic> extract, which showed good antifungal activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B296-marinedrugs-18-00570" ref-type="bibr">296</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body &#8225;&#8225;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 sialic acid-binding lectin recombinant proteins (rSgSABL-1, -2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus, Micrococcus luteus</italic>; <italic toggle="yes">Solen grandis</italic> (mollusc) hemocytes; <break/>mice (n = NA) immunised i.p. 2x w rSgSABL-1 (100 &#956;g/mL) or rSgSABL-2 (180 &#956;g/mL) in CFA <sup>&#8214;&#8214;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#956;g/mL (phagocytosis), 90 &#956;g/mL (microbe agglutination, and encapsulation); 100&#8211;180 &#956;g/mL (Ab production)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High binding affinity to <italic toggle="yes">S. aureus</italic> peptidoglycan (PAMP) (also LPS, &#946;-glucan); agglutination effect on <italic toggle="yes">M. luteus</italic>; enhanced phagocytosis and encapsulation ability (<italic toggle="yes">p &lt;</italic> 0.05); antisera Ab reactivity with rSgSABL-1 and -2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-marinedrugs-18-00570" ref-type="bibr">188</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plakobranchidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kahalalide F and 8 analogues </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria: <italic toggle="yes">P. aeruginosa,</italic> methicillin resistant <italic toggle="yes">S. aureus, M. tuberculosis</italic> (H37Rv), <italic toggle="yes">M. intracellulare</italic>; Fungi: <italic toggle="yes">Cryptococcus neoformans, A. fumigatus, Fusarium</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC 9.4&#8211;&gt;16 &#956;g/mL Kahalalide F analogues (<italic toggle="yes">M. tuberculosis</italic>); 30 &#956;M antifungal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;90% inhibition of <italic toggle="yes">M. tuberculosis</italic> and up to 100% fungicidal activity comparable to controls; no activity against <italic toggle="yes">P. aeruginosa</italic> or <italic toggle="yes">S. aureus</italic>; high test concs- cytotoxicity test concs lower than MICs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kahalalide F, analogues KZ1 and KZ2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus</italic> sp., <italic toggle="yes">Fusarium</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 mg KZ1 and KZ2 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analogue bioactivity profiles comparable to KF; antifungal activity comparable to ketonazole </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B257-marinedrugs-18-00570" ref-type="bibr">257</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strombidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extracts <sup>##</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. aureus, P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;100 &#956;g/mL H<sub>2</sub>O extract (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stronger activity against <italic toggle="yes">P. aeruginosa</italic> over <italic toggle="yes">S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B297-marinedrugs-18-00570" ref-type="bibr">297</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Truncatellidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body (symbiotic <italic toggle="yes">Streptomyces</italic> sp.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7,8-dideoxygriseorhodin C (DC) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methicillin-resistant <italic toggle="yes">S. aureus;</italic> MDCK and AA8 cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MICs (&#956;g/mL): 0.08&#8211;0.12 DC, 1.59&#8211;6.24 oxacillin; combination DC 0.01&#8211;0.02 DC and 0.02&#8211;0.298 Oxacillin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC stronger than oxacillin as single agents; reduction MICs w combination; no cytotoxicity (IC<sub>50</sub> 15.84 &#956;g/mL and &gt;49.5 &#956;g/mL for MDCK and AA8 cells, respectively) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-marinedrugs-18-00570" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veronicellidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concentrated crude mucus and 4 fractions (PUFA 39, 40, 49, 50) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles virus (Edmonston wild-type), cultured in Vero cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#8211;220 ng/mL mucus/fraction 39 inhibition of viral replication; 2% mucus/fraction 39 inhibition of CPE </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effect attributed to disruption of the virus&#8217; lipoprotein envelope; not cytotoxic to Vero cells (IC<sub>50</sub> 41 &#956;L crude, 92.6 &#956;L fraction 39)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-marinedrugs-18-00570" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude concentrated mucus and 3 fractions (PUFAs 39, 40, 49) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A (H1N1) virus, cultured in MDCK cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2% or 60&#8211;80 ng/mL crude mucus and fraction 39 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of viral replication and &gt;80% decrease in viral load in infected cells w crude mucus and frac 39; not cytotoxic (although IC<sub>50</sub> NA); may interfere w binding of virus to host cell receptor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-marinedrugs-18-00570" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 families <sup>&#167;&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egg masses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude homogenised egg material and extracts &#8224;&#8224;&#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa, S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;10 mg/mL CHCl<sub>3</sub> and CH<sub>3</sub>OH-H<sub>2</sub>O extracts (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. aeruginosa</italic> inhibited by 79% and 72% of tested egg masses, respectively; no dif in activity between tough and gelatinous egg masses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-marinedrugs-18-00570" ref-type="bibr">65</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 families ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHCl<sub>3</sub> extracts </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria: <italic toggle="yes">S. aureus, P. aeruginosa, K. pneumoniae;</italic> Fungi: <italic toggle="yes">A. fumigatus</italic>; chicken red blood cells and brine shrimp </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extracts (preliminary)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive antimicrobial activity; best result w extract of <italic toggle="yes">Conus betulinus</italic>; low toxicity to brine shrimp (LC<sub>50</sub> 12&#8211;42 &#956;g/mL); 10/25 sp. extracts showed hemolytic activity; no antibiotic controls</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B298-marinedrugs-18-00570" ref-type="bibr">298</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 families &#8225;&#8225;&#8225;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body, gill and mantle (GM), digestive gland (DG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 40 and 80% SPE fractions of acidic (HCl) extract in sterile water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. luteus</italic> and <italic toggle="yes">B. megaterium</italic>; Vero cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Most effective MICs (&#956;g/mL): 43 80% DG extract both bacteria, 63 80% DG extract <italic toggle="yes">M. luteus</italic>, 40 80% G+M extract <italic toggle="yes">B. megaterium,</italic> 2560 <italic toggle="yes">M. luteus</italic>) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 and 80% fractions from all sp. effective; <italic toggle="yes">Crassostrea edule</italic> extracts showed best activity (also against non resp viruses); &lt;50% cytotoxicity; positive controls (lysozyme and polymyxine B) more effective than extracts</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-marinedrugs-18-00570" ref-type="bibr">45</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Hc: hemocyanin; w: with; TB: tuberculosis; EC<sub>50</sub>: 50% effective concentration; IC<sub>50</sub>: concentration causing 50% growth inhibition; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; PUFA: polyunsaturated fatty acid; CPE: cytopathic effects; ZI: zone of inhibition; PBS: phosphate buffer solution; NA: not available; AMP: antimicrobial peptide. * Description of methods and test concentrations provided in supplementary tables; preliminary data derived from agar disc diffusion methods reporting ZIs. &#8224; <italic toggle="yes">Sepiella inermis</italic> originally listed as <italic toggle="yes">Sepia inermis</italic> (Ferussac &amp; d&#8217;Orbigny 1835); <italic toggle="yes">Sepioteuthis lessoniana</italic> originally listed as <italic toggle="yes">Sepia lessoniana</italic> (d&#8217;Orbigny, 1826); <italic toggle="yes">Amphioctopus aegina</italic> originally listed as <italic toggle="yes">Octopus aegina</italic> (Gray 1849) and <italic toggle="yes">O. dollfusi</italic> (Robson 1928); <italic toggle="yes">A. fangsiao.</italic> originally listed as <italic toggle="yes">O. areolatus</italic> (in Ferussac &amp; d&#8217;Orbigny 1839&#8211;1841). &#8225; Methanol, ethanol, chloroform, and acetone solvents. <sup>&#8214;</sup>
<italic toggle="yes">Monetaria moneta</italic> originally listed as <italic toggle="yes">Cypraea moneta</italic> (Linnaeus 1758). <sup>#</sup> Extracts using chloroform (CHCl<sub>3</sub>), methanol-water (CH<sub>3</sub>OH-H<sub>2</sub>O), diethyl ether (de) and ethanol (eth) solvents. <sup>&#167;</sup> Tyrindoleninone (ty), tyriverdin (tv), Tyrian purple (Tp) and 6-bromoisatin (6-b). ** Ethyl acetate, acetone, dichloromethane and methanol solvents and cold-steeped; <italic toggle="yes">Drupella margariticola</italic> originally listed as <italic toggle="yes">Drupa margariticola</italic> (Broderip, 1833). &#8224;&#8224; Bivalvia. &#8225;&#8225; Described as body extract in text although lectins are commonly found in hemolymph. <sup>&#8214;&#8214;</sup> Antisera used in Western Blot analysis; rSgSABL-1 and -2 and antisera used in PAMP assay; rSgSABL-1 and -2 used in phagocytosis, agglutination and encapsulation assays. <sup>##</sup> Chloroform, methanol, hexane, acetone and water solvents. <sup>&#167;&#167;</sup> Major represented families include Muricidae (7 sp.), Aplysiidae (6 sp.), Amphibolidae (2 sp.) Planorbidae (2 sp.), Pleurobranchidae (2 sp.) and Doridae (2 sp.) representing classes Bivalvia and Gastropoda. &#8224;&#8224;&#8224; Chloroform and methanol/water extracts. *** Major represented families include Strombidae (4 sp.), Conidae (3 sp.), Octopodidae (2 sp.), Sepiidae (2 sp.), Veneridae (2 sp.) and Aplysiidae (2p.) representing classes Bivalvia and Gastropoda. &#8225;&#8225;&#8225; Cardiidae, Veneridae, Ostreidae, Calyptraeidae and Buccinidae representing classes Bivalvia and Gastropoda.</p></fn></table-wrap-foot></table-wrap><table-wrap id="marinedrugs-18-00570-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t006_Table 6</object-id><label>Table 6</label><caption><p>Molluscan extracts and compounds showing anticancer and immune modulatory activity in vitro.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mollusc Class<break/>Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Derivative Part</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specific Extract/<break/>Compound </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microbial or Cellular Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effective Concentrations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Other Important Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bivalvia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mactridae <italic toggle="yes">*</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spisulosine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW1573 (human alveolar carcinoma) cell line (and 4 other human tumor cell lines)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub>: 1.3 &#956;M </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spisulosine most effective of tested compounds- &gt;positive controls Cisplatin (3.0 &#956;M) and Etoposide (15.0 &#956;M); GI<sub>50&#8242;</sub>s 0.7&#8211;2.6 &#956;M for range of cell lines- SW1573 intermediate sensitivity; selective CK1&#949; inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B299-marinedrugs-18-00570" ref-type="bibr">299</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ostreidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph (hemocytes)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor necrosis factor (<italic toggle="yes">Cg</italic>TNF-2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 (human alveolar carcinoma)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 ng/mL recombinant <italic toggle="yes">Cg</italic>TNF-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Cg</italic>TNF-2 expression upregulated in response to bacterial PAMPs (incl. <italic toggle="yes">Staphylococcus aureus</italic>), and serum lysosome activity, NO content and antibacterial activity (non-resp) increased (<italic toggle="yes">p &lt;</italic> 0.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B247-marinedrugs-18-00570" ref-type="bibr">247</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veneridae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> fractionated peptide (&#8216;Mere15&#8242;) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and range of other non-respiratory cancer cell lines (breast, cervical, colorectal, pancreatic, liver); benign cells NIH 3T3<break/>and MCF-10A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 31.8 &#956;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 most susceptible among cancer types, therefore used in subsequent assays and animal model; not cytotoxic to benign cells (IC<sub>50</sub> &gt; 120 &#956;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B252-marinedrugs-18-00570" ref-type="bibr">252</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Cephalopoda</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loliginidae &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Digestive gland/liver</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid extract </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and Vero cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70% growth inhibition at 960 &#956;L/mL, 55% at 480 &#956;L/mL; CC<sub>50</sub> 260 &#956;g/mL for A549 (NA for Vero) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Better growth inhibition of A549 (max 70%) compared to Vero (max 7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B249-marinedrugs-18-00570" ref-type="bibr">249</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastropoda</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ampullariidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;Polysaccharide extract&#8221; &#8225; </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#8211;200 &#956;g/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24-h reduction in tumor growth: 31% at 20 mg/mL, 43% at 50 mg/mL, 46%, at 100mg/mL, 57% at 200 &#956;g/mL; 84% antioxidant at 5 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B250-marinedrugs-18-00570" ref-type="bibr">250</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aplysiidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dolastatin-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human SCLC cell lines (NCI-H69, NCI-H82, NCI-H446, NCI-H510)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> range 0.03&#8211;0.184 nM<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;50% G<sub>2</sub>/M phase arrest, bcl-2 phosphorylation; pro-apoptotic mechanism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B254-marinedrugs-18-00570" ref-type="bibr">254</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chilondontidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude CHCl<sub>3</sub> extract (1.25%) in Hanks Balanced Solution </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8211;20 &#956;g/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#8211;40% cytotoxicity at 5&#8211;20 &#956;g/mL; apoptosis at 10 &#956;g/mL, not increasing w higher doses or exposure time; wound area reduced by 28.3% at 5 &#956;g/mL; all results <italic toggle="yes">p &lt;</italic> 0.05; inhibitory effect on matrix metalloproteinase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B248-marinedrugs-18-00570" ref-type="bibr">248</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicidine formula (glycoproteins) (purified NaCl extract)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tracheas dissected from Dunkin-Hartley guinea pigs; epithelium (E+) and epithelium-free (E&#8722;) strips prepared </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005&#8211;0.5 mg/mL (min-max effective) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose dependent reduction of contraction by 35% in E+ and 25% in E&#8722;; PGE<sub>2</sub> higher post treatment (<italic toggle="yes">p &lt;</italic> 0.01); related to COX inhibition (<italic toggle="yes">p &lt;</italic> 0.01)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-marinedrugs-18-00570" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimentally purified Hc (HpH) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza (H3N2) immunisation model using Balb/c mice (n = 5&#8211;8/group) immunised w 50 &#956;g influenza peptide (IP), IP w CFA, IP w alum, or IP w HpH (16, 40, 100 &#956;g) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#956;g HpH; 50 &#956;g antigen + 100 &#956;g HpH </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ex vivo spleenocytes of mice treated w IP+100 &#956;g HpH showed stronger cytotoxicity against infected cells in vitro compared to all other groups (<italic toggle="yes">p &lt;</italic> 0.0005)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plakobranchid-ae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kahalalide F (KF) and 8 analogues </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and NCI-H322M (human bronchioalveolar carcinoma) and Vero cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GI<sub>50</sub>: 0.131&#8211;13.7 &#956;M (compound-tumor specific e.g., for A549 analogues 8 and 16 IC<sub>50</sub> 0.166 and 13.189 &#956;M, 0.165 and 0.167 &#181;M for NCI-H322M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Some compounds showed higher potency than Paclitaxel; similar anticancer activity among other tested cancer cell lines; no cytotoxicity at 4.76 &#956;g/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B253-marinedrugs-18-00570" ref-type="bibr">253</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body<break/>(originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KF (synthetic) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4x human NSCLC cell lines (A549, SW1573, NCI-H292 and NCI-H460)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> 0.1&#8211;7.0 &#956;M </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and H292 particularly sensitive, H460 least sensitive; inhibition of ErbB andPI3K-Akt signaling at IC<sub>50</sub> concs and necrosis-like cell death </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B256-marinedrugs-18-00570" ref-type="bibr">256</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body<break/>(originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM02734 (elisidepsin trifluoroacetate; synthetic KF3 derivative) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOP62 (human lung adenocarcinoma), A549 (human alveolar carcinoma), DV90 (human metastatic pleural carcinoma) cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elisidepsin IC<sub>50</sub> ~4 &#956;M for HOP62, &lt;0.25 &#956;M for A549, ~0.3 &#956;M for DV90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Downregulation of ErbB3, Akt and MAPK pathways in all cell lines; synergistic/additive effects w other cisplatin, paclitaxel and gemcitabine in all cell lines- combination therapy to improve clinical efficiency</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B258-marinedrugs-18-00570" ref-type="bibr">258</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body<break/>(originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM02734 (elisidepsin trifluoroacetate; synthetic KF3 derivative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 x human NSCLC cell lines (H322, A549, H661, H1299, H1975, H358, H460, H1650)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> 0.3 &#956;M to &gt;5 &#956;M (0.58 &#956;M for A549)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All cell lines sensitive to PM02734, only 2 cell lines sensitive to erlotinib; positive correlation between ErbB expression and sensitivity to PM02734; erlotinib inhibited EGFR, AKT and ERK1/2 phosphorylation whereas PM02734 strongly inhibited phosphorylation of ErbB3 and AKT and, to a lower extent, EGFR and ERK1/2 hence the efficacy of combined treatment in vivo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B263-marinedrugs-18-00570" ref-type="bibr">263</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus (and body)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KF, analogues KZ1 and KZ2, crude CHCl<sub>3</sub>-CH<sub>3</sub>OH extract </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 (and other non-respiratory cancer) cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 IC<sub>50</sub>: 1 &#956;M KZ1, 3 &#956;M KZ2, 1 &#956;M </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analogue bioactivity comparable to KF; low IC<sub>50</sub> values for lung cancer relative to other tested cancer cell lines; mucus extracts stronger</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B257-marinedrugs-18-00570" ref-type="bibr">257</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 families <sup>&#8214;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% C<sub>2</sub>H<sub>5</sub>OH extract </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cell line; mouse spleenocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25&#8211;1 mg/mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73&#8211;96% tumor growth inhibition at 1 mg/mL, 63&#8211;89% at 0.25 mg/mL; molluscan extracts showed stronger anti-tumor properties than other invertebrate extracts and had strong promotion activity on T and B lymphocytes (+25% at 1 &#956;g/mL); low toxicity (not quantified) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B251-marinedrugs-18-00570" ref-type="bibr">251</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: w: with; NA: not available; CC<sub>50</sub>: 50% cytotoxic concentration; EC<sub>50</sub>: 50% effective concentration; IC<sub>50</sub>/GI<sub>50</sub>: concentration causing 50% growth inhibition; CFA: Complete Freund&#8217;s Adjuvant; SCLC: small-cell lung cancer; NSCLC: non-small-cell lung cancer; PAMPs: pathogen associated microbial patterns. * <italic toggle="yes">Mactromeris polynyma</italic> originally listed as <italic toggle="yes">Spisula polynyma</italic> (Stimpson, 1860). &#8224; <italic toggle="yes">Uroteuthis</italic> (<italic toggle="yes">Photololigo</italic>) <italic toggle="yes">duvaucelii</italic> originally listed as <italic toggle="yes">Loligo duvaucelii</italic> (in Ferussac &amp; d&#8217;Orbigny 1835). &#8225; Methanol (CH<sub>3</sub>OH), ethanol (C<sub>2</sub>H<sub>5</sub>OH), acetone (C<sub>3</sub>H<sub>6</sub>O) and ether solvents. <sup>&#8214;</sup> Acanthochitonidae, Arcidae, Veneridae, Muricidae (2 sp.), Nacellidae, Naticidae representing classes Bivalvia, Gastropoda and Polyplacophora; <italic toggle="yes">Glossaulax didyma ampla</italic> originally listed as <italic toggle="yes">Neverita ampla</italic> (Phillipi 1849), <italic toggle="yes">Reishia clavigera</italic> originally listed as <italic toggle="yes">Thais clavigera</italic> (Kuster 1860).</p></fn></table-wrap-foot></table-wrap><table-wrap id="marinedrugs-18-00570-t007" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t007_Table 7</object-id><label>Table 7</label><caption><p>In vivo animal models of respiratory disease using molluscan extracts and compounds showing various bioactivities.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mollusc Class<break/>Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Derivative Part</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specific Extract/<break/>Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Design *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effective Concentrations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bivalvia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mytilidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid extract (&#8216;Lyprinol&#8217;) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine model of allergic airway disease using Balb/c mice (n = 3&#8211;8/group) fed a low-fat background diet treated w 200 uL Lyprinol (or fish oil control) p.o daily, 14 d prior to challenge w i.n. OVA (10 mg in 0.9% saline) (or PBS alone) on days 12&#8211;15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyprinol group had lower eosinophil counts and fewer mucus-secreting cells (<italic toggle="yes">p &lt;</italic> 0.05), other inflammatory cells lower (not sig); no sig dif. in Ab levels between fish oil and Lyprinol; lower IL-13, higher IL-4 and IFN-y in Lyprinol group (<italic toggle="yes">p &lt;</italic> 0.05); both fish oil and Lyprinol suppressed airway resistance (<italic toggle="yes">p &lt;</italic> 0.05); Lyprinol efficacy suggested re. synergistic effects between multiple nutritional components/PUFA profile</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 &#956;L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B208-marinedrugs-18-00570" ref-type="bibr">208</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pectinidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protease extracted polysaccaride heparin sulfate analog (HS) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung metastasis model using mice (n = 9) treated w 8 mg/kg HS i.v. (or mammalian heparin or chondroitin controls) 10 min before challenge w i.v. Lewis lung carcinoma cells; separate model of P-selectin-mediated tumor cell-platelet association using labelled LLC cells w or w/out pre-treatment w 200 &#956;g HS &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molluscan HS inhibited lung metastasis (10 foci/lung control vs. 1 foci/lung HS; <italic toggle="yes">p &lt;</italic> 0.05) w markedly smaller tumor size, and reduced heparinase activity (<italic toggle="yes">p &lt;</italic> 0.05); reduced tumor&#8211;platelet complex to 30% (control 70%); similar effect to mammalian heparin at lower molar concentration; blocks both P-selectin-mediated interactions and heparinase activity blunting metastasis and inflammation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 mg/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B274-marinedrugs-18-00570" ref-type="bibr">274</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body &#8225;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 sialic acid-binding lectin recombinant proteins (rSgSABL-1, -2) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-specific pathogen immunisation model using mice (n = NA) immunised i.p. 2x w rSgSABL-1 (100 &#956;g/mL) or rSgSABL-2 (180 &#956;g/mL) in CFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antisera antibodies reactive with rSgSABL-1 and -2 in Western Blot Analysis; strong <italic toggle="yes">Staphylococcus aureus</italic> peptidoglycan (PAMP) binding affinity (<italic toggle="yes">p &lt;</italic> 0.05 compared to PBS and pre-serum)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100&#8211;180 &#956;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-marinedrugs-18-00570" ref-type="bibr">188</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veneridae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> fractionated peptide (&#8216;Mere15&#8242;) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human lung cancer (A549) xenograft model using Balb/c mice (n = 6/group) immunised s.c. w Mere15 12.5, 25.0 or 50.0 mg/kg (or cyclophosphamide [CTX] 50 mg/kg or normal saline) each day for 10 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mere15 at 25 and 50 mg/kg doses displayed 51% and 69% growth inhibition (<italic toggle="yes">p &lt;</italic> 0.01), respectively; comparable to (though not sig dif than) CTX causing 53% inhibition; A549 most susceptible among cancer types in vitro therefore used in subsequent assays and animal model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25&#8211;50 mg/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B252-marinedrugs-18-00570" ref-type="bibr">252</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Gastropoda</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aplysiidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dolastatin-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human small cell lung cancer (SCLC) (NCI-H446) xenograft model using CB-17 SCID mice (n = 8&#8211;10/group) treated w 450 &#956;g/kg dolastatin 10 i.v. 26 and 36 d (or 7 and 17 d) after tumor inoculation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatments at 7 and 17 d completely inhibited tumor formation and increased survival (median 59 d control, &gt;214 d treatment); treatments at 26 and 36 d (after tumor formation) caused tumor shrinkage (mass 1635 mg control, 44 mg treatment), growth delay, and increased survival (median 42 control, 91 treatment); pro-apoptotic mechanism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">450 &#956;g/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B254-marinedrugs-18-00570" ref-type="bibr">254</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZT-1027, (dolastatin 10 derivative) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human LX-1 lung carcinoma xenograft model using Balb/c mice treated w 0.5, 1 and 2 mg/kg TZT-1027 (and Cisplatin- 5 and 10 mg/kg) administered i.v. after tumor established at 7 d, or both 7 and 14 d <sup>&#8214;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;2 treatments caused tumor regression of 84&#8211;98% at 1 mg/kg, 99% at 2 mg/kg (&gt; cisplatin: 49&#8211;52% at 5 mg/kg, 83% at 10 mg/kg); greater regression of lung cancer compared to breast cancer; 10% and 80% de-polymerisation of microtubule proteins 10% at 1.0 &#956;M, 80% at 10 &#956;M </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;2 mg/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B255-marinedrugs-18-00570" ref-type="bibr">255</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limacidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aqueous Limax extract in MEM </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COPD model using C57BL/6J mice (n = 8/group) treated w A) normal air + 2.18 g/kg extract; B) cigarette smoke (CS) + purified water; C) CS + 2.18 g/kg extract; CS = 9 cigarettes/h, 4 h per d, 6 d per wk in whole body exposure chamber for 90 d; extract given i.g. 0.5 h before daily CS exposure; cytotoxicity assay 0.01 &#956;g/mL&#8211;10 mg/mL extract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CS-exposed Limax-treated mice improved pulmonary function compared to untreated mice (<italic toggle="yes">p &lt;</italic> 0.05); less visual symptoms (e.g., weakness, wheezing), reduced lung damage, hyperplasia, inflammation, alveolar intercept and airway thickness (<italic toggle="yes">p &lt;</italic> 0.01); reduced BALF inflammatory cell count (<italic toggle="yes">p &lt;</italic> 0.01), inflammatory cytokines (<italic toggle="yes">p</italic> = 0.01&#8211;0.05) and Muc5AC secretion/expression (<italic toggle="yes">p &lt;</italic> 0.01); suppression of inflammatory signaling cascades (<italic toggle="yes">p &lt;</italic> 0.05); no sig cytotoxicity at effective doses; PPAR-&#947; enhancement and P38 MAPK pathway suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18 g/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-marinedrugs-18-00570" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limax lyophilized powder H<sub>2</sub>O suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allergic asthma model using guinea pigs (n = 15/group); sensitization using AlOH<sub>2</sub> and egg albumin, treated w Limax (189, 63, 21 mg/kg/d) (or Aminophylline 80 mg/kg/d control); inhalation challenge after 7 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced asthma onset time, mortality, inflammatory markers (BALF/peripheral blood leukocyte count, eosinophil infiltration, IL-2 and IL-4) (<italic toggle="yes">p &lt;</italic> 0.05); 63 mg/kg more effective than Aminophylline at reducing onset time (<italic toggle="yes">p &lt;</italic> 0.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-marinedrugs-18-00570" ref-type="bibr">140</xref>] <sup>&#182;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limax powder in H<sub>2</sub>O </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lewis lung carcinoma model using mice (n = 10/group); treatments 800&#8211;2500 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitory effect on tumor growth (47% inhibition at 800 mg/kg) and prolonged survival (<italic toggle="yes">p &lt;</italic> 0.01)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">800 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-marinedrugs-18-00570" ref-type="bibr">111</xref>] <sup>#</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Muricidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypobranchial gland (HBG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude CHCl<sub>3</sub>-CH<sub>3</sub>OH extracts, 6-bromoisatin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute lung injury/inflammation model using C57Black/6 mice (n = 5&#8211;6/group) treated w HBG extract (0.5 or 0.1 mg/g), or 6-bromoisatin (0.05 or 0.1 mg/g) in 100 &#956;L grape seed carrier oil (or PBS/carrier controls) administered p.o. 48 h, 24 h and 1 h prior to challenge w i.n. LPS (<italic toggle="yes">E. coli</italic>-derived) (1.25 mg/kg in 50 &#956;L PBS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower BALF total cells, neutrophils, TFN-&#945;, IL-1&#946;, and total protein in all treatments (<italic toggle="yes">p &lt;</italic> 0.0001); 6-bromoisatin generally stronger effect (and lower concs used) but no sig difference between treatments; all doses of each compound significantly minimised all indicators of acute inflammatory damage to the lungs (<italic toggle="yes">p &lt;</italic> 0.0001); positive correlation between histopathological scores and inflammatory markers (particularly TNF-&#945;, IL-1&#946; and neutrophils) in BALF (R<sup>2</sup> 0.53&#8211;0.77, <italic toggle="yes">p &lt;</italic> 0.0001)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5&#8211;0.1 mg/g HBG extract; 0.05&#8211;0.1 mg/g 6-bromoisatin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-marinedrugs-18-00570" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Muricidae **, Helicidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemolymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimentally purified Hc (RvH or HpH) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon cancer (C-26) model measuring lung metastasis in Balb/c mice (n = 20/group) sensitised i.p. w 200 &#956;g RvH or HpH 2 wks before tumor inoculation and 100 &#956;g weekly i.t.t. after solid tumor formation (sensitised) or 100 &#956;g weekly i.t.t. only (non-sensitised); controls: PBS+challenge, RvH/HpH only no challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower surface lung metastases count in sens RvH, sens HpH and non-sens HpH groups; no sig dif. in cytokine profiles between groups; &gt;anti-C-26 antibodies (<italic toggle="yes">p &lt;</italic> 0.05); higher % survival in sens groups; &gt;body weight in unsens groups (<italic toggle="yes">p =</italic> 0.001-0.05); reduced C-26 tumor size (<italic toggle="yes">p &lt;</italic> 0.01) although all developed small tumors; HpH/RvH control survival NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#956;g (w/w-out 200 &#956;g dose pre-tumor formation) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-marinedrugs-18-00570" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plakobranchid-ae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus (originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM02734 (Elisidepsin- synthetic KF3 derivative) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC (A549) model using NUR-NU-F-M mice (n = 5&#8211;7/group) treated w PM02734 (0.1 mg/kg &#215; 3/wk for 2 wk i.v.), Erlotinib (50 mg/kg &#215; 5/wk for 2 wks p.o.), combination (PM02734 i.v. 0.1 mg/kg &#215; 3/wk for 2 wks i.v + Erlotinib p.o. 50 mg/kg &#215; 5/wk for 2 wks p.o.), or no treatment; in vitro component used PM02734 0&#8211;10 uM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination treatment enhanced survival (&gt;150 d) compared to PM02734 (54 d), Erlotinib (39) and control (23) (<italic toggle="yes">p</italic> = 0.0003&#8211;0.002); Erlotinib inhibited EGFR, AKT and ERK1/2 phosphorylation in vitro whereas PM02734 inhibited phosphorylation of ErbB3 and AKT and, to a lower extent, EGFR and ERK1/2 hence the efficacy of combined treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM02734 0.1 mg/kg w or w/out 50 mg/kg Erlotinib </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B263-marinedrugs-18-00570" ref-type="bibr">263</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Ab: antibody; w: with; PBS: phosphate buffer solution; CFA: Complete Freund&#8217;s Adjuvant; IFA: Incomplete Freund&#8217;s Adjuvant; OVA: ovalbumin; BALF: bronchoalveolar lavage fluid; LPS: lipopolysaccharide; PUFA: polyunsaturated fatty acid; PAMP: pathogen associated molecular pattern; MEM: Modified Eagles Medium; PAMP: pathogen associated microbial pattern. * Administration routes: i.p.- intraperitoneal, i.n.- intranasal, s.c.- subcutaneous, i.v.- intravenous, p.o.- per oral, i.t.t.- intratumoral, i.g.- intragastric. &#8224; Also included thioglycolate-induced peritoneal inflammation model and leukocyte rolling models. &#8225; Described as body extract in text although lectins are commonly found in hemolymph. <sup>&#8214;</sup> Also included a similar breast cancer model. <sup>&#182;</sup> Published in Chinese, translated by L. Liu, abstract available in English. <sup>#</sup> Published in Chinese, translated by L. Liu, abstract available in English. ** <italic toggle="yes">Rapana venosa</italic> originally listed as <italic toggle="yes">R. thomasiana</italic> (Crosse 1861).</p></fn></table-wrap-foot></table-wrap><table-wrap id="marinedrugs-18-00570-t008" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-18-00570-t008_Table 8</object-id><label>Table 8</label><caption><p>Human clinical trials using molluscan extracts and compounds related to the treatment of respiratory disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mollusc Class<break/>Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Derivative Part</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specific Extract/<break/>Compound </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type and Design *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effective Concentrations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Gastropoda</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Helicidine </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double-bind, placebo-controlled, parallel-group clinical trial involving 30 COPD patients w history of chronic bronchitis and stabilised nocturnal cough (&gt;20 cough episodes/night) treated w 2x 15-mL doses of 10% helicidine syrup (or placebo syrup) p.o. 3x daily for 3 d over 5-d observation period</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Frequency of cough episodes/night reduced: 4.7&#8211;5.1 pre-treatment, 2.7&#8211;4.9 placebo, 1.3 helicidine group (<italic toggle="yes">p &lt;</italic> 0.05); duration of cough period (during sleep and awakening) also reduced (<italic toggle="yes">p &lt;</italic> 0.05); no sig difference between subjective endpoints (Spiegel questionnaire, CGI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15-mL 10% </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-marinedrugs-18-00570" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plakobranchidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body (originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kahalalide F (KF) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trial and pharmacokinetic study involving 38 cancer patients (13 w lung cancer) administered i.v. 50 &#956;g/mL kahalalide F weekly starting at 266 &#956;g/m<sup>2</sup> increasing between 25&#8211;100% over 21&#8211;109 cycles </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor shrinkage by 25&#8211;50% or stable disease in lung cancer patients; mild-moderate side effects w severe blood transaminase activity being the dose-limiting factor (3 cases); 650 &#956;g/m<sup>2</sup> recommended for future studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">650 &#956;g/m<sup>2</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B260-marinedrugs-18-00570" ref-type="bibr">260</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body (originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KF </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-randomised, multi-centre phase II clinical trial of KF as a second line therapy in 31 patients w advanced non-small cell lung cancer (NSCLC) administered i.v. 650 &#956;g/m<sup>2</sup> for 1 h/wk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One partial response observed; stable disease reported in 8 patients; majority of clinical benefit seen in patients with squamous cell carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">650 &#956;g/m<sup>2</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B261-marinedrugs-18-00570" ref-type="bibr">261</xref>,<xref rid="B262-marinedrugs-18-00570" ref-type="bibr">262</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body (originally)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM02734 (Elisidepsin- synthetic KF3 derivative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1 clinical trial and pharmacokinetic study involving 42 cancer patients (16 w lung cancer) administered i.v. 0.5 mg/m<sup>2</sup> escalated at 100% increments (depending on grade of toxicity; median 2 cycles/patient, 3.2 mg/wk)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease stabilization in 12 patients (none w lung cancer), 1 patient (with metastatic esophageal adenocarcinoma) complete response; mild-moderate grade toxicities in ~17% of patients, grade 3 toxicities (hematologic, biochemical [transaminase]) in ~15% of patients lasting 7&#8211;14 d; necrosis-like cell-death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max tolerable dose: 6.8 mg/m<sup>2</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B259-marinedrugs-18-00570" ref-type="bibr">259</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bivalvia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mytilidae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid extract (&#8216;Lyprinol&#8217;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double blind, randomised placebo-controlled parallel-group clinical trial involving 23 atopic asthma (mild-mod) patients (and 23 healthy subjects) treated w 2x 150 mg Lyprinol (or olive oil) capsules p.o. 2x daily for 8 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean daytime wheeze and exhaled H<sub>2</sub>O<sub>2</sub> sig reduced and morning PEF sig higher w Lyprinol treatment (<italic toggle="yes">p &lt;</italic> 0.05); no differences in night awakenings and use of short-acting B2 agonist meds; inhibition of 5&#8217;-lipoxygenase and cyclo-oxygenase pathways responsible for production of eicosanoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 mg Lyprinol (50 mg extract in 100 mg olive oil)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-marinedrugs-18-00570" ref-type="bibr">210</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid extract (&#8216;Lyprinol&#8217;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double blind, randomised placebo-controlled clinical trial using 73 (71 completed) children aged 6&#8211;13yrs treated w 2x 150 mg Lyprinol (or olive oil) capsules p.o. 2x daily for 7 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction in Fluticasone use (&lt; 57.8 &#956;g/d vs. 42.8 &#956;g/d; <italic toggle="yes">p</italic> = 0.27), rescue &#946;-agonist use (42.6% vs. 53.8%; <italic toggle="yes">p</italic> = 0.67); fewer asthma exacerbations (annualised rate of exacerbation 0.5 Lyprinol vs. 0.86 control); higher % reporting little/no trouble w their asthma (97 vs. 76%; <italic toggle="yes">p</italic> = 0.057); many other clinically important though non-significant improvements </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 mg Lyprinol (50 mg extract in 100 mg olive oil)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B209-marinedrugs-18-00570" ref-type="bibr">209</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid extract PCSO-524 (&#8216;Lyprinol/OmegaXL&#8217;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double blind, randomised placebo-controlled clinical trial involving 20 patients w asthma and hyperpnea-induced bronchoconstriction treated w 8x 150 mg Lyprinol capsules p.o. daily for 8 weeks, followed by 2 weeks washout phase (usual diet) followed by 3-week special PCSO-524 diet phase (or usual diet control)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After the final phase, Lyprinol treatment and specific diet caused reduction in bronchodilator use and increase in mean morning and evening PEF (<italic toggle="yes">p &lt;</italic> 0.05); no sif dif. in asthma symptom scores or FEV<sub>1</sub>; lower expired breath NO and urinary markers (<italic toggle="yes">p &lt;</italic> 0.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 mg Lyprinol (50 mg extract in 100 mg olive oil)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-marinedrugs-18-00570" ref-type="bibr">207</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Ab: antibody; Hc: hemocyanin; w: with; FEV<sub>1</sub>: forced expiratory volume; PEF: peak expiratory flow; COPD: chronic obstructive pulmonary disease; KLH: keyhole limpet hemocyanin. * Administration routes: s.c.- subcutaneous, i.v.- intravenous, i.m.- intramuscular, p.o.- per oral.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec5-marinedrugs-18-00570"><title>5. Molluscan Hemocyanins as Therapeutic Adjuvants and Model Antigens</title><p>When inoculated into mammals, molluscan Hcs have remarkable immunogenic effects: they generate a strong cellular reaction, promote high antibody levels and Th<sub>1</sub>/Th<sub>2</sub> cytokine release, and prime antitumor CD8<sup>+</sup> and CD4<sup>+</sup> T cells [<xref rid="B272-marinedrugs-18-00570" ref-type="bibr">272</xref>] (<xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>). Because of these versatile properties along with their large size (3.3&#8211;13.5 MDa), Hcs are regularly used as vaccine adjuvants and hapten carriers (subunit conjugates) [<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>]. As biomolecules, they are also considered safer than synthetic adjuvants (e.g., aluminium derivatives) [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>]. Keyhole limpet hemocyanin (KLH) from the marine gastropod <italic toggle="yes">Megathura crenulata</italic> (Fissurellidae) is the most extensively used Hc, and is commercially available to biomedical researchers for vaccine development and immunological studies [<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Tables S3 and S4</xref>). KLH has also been prescribed as an adjuvant in superficial bladder carcinoma therapy for over 30 years, and has shown potential in the treatment of other epithelial-derived adenocarcinomas, including of the lungs and respiratory tract [<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>].</p><p>There is ongoing interest in the inclusion of molluscan Hcs (mostly KLH) in vaccine preparations targeting respiratory tumors [<xref rid="B300-marinedrugs-18-00570" ref-type="bibr">300</xref>,<xref rid="B301-marinedrugs-18-00570" ref-type="bibr">301</xref>,<xref rid="B302-marinedrugs-18-00570" ref-type="bibr">302</xref>] and pathogens (including influenza [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>,<xref rid="B150-marinedrugs-18-00570" ref-type="bibr">150</xref>,<xref rid="B303-marinedrugs-18-00570" ref-type="bibr">303</xref>,<xref rid="B304-marinedrugs-18-00570" ref-type="bibr">304</xref>,<xref rid="B305-marinedrugs-18-00570" ref-type="bibr">305</xref>], <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B166-marinedrugs-18-00570" ref-type="bibr">166</xref>,<xref rid="B306-marinedrugs-18-00570" ref-type="bibr">306</xref>,<xref rid="B307-marinedrugs-18-00570" ref-type="bibr">307</xref>,<xref rid="B308-marinedrugs-18-00570" ref-type="bibr">308</xref>], <italic toggle="yes">M. tuberculosis</italic> [<xref rid="B309-marinedrugs-18-00570" ref-type="bibr">309</xref>], and respiratory syncytial virus [<xref rid="B310-marinedrugs-18-00570" ref-type="bibr">310</xref>]), as well as allergic asthma [<xref rid="B311-marinedrugs-18-00570" ref-type="bibr">311</xref>,<xref rid="B312-marinedrugs-18-00570" ref-type="bibr">312</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>). Immunisation with molluscan Hcs conjugated to, or mixed with, a subunit antigen generates a significantly stronger antigen-specific antibody (particularly IgM and IgG) response compared to immunisation with the antigen alone [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>,<xref rid="B84-marinedrugs-18-00570" ref-type="bibr">84</xref>,<xref rid="B150-marinedrugs-18-00570" ref-type="bibr">150</xref>,<xref rid="B166-marinedrugs-18-00570" ref-type="bibr">166</xref>,<xref rid="B304-marinedrugs-18-00570" ref-type="bibr">304</xref>,<xref rid="B309-marinedrugs-18-00570" ref-type="bibr">309</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>). Hc-only control treatments demonstrate its immunogenicity with high anti-Hc antibody titers [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>] and increased B and T lymphocyte proliferation [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>], immune cell infiltration [<xref rid="B310-marinedrugs-18-00570" ref-type="bibr">310</xref>], cytokine (IL-4, IL-5, IFN-&#947;) expression [<xref rid="B150-marinedrugs-18-00570" ref-type="bibr">150</xref>,<xref rid="B311-marinedrugs-18-00570" ref-type="bibr">311</xref>], and opsonophagocytic activity [<xref rid="B84-marinedrugs-18-00570" ref-type="bibr">84</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>). Several authors have proposed mechanisms by which Hcs exert such immunogenic effects [<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>,<xref rid="B198-marinedrugs-18-00570" ref-type="bibr">198</xref>,<xref rid="B313-marinedrugs-18-00570" ref-type="bibr">313</xref>].</p><p>There also exists a large body of research using molluscan Hcs (again, mostly KLH) as a model protein antigen, which has contributed to the assessment and understanding of immune responses involved in respiratory diseases (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). For example, atopic asthmatics have been shown to produce more serum anti-Hc IgG4 [<xref rid="B314-marinedrugs-18-00570" ref-type="bibr">314</xref>] and IgE [<xref rid="B30-marinedrugs-18-00570" ref-type="bibr">30</xref>] than normal individuals, indicative of an increased/overactive Th<sub>2</sub> response, while administration of molluscan Hcs to patients with respiratory cancer has revealed the immunosuppressive effects of chemotherapy and the disease itself [<xref rid="B315-marinedrugs-18-00570" ref-type="bibr">315</xref>,<xref rid="B316-marinedrugs-18-00570" ref-type="bibr">316</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). Sensitisation to KLH has been found to have an effect that is more-so protective than allergenic [<xref rid="B317-marinedrugs-18-00570" ref-type="bibr">317</xref>,<xref rid="B318-marinedrugs-18-00570" ref-type="bibr">318</xref>], but serum IL-4 and anti-KLH IgG4 and IgE increase in the presence of diesel exhaust particles [<xref rid="B319-marinedrugs-18-00570" ref-type="bibr">319</xref>], demonstrating the promotion effect of environmental pollutants on allergic airway diseases (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). KLH has an excellent clinical safety profile [<xref rid="B103-marinedrugs-18-00570" ref-type="bibr">103</xref>] with no adverse events related to the use of this, or other Hcs, in any study reviewed for this paper (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>).</p><p>The versatile biomedical applications of KLH have led to increasing commercial demand and interest in obtaining novel Hcs with better/different immunogenicities [<xref rid="B313-marinedrugs-18-00570" ref-type="bibr">313</xref>]. Gesheva et al. [<xref rid="B83-marinedrugs-18-00570" ref-type="bibr">83</xref>,<xref rid="B150-marinedrugs-18-00570" ref-type="bibr">150</xref>] carried out two models whereby mice were immunised with influenza hemagglutinin subunit with adjuvant Hcs from <italic toggle="yes">H. pomatia</italic> (HpH) and <italic toggle="yes">R. venosa</italic> (RvH; <xref ref-type="fig" rid="marinedrugs-18-00570-f003">Figure 3</xref>): although antibody and cytokine profiles varied, HpH produced immunogenic effects comparable to alum (AlOH<sub>2</sub>); RvH was comparable to KLH and Complete Freund&#8217;s Adjuvant, and ultimately superior to KLH in terms of spleenocyte cytotoxicity to virus-infected cells three-months post-immunisation (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>, <xref ref-type="fig" rid="marinedrugs-18-00570-f002">Figure 2</xref>). HpH has also been used effectively as a model antigen in studies of asthma [<xref rid="B30-marinedrugs-18-00570" ref-type="bibr">30</xref>,<xref rid="B320-marinedrugs-18-00570" ref-type="bibr">320</xref>] and bronchial carcinoma [<xref rid="B315-marinedrugs-18-00570" ref-type="bibr">315</xref>] (<xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). Hc from the Chilean abalone (<italic toggle="yes">Concholepas concholepas</italic>) is known to have immunogenic properties equal to or better than KLH; it is also commercially available and currently used in a clinical trial as an adjuvant in a prostate cancer vaccine [<xref rid="B272-marinedrugs-18-00570" ref-type="bibr">272</xref>].</p></sec><sec><title>6. Sustainable Supply and Traditional Knowledge Considerations</title><p>A critical question concerning natural product research is the technical and economic feasibility of obtaining large quantities of a given compound in a consistent and ecologically sound manner [<xref rid="B321-marinedrugs-18-00570" ref-type="bibr">321</xref>]. The ecology and life-history of a given species should be well-understood prior to intensive study and opportunities for non-lethal harvest should be sought where possible. Chemical synthesis of bioactive compounds is preferred for pharmaceutical supply due to the relative ease of quantification and purity assessment of active factors, although this is generally not suitable for nutraceuticals which imply a natural origin [<xref rid="B141-marinedrugs-18-00570" ref-type="bibr">141</xref>]. Sustainable production, with respect to both compound sources and other materials used in experimental processes, will be essential for the registration of new molluscan medicines by the FDA, Therapeutic Goods Administration, and counterpart authorities in developed countries.</p><p>The identification and collection of samples based on traditional knowledge adds a layer of legal complexity to the drug discovery process. For many years, it has been recognized that countries and indigenous groups have the right to take control of their biological property, and that the knowledge forming the basis of their traditional medical practices could be protected [<xref rid="B322-marinedrugs-18-00570" ref-type="bibr">322</xref>,<xref rid="B323-marinedrugs-18-00570" ref-type="bibr">323</xref>]. This is a contentious topic and opinions on its resolution vary widely. Nonetheless, as summarized well by Cordell &amp; Colvard [<xref rid="B323-marinedrugs-18-00570" ref-type="bibr">323</xref>], acknowledging and compensating indigenous groups for their knowledge and for providing access to the local environment is a reasonable expectation for those who hold the resources, as well as those who seek them.</p></sec><sec sec-type="conclusions" id="sec7-marinedrugs-18-00570"><title>7. Conclusions: Promising Molluscan Extracts and Compounds for the Treatment and Prevention of Respiratory Disease</title><list list-type="bullet"><list-item><p>This review highlights that there is a paucity of research on the bioactivity of molluscan extracts and compounds, considering the high diversity of species in this phylum and their merit as traditional medicines. Here, we have demonstrated the links between the anti-inflammatory, antimicrobial, anticancer, and immunomodulatory activity of molluscan extracts and compounds and their therapeutic potential in the prevention and treatment of respiratory diseases.</p></list-item><list-item><p>At least 100 traditional medicines incorporating over 300 species of Mollusca have been used to treat respiratory diseases for thousands of years. Most of these are yet to receive research attention, and those few that have shown interesting bioactivities that validate some applications. There is a continued need to develop an evidence base toward the integration of quality-controlled traditional medicines.</p></list-item><list-item><p>We identified particular incentive for biomedical research that elucidates anti-inflammatory factors from mollusc species/families comprising traditional medicines as there is likely to be some chemical basis consistent with their extensive use for alleviating inflammatory symptoms. Shell extracts are widely used but understudied and worthy of further investigation, as are certain taxonomic classes and families used in traditional medicines. The Polyplacophora and Scaphopoda, a wider range of Bivalvia including Veneridae, and shelled Gastropoda including Muricidae are of interest. Respiratory disease-focused ethnomedical studies would also be useful.</p></list-item><list-item><p>Based on biomedical data, we expect that studies using molluscan compounds isolated from specialized glands, reproductive organs, microbial symbionts, and hemolymph would prove worthwhile.</p></list-item><list-item><p>The exploration of novel molluscan Hcs holds good potential for the discovery of new antiviral and immunomodulatory agents, and therapeutic alternatives to KLH. Hcs could be tested in combination with other antiviral factors (e.g., zinc) from the same mollusc. Snail mucus should also be further investigated for anti-spasmodic, anti-inflammatory and anti-viral activities.</p></list-item><list-item><p>Molluscan compounds may be valuable in the treatment of biofilm-associated respiratory infection and improve the efficacy of antibiotics. Further biofilm inhibition/disruption studies are needed and should be inclusive of <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">P. aeruginosa</italic>.</p></list-item><list-item><p>Derivatives of KF and dolastatin 10 are the most potent molluscan anticancer compounds and of continued interest. Several compounds show anticancer activity and need to be tested against respiratory cancers (e.g., brominated indole/isatin derivatives; others in [<xref rid="B66-marinedrugs-18-00570" ref-type="bibr">66</xref>] and structural modifications). In vivo models of various cancer types should include measures of lung metastases and cytotoxicity to healthy cells.</p></list-item><list-item><p>Compounds with bioactivities relevant to a range of respiratory diseases (e.g., anti-inflammatory activity) should be further explored, as well as combinations of compounds (molluscan-molluscan and molluscan-standard agents) to improve treatment efficacy for a single disease and address issues of chemotherapeutic and antimicrobial resistance.</p></list-item><list-item><p>Overall, there is a need for more targeted research based on specific hypotheses related to respiratory disease using extracts and compounds derived from molluscs, with consideration to the sustainability of supply and attribution of traditional knowledge.</p></list-item></list></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the reviewers for their feedback on the manuscript.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-marinedrugs-18-00570"><title>Supplementary Materials</title><p>The following are available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/1660-3397/18/11/570/s1">https://www.mdpi.com/1660-3397/18/11/570/s1</uri>, Table S1: Traditional medicinal uses of molluscs for respiratory related conditions used in ancient and modern cultures around the world appearing in ethnomedical texts and peer-reviewed articles. Table S2: Traditional Chinese medicines (TCMs) derived from molluscs relevant to the treatment of respiratory disease listed in the Chinese <italic toggle="yes">Marine Materia Medica</italic>. Table S3: Human clinical trials and in vivo animal models using molluscan hemocyanins as vaccine adjuvants/conjugates for respiratory disease. Table S4: In vivo animal models and human studies using molluscan hemocyanins as a model antigen for research investigating respiratory diseases. Table S5: Selected patents relating to pharmaceutical compounds derived from molluscs for the treatment of respiratory disease. Table S6: Classes of purified compounds tested against respiratory pathogens, cancers and inflammatory diseases.</p><supplementary-material content-type="local-data" id="marinedrugs-18-00570-s001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marinedrugs-18-00570-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Funding</title><p>This research was funded by the Australian Government Research Training Program and Southern Cross University School of Environment, Science and Engineering.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no potential conflict of interest.</p></notes><glossary><title>Common Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCMs</td><td align="left" valign="middle" rowspan="1" colspan="1">traditional Chinese medicines</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OTMs</td><td align="left" valign="middle" rowspan="1" colspan="1">other traditional medicines</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hc</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemocyanin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="left" valign="middle" rowspan="1" colspan="1">chronic obstructive pulmonary disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ARDS</td><td align="left" valign="middle" rowspan="1" colspan="1">acute respiratory distress syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSAIDs</td><td align="left" valign="middle" rowspan="1" colspan="1">non-steroidal anti-inflammatory drugs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MIC/MBC</td><td align="left" valign="middle" rowspan="1" colspan="1">minimum inhibitory/bactericidal concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC<sub>50</sub>/GI<sub>50</sub>/CC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">concentration causing 50% inhibition/growth inhibition/cytotoxicity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PUFAs</td><td align="left" valign="middle" rowspan="1" colspan="1">polyunsaturated fatty acids</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">United States Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Abs</td><td align="left" valign="middle" rowspan="1" colspan="1">antibodies</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-marinedrugs-18-00570"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>K.A.M.</given-names></name></person-group><article-title>Allergic respiratory inflammation and remodeling</article-title><source>Turk. Thorac. J.</source><year>2015</year><volume>16</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.5152/ttd.2015.4942</pub-id><pub-id pub-id-type="pmid">29404091</pub-id><pub-id pub-id-type="pmcid">PMC5793767</pub-id></element-citation></ref><ref id="B2-marinedrugs-18-00570"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>FIRS</collab></person-group><source>The Global Impact of Respiratory Disease</source><edition>2nd ed.</edition><publisher-name>European Respiratory Society</publisher-name><publisher-loc>Sheffield, UK</publisher-loc><year>2017</year><fpage>42</fpage></element-citation></ref><ref id="B3-marinedrugs-18-00570"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jardins</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>G.G.</given-names></name></person-group><source>Clinical Manifestations and Assessment of Respiratory Disease</source><edition>7th ed.</edition><publisher-name>Mosby Elsevier</publisher-name><publisher-loc>St. Louis, MO, USA</publisher-loc><year>2016</year><fpage>648</fpage></element-citation></ref><ref id="B4-marinedrugs-18-00570"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferkol</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schraufnagel</surname><given-names>D.</given-names></name></person-group><article-title>The global burden of respiratory disease</article-title><source>Ann. Am. Thorac. Soc.</source><year>2014</year><volume>11</volume><fpage>404</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201311-405PS</pub-id><pub-id pub-id-type="pmid">24673696</pub-id></element-citation></ref><ref id="B5-marinedrugs-18-00570"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Global Asthma Network</collab></person-group><source>The Global Asthma Report 2018</source><publisher-name>Global Asthma Network</publisher-name><publisher-loc>Auckland, New Zealand</publisher-loc><year>2018</year><fpage>92</fpage></element-citation></ref><ref id="B6-marinedrugs-18-00570"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Forum of International Respiratory Societies</collab></person-group><source>Respiratory Diseases in the World</source><publisher-name>European Respiratory Society</publisher-name><publisher-loc>Sheffield, UK</publisher-loc><year>2013</year><fpage>35</fpage></element-citation></ref><ref id="B7-marinedrugs-18-00570"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ksiazek</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Peret</surname><given-names>T.</given-names></name><name name-style="western"><surname>Emery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urbani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030781</pub-id><pub-id pub-id-type="pmid">12690092</pub-id></element-citation></ref><ref id="B8-marinedrugs-18-00570"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Galiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name><etal/></person-group><article-title>Middle east respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>7790</fpage><lpage>7792</lpage><pub-id pub-id-type="doi">10.1128/JVI.01244-13</pub-id><pub-id pub-id-type="pmid">23678167</pub-id><pub-id pub-id-type="pmcid">PMC3700179</pub-id></element-citation></ref><ref id="B9-marinedrugs-18-00570"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="B10-marinedrugs-18-00570"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moldoveanu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Otmishi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guardiola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Inflammatory mechanisms in the lung</article-title><source>J. Inflamm. Res.</source><year>2009</year><volume>2009</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmcid">PMC3218724</pub-id><pub-id pub-id-type="pmid">22096348</pub-id></element-citation></ref><ref id="B11-marinedrugs-18-00570"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Matthay</surname><given-names>M.A.</given-names></name></person-group><article-title>The acute respiratory distress syndrome</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1334</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421806</pub-id><pub-id pub-id-type="pmid">10793167</pub-id></element-citation></ref><ref id="B12-marinedrugs-18-00570"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murrow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Oglesby</surname><given-names>F.M.</given-names></name></person-group><article-title>Acute and chronic illness: Similarities, differences and challenges</article-title><source>Orthop. Nurs. Natl. Assoc. Orthop. Nurses</source><year>1996</year><volume>15</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/00006416-199609000-00014</pub-id><pub-id pub-id-type="pmid">8954463</pub-id></element-citation></ref><ref id="B13-marinedrugs-18-00570"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rommens</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Alon</surname><given-names>N.O.A.</given-names></name><name name-style="western"><surname>Rozmahel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grzelczak</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zielenski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Plavsic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1126/science.2475911</pub-id><pub-id pub-id-type="pmid">2475911</pub-id></element-citation></ref><ref id="B14-marinedrugs-18-00570"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C.W.</given-names></name></person-group><article-title>Role of viral infections in asthma and chronic obstructive pulmonary disease</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2006</year><volume>35</volume><fpage>513</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2006-0199TR</pub-id><pub-id pub-id-type="pmid">16778148</pub-id></element-citation></ref><ref id="B15-marinedrugs-18-00570"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umeki</surname><given-names>S.</given-names></name></person-group><article-title>Re-evaluation of eosinophilic pneumonia and its diagnostic criteria</article-title><source>Arch. Intern. Med.</source><year>1992</year><volume>152</volume><fpage>1913</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1001/archinte.1992.00400210133023</pub-id><pub-id pub-id-type="pmid">1520060</pub-id></element-citation></ref><ref id="B16-marinedrugs-18-00570"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Inflammation 2010: New adventures of an old flame</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.006</pub-id><pub-id pub-id-type="pmid">20303867</pub-id></element-citation></ref><ref id="B17-marinedrugs-18-00570"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminska</surname><given-names>B.</given-names></name></person-group><article-title>MAPK signalling pathways as molecular targets for anti-inflammatory therapy: From molecular mechanisms to therapeutic benefits</article-title><source>Biochim. Biophys. Acta</source><year>2005</year><volume>1754</volume><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2005.08.017</pub-id><pub-id pub-id-type="pmid">16198162</pub-id></element-citation></ref><ref id="B18-marinedrugs-18-00570"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reber</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>S.J.</given-names></name></person-group><article-title>The pathophysiology of anaphylaxis</article-title><source>J. Allergy Clin. Immunol.</source><year>2017</year><volume>140</volume><fpage>335</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.06.003</pub-id><pub-id pub-id-type="pmid">28780941</pub-id><pub-id pub-id-type="pmcid">PMC5657389</pub-id></element-citation></ref><ref id="B19-marinedrugs-18-00570"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthay</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Zemans</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Arabi</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Beitler</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mercat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Herridge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Calfee</surname><given-names>C.S.</given-names></name></person-group><article-title>Acute respiratory distress syndrome</article-title><source>Nat. Rev. Dis. Primers</source><year>2019</year><volume>5</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0069-0</pub-id><pub-id pub-id-type="pmid">30872586</pub-id><pub-id pub-id-type="pmcid">PMC6709677</pub-id></element-citation></ref><ref id="B20-marinedrugs-18-00570"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engels</surname><given-names>E.A.</given-names></name></person-group><article-title>Inflammation in the development of lung cancer: Epidemiological evidence</article-title><source>Expert Rev. Anticancer Ther.</source><year>2008</year><volume>8</volume><fpage>605</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1586/14737140.8.4.605</pub-id><pub-id pub-id-type="pmid">18402527</pub-id></element-citation></ref><ref id="B21-marinedrugs-18-00570"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moochhala</surname><given-names>S.</given-names></name></person-group><article-title>Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome</article-title><source>J. Pathol.</source><year>2004</year><volume>202</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/path.1491</pub-id><pub-id pub-id-type="pmid">14743496</pub-id></element-citation></ref><ref id="B22-marinedrugs-18-00570"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#246;rmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lustenberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Relja</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marzi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wutzler</surname><given-names>S.</given-names></name></person-group><article-title>Role of biomarkers in acute traumatic lung injury</article-title><source>Injury</source><year>2017</year><volume>48</volume><fpage>2400</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2017.08.041</pub-id><pub-id pub-id-type="pmid">28888717</pub-id></element-citation></ref><ref id="B23-marinedrugs-18-00570"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piliponsky</surname><given-names>A.M.</given-names></name></person-group><article-title>The development of allergic inflammation</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature07204</pub-id><pub-id pub-id-type="pmid">18650915</pub-id><pub-id pub-id-type="pmcid">PMC3573758</pub-id></element-citation></ref><ref id="B24-marinedrugs-18-00570"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacNee</surname><given-names>W.</given-names></name></person-group><article-title>Oxidative stress and lung inflammation in airways disease</article-title><source>Eur. J. Pharmacol.</source><year>2001</year><volume>429</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(01)01320-6</pub-id><pub-id pub-id-type="pmid">11698041</pub-id></element-citation></ref><ref id="B25-marinedrugs-18-00570"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizgerd</surname><given-names>J.P.</given-names></name></person-group><article-title>Acute lower respiratory tract infection</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>358</volume><fpage>716</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1056/NEJMra074111</pub-id><pub-id pub-id-type="pmid">18272895</pub-id><pub-id pub-id-type="pmcid">PMC2711392</pub-id></element-citation></ref><ref id="B26-marinedrugs-18-00570"><label>26.</label><element-citation publication-type="web"><article-title>Worldometer COVID-19 Coronavirus Pandemic</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-18">(accessed on 18 November 2020)</date-in-citation></element-citation></ref><ref id="B27-marinedrugs-18-00570"><label>27.</label><element-citation publication-type="web"><article-title>World Health Organisation Fact Sheets</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets">https://www.who.int/news-room/fact-sheets</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B28-marinedrugs-18-00570"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>W.J.</given-names></name></person-group><article-title>Nontuberculous Mycobacteria-Overview</article-title><source>Microbiol Spectr</source><year>2017</year><fpage>5</fpage><pub-id pub-id-type="doi">10.1128/microbiolspec.TNMI7-0024-2016</pub-id><pub-id pub-id-type="pmcid">PMC11687458</pub-id><pub-id pub-id-type="pmid">28128073</pub-id></element-citation></ref><ref id="B29-marinedrugs-18-00570"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brusselle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name></person-group><article-title>Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD</article-title><source>Prim. Care Respir. J.</source><year>2013</year><volume>22</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4104/pcrj.2012.00092</pub-id><pub-id pub-id-type="pmid">23135217</pub-id><pub-id pub-id-type="pmcid">PMC6548052</pub-id></element-citation></ref><ref id="B30-marinedrugs-18-00570"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Kallenberg</surname><given-names>C.G.M.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Torensma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>R.J.L.</given-names></name><name name-style="western"><surname>Weller</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Orie</surname><given-names>N.G.M.</given-names></name><name name-style="western"><surname>The</surname><given-names>T.H.</given-names></name></person-group><article-title>The primary immune response in bronchial asthma. I. A kinetic study of <italic toggle="yes">Helix pomatia</italic> hemocyanin-specific IgE, IgG, IgA, and IgM antibody responses in patients with asthma and in matched controls</article-title><source>J. Allergy Clin. Immunol.</source><year>1985</year><volume>76</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/0091-6749(85)90800-0</pub-id><pub-id pub-id-type="pmid">4008812</pub-id></element-citation></ref><ref id="B31-marinedrugs-18-00570"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vissers</surname><given-names>J.L.M.</given-names></name><name name-style="western"><surname>van Esch</surname><given-names>B.C.A.M.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>van Oosterhout</surname><given-names>A.J.M.</given-names></name></person-group><article-title>Macrophages induce an allergen-specific and long-term suppression in a mouse asthma model</article-title><source>Eur. Respir. J.</source><year>2005</year><volume>26</volume><fpage>1040</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1183/09031936.05.00089304</pub-id><pub-id pub-id-type="pmid">16319333</pub-id></element-citation></ref><ref id="B32-marinedrugs-18-00570"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Macek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Madge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Burgel</surname><given-names>P.-R.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Casta&#241;os</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The future of cystic fibrosis care: A global perspective</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>65</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(19)30337-6</pub-id><pub-id pub-id-type="pmid">31570318</pub-id><pub-id pub-id-type="pmcid">PMC8862661</pub-id></element-citation></ref><ref id="B33-marinedrugs-18-00570"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geddes</surname><given-names>D.</given-names></name></person-group><article-title>The history of respiratory disease management</article-title><source>Medicine</source><year>2016</year><volume>44</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.mpmed.2016.03.006</pub-id><pub-id pub-id-type="pmid">32288580</pub-id><pub-id pub-id-type="pmcid">PMC7108320</pub-id></element-citation></ref><ref id="B34-marinedrugs-18-00570"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acemoglu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name></person-group><article-title>Disease and development: The effect of life expectancy on economic growth</article-title><source>J. Political Econ.</source><year>2007</year><volume>115</volume><fpage>925</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1086/529000</pub-id></element-citation></ref><ref id="B35-marinedrugs-18-00570"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>R.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Maselli</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sande</surname><given-names>M.A.</given-names></name></person-group><article-title>Excessive antibiotic use for acute respiratory infections in the United States</article-title><source>Clin. Infect. Dis.</source><year>2001</year><volume>33</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1086/322627</pub-id><pub-id pub-id-type="pmid">11512079</pub-id></element-citation></ref><ref id="B36-marinedrugs-18-00570"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laine</surname><given-names>L.</given-names></name></person-group><article-title>Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><fpage>594</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.21907</pub-id><pub-id pub-id-type="pmid">11179238</pub-id></element-citation></ref><ref id="B37-marinedrugs-18-00570"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyston</surname><given-names>P.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>K.</given-names></name></person-group><article-title>The current challenges for vaccine development</article-title><source>J. Med. Microbiol.</source><year>2012</year><volume>61</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.039180-0</pub-id><pub-id pub-id-type="pmid">22322337</pub-id></element-citation></ref><ref id="B38-marinedrugs-18-00570"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vane</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Botting</surname><given-names>R.M.</given-names></name></person-group><article-title>Anti-inflammatory drugs and their mechanism of action</article-title><source>Inflamm. Res.</source><year>1998</year><volume>47</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s000110050284</pub-id><pub-id pub-id-type="pmid">9831328</pub-id></element-citation></ref><ref id="B39-marinedrugs-18-00570"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>K.</given-names></name></person-group><article-title>Efflux-mediated antimicrobial resistance</article-title><source>J. Antimicrob. Chemother.</source><year>2005</year><volume>56</volume><fpage>20</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1093/jac/dki171</pub-id><pub-id pub-id-type="pmid">15914491</pub-id></element-citation></ref><ref id="B40-marinedrugs-18-00570"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mader</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Hoskin</surname><given-names>D.W.</given-names></name></person-group><article-title>Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment</article-title><source>Expert Opin. Investig. Drugs</source><year>2006</year><volume>15</volume><fpage>933</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1517/13543784.15.8.933</pub-id><pub-id pub-id-type="pmid">16859395</pub-id></element-citation></ref><ref id="B41-marinedrugs-18-00570"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelmohsen</surname><given-names>U.R.</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oelschlaeger</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Grkovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hentschel</surname><given-names>U.</given-names></name></person-group><article-title>Potential of marine natural products against drug-resistant fungal, viral, and parasitic infections</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>e30</fpage><lpage>e41</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30323-1</pub-id><pub-id pub-id-type="pmid">27979695</pub-id></element-citation></ref><ref id="B42-marinedrugs-18-00570"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Fachini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delerue-Matos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montenegro</surname><given-names>M.C.B.S.M.</given-names></name></person-group><article-title>Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment</article-title><source>J. Hazard. Mater.</source><year>2010</year><volume>175</volume><fpage>45</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jhazmat.2009.10.100</pub-id><pub-id pub-id-type="pmid">19954887</pub-id></element-citation></ref><ref id="B43-marinedrugs-18-00570"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corcoran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>C.R.</given-names></name></person-group><article-title>Pharmaceuticals in the aquatic environment: A critical review of the evidence for health effects in fish</article-title><source>Crit. Rev. Toxicol.</source><year>2010</year><volume>40</volume><fpage>287</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.3109/10408440903373590</pub-id><pub-id pub-id-type="pmid">20225984</pub-id></element-citation></ref><ref id="B44-marinedrugs-18-00570"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Australian Government</collab></person-group><source>Australia&#8217;s National Antimicrobial Resistance Strategy-2020 and Beyond</source><publisher-name>Department of Health/Department of Agriculture, Water and the Environment</publisher-name><publisher-loc>Canberra, Australia</publisher-loc><year>2019</year><fpage>18</fpage></element-citation></ref><ref id="B45-marinedrugs-18-00570"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Defer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bourgougnon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fleury</surname><given-names>Y.</given-names></name></person-group><article-title>Screening for antibacterial and antiviral activities in three bivalve and two gastropod marine molluscs</article-title><source>Aquaculture</source><year>2009</year><volume>293</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2009.03.047</pub-id></element-citation></ref><ref id="B46-marinedrugs-18-00570"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Piao</surname><given-names>G.</given-names></name></person-group><article-title>The traditional medicine and modern medicine from natural products</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21050559</pub-id><pub-id pub-id-type="pmcid">PMC6273146</pub-id><pub-id pub-id-type="pmid">27136524</pub-id></element-citation></ref><ref id="B47-marinedrugs-18-00570"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>A.L.</given-names></name></person-group><article-title>Natural products as a screening resource</article-title><source>Curr. Opin. Chem. Biol.</source><year>2007</year><volume>11</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2007.08.012</pub-id><pub-id pub-id-type="pmid">17884696</pub-id></element-citation></ref><ref id="B48-marinedrugs-18-00570"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeelian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Le Leu</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Simultaneous assessment of the efficacy and toxicity of marine mollusc&#8211;derived brominated indoles in an in vivo model for early stage colon cancer</article-title><source>Integr. Cancer Ther.</source><year>2018</year><volume>17</volume><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1177/1534735417699880</pub-id><pub-id pub-id-type="pmid">28381120</pub-id><pub-id pub-id-type="pmcid">PMC6041907</pub-id></element-citation></ref><ref id="B49-marinedrugs-18-00570"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kotiw</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Review of anti-inflammatory, immune-modulatory and wound healing properties of molluscs</article-title><source>J. Ethnopharmacol.</source><year>2018</year><volume>210</volume><fpage>156</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.08.008</pub-id><pub-id pub-id-type="pmid">28830818</pub-id></element-citation></ref><ref id="B50-marinedrugs-18-00570"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaspars</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Pascale</surname><given-names>D.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Ianora</surname><given-names>A.</given-names></name></person-group><article-title>The marine biodiscovery pipeline and ocean medicines of tomorrow</article-title><source>J. Mar. Biol. Assoc. UK</source><year>2016</year><volume>96</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1017/S0025315415002106</pub-id></element-citation></ref><ref id="B51-marinedrugs-18-00570"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadines</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Le</surname><given-names>K.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>A.M.</given-names></name></person-group><article-title>The marine pharmacology and pharmaceuticals pipeline in 2018</article-title><source>FASEB J.</source><year>2019</year><volume>33</volume><fpage>255</fpage><lpage>265</lpage></element-citation></ref><ref id="B52-marinedrugs-18-00570"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Cuevas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kem</surname><given-names>W.</given-names></name><name name-style="western"><surname>Little</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Shuster</surname><given-names>D.E.</given-names></name></person-group><article-title>The odyssey of marine pharmaceuticals: A current pipeline perspective</article-title><source>Trends Pharmacol. Sci.</source><year>2010</year><volume>31</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2010.02.005</pub-id><pub-id pub-id-type="pmid">20363514</pub-id></element-citation></ref><ref id="B53-marinedrugs-18-00570"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources produced by marine molluscs</article-title><source>Biol. Rev.</source><year>2010</year><volume>85</volume><fpage>757</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1111/j.1469-185X.2010.00124.x</pub-id><pub-id pub-id-type="pmid">20105155</pub-id></element-citation></ref><ref id="B54-marinedrugs-18-00570"><label>54.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pyron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name></person-group><article-title>Introduction to Mollusca and the class Gastropoda (ch. 18)</article-title><source>Ecology and General Biology: Thorp and Covich&#8217;s Freshwater Invertebrates</source><edition>4th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Thorp</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>D.C.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2015</year><fpage>383</fpage><lpage>421</lpage></element-citation></ref><ref id="B55-marinedrugs-18-00570"><label>55.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bouchet</surname><given-names>P.</given-names></name></person-group><article-title>The magnitude of marine biodiversity</article-title><source>The Exploration of Marine Biodiveristy, Scientific and Technological Challenges</source><person-group person-group-type="editor"><name name-style="western"><surname>Duarte</surname><given-names>C.M.</given-names></name></person-group><publisher-name>Fundacion BBVA</publisher-name><publisher-loc>Bilboao, France</publisher-loc><year>2006</year><fpage>33</fpage><lpage>64</lpage></element-citation></ref><ref id="B56-marinedrugs-18-00570"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><name name-style="western"><surname>Speck</surname><given-names>P.</given-names></name></person-group><article-title>Marine snails and slugs: A great place to look for antiviral drugs</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>8114</fpage><lpage>8118</lpage><pub-id pub-id-type="doi">10.1128/JVI.00287-15</pub-id><pub-id pub-id-type="pmid">26063420</pub-id><pub-id pub-id-type="pmcid">PMC4524231</pub-id></element-citation></ref><ref id="B57-marinedrugs-18-00570"><label>57.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Coutellec</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Caquet</surname><given-names>T.</given-names></name></person-group><article-title>Gastropod ecophysiological response to stress (ch. 9)</article-title><source>Physiology of Molluscs: A Collection of Selected Reviews (Vol. 1)</source><person-group person-group-type="editor"><name name-style="western"><surname>Saleuddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>S.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2016</year><fpage>932</fpage></element-citation></ref><ref id="B58-marinedrugs-18-00570"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammerman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fuhrman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hagstr&#246;m</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azam</surname><given-names>F.</given-names></name></person-group><article-title>Bacterioplankton growth in seawater: I. Growth kinetics and cellular characteristics in seawater cultures</article-title><source>Mar. Ecol. Prog. Ser.</source><year>1984</year><volume>18</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.3354/meps018031</pub-id></element-citation></ref><ref id="B59-marinedrugs-18-00570"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitman</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Wiebe</surname><given-names>W.J.</given-names></name></person-group><article-title>Prokaryotes: The unseen majority</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>6578</fpage><lpage>6583</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.12.6578</pub-id><pub-id pub-id-type="pmid">9618454</pub-id><pub-id pub-id-type="pmcid">PMC33863</pub-id></element-citation></ref><ref id="B60-marinedrugs-18-00570"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raynaud</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nunan</surname><given-names>N.</given-names></name></person-group><article-title>Spatial ecology of bacteria at the microscale in soil</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e87217</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0087217</pub-id><pub-id pub-id-type="pmid">24489873</pub-id><pub-id pub-id-type="pmcid">PMC3905020</pub-id></element-citation></ref><ref id="B61-marinedrugs-18-00570"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Day</surname><given-names>R.</given-names></name><name name-style="western"><surname>Slocombe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Handlinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Stress and immune responses in abalone: Limitations in current knowledge and investigative methods based on other models</article-title><source>Fish Shellfish. Immunol.</source><year>2007</year><volume>22</volume><fpage>363</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2006.06.009</pub-id><pub-id pub-id-type="pmid">16962793</pub-id></element-citation></ref><ref id="B62-marinedrugs-18-00570"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummins</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Schein</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Nagle</surname><given-names>G.T.</given-names></name></person-group><article-title>Newly identified water-borne protein pheromones interact with attractin to stimulate mate attraction in <italic toggle="yes">Aplysia</italic></article-title><source>Peptides</source><year>2006</year><volume>27</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2005.08.026</pub-id><pub-id pub-id-type="pmid">16309784</pub-id></element-citation></ref><ref id="B63-marinedrugs-18-00570"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bornancin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonnard</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Banaigs</surname><given-names>B.</given-names></name></person-group><article-title>Chemical mediation as a structuring element in marine gastropod predator-prey interactions</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>644</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1039/C6NP00097E</pub-id><pub-id pub-id-type="pmid">28466897</pub-id></element-citation></ref><ref id="B64-marinedrugs-18-00570"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Continuous inking affects the biological and biochemical responses of cuttlefish <italic toggle="yes">Sepia pharaonis</italic></article-title><source>Front. Physiol.</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3389/fphys.2019.01429</pub-id><pub-id pub-id-type="pmid">31849695</pub-id><pub-id pub-id-type="pmcid">PMC6896823</pub-id></element-citation></ref><ref id="B65-marinedrugs-18-00570"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>J.</given-names></name></person-group><article-title>Chemical defense in the egg masses of benthic invertebrates: An assessment of antibacterial activity in 39 mollusks and 4 polychaetes</article-title><source>J. Invertebr. Pathol.</source><year>2001</year><volume>78</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1006/jipa.2001.5047</pub-id><pub-id pub-id-type="pmid">11812113</pub-id></element-citation></ref><ref id="B66-marinedrugs-18-00570"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciavatta</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lefranc</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mollo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gavagnin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Betancourt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dasari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kornienko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>R.</given-names></name></person-group><article-title>Marine mollusk-derived agents with antiproliferative activity as promising anticancer agents to overcome chemotherapy resistance</article-title><source>Med. Res. Rev.</source><year>2017</year><volume>37</volume><fpage>702</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1002/med.21423</pub-id><pub-id pub-id-type="pmid">27925266</pub-id><pub-id pub-id-type="pmcid">PMC5484305</pub-id></element-citation></ref><ref id="B67-marinedrugs-18-00570"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Chemical diversity in molluscan communities: From natural products to chemical ecology</article-title><source>Neuroecology and Neuroethology in Molluscs: The Interface between Behaviour and Environment</source><person-group person-group-type="editor"><name name-style="western"><surname>Cosmo</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Winlow</surname><given-names>W.</given-names></name></person-group><publisher-name>Nova Science Publishers</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year><fpage>13</fpage><lpage>41</lpage></element-citation></ref><ref id="B68-marinedrugs-18-00570"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blunt</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Munro</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>235</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1039/C6NP00124F</pub-id><pub-id pub-id-type="pmid">28290569</pub-id></element-citation></ref><ref id="B69-marinedrugs-18-00570"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blunt</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Munro</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Prinsep</surname><given-names>M.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>382</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1039/C5NP00156K</pub-id><pub-id pub-id-type="pmid">26837534</pub-id></element-citation></ref><ref id="B70-marinedrugs-18-00570"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blunt</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>8</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1039/C7NP00052A</pub-id><pub-id pub-id-type="pmid">29335692</pub-id></element-citation></ref><ref id="B71-marinedrugs-18-00570"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>122</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1039/C8NP00092A</pub-id><pub-id pub-id-type="pmid">30663727</pub-id></element-citation></ref><ref id="B72-marinedrugs-18-00570"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2020</year><volume>37</volume><fpage>175</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1039/C9NP00069K</pub-id><pub-id pub-id-type="pmid">32025684</pub-id></element-citation></ref><ref id="B73-marinedrugs-18-00570"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolashka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dolashki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Beeumen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Floetenmeyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Velkova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stevanovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Voelter</surname><given-names>W.</given-names></name></person-group><article-title>Antimicrobial activity of molluscan hemocyanins from <italic toggle="yes">Helix</italic> and <italic toggle="yes">Rapana</italic> snails</article-title><source>Curr. Pharm. Biotechnol.</source><year>2016</year><volume>17</volume><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.2174/1389201016666150907113435</pub-id><pub-id pub-id-type="pmid">26343131</pub-id></element-citation></ref><ref id="B74-marinedrugs-18-00570"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>J.B.</given-names></name></person-group><article-title>Free fatty acids and sterols in the benthic spawn of aquatic molluscs, and their associated antimicrobial properties</article-title><source>J. Exp. Mar. Biol. Ecol.</source><year>2005</year><volume>316</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jembe.2004.10.001</pub-id></element-citation></ref><ref id="B75-marinedrugs-18-00570"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vine</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Locke</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pyne</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>J.B.</given-names></name></person-group><article-title>In vitro cytotoxicity evaluation of some substituted isatin derivatives</article-title><source>Bioorg. Med. Chem.</source><year>2007</year><volume>15</volume><fpage>931</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.10.035</pub-id><pub-id pub-id-type="pmid">17088067</pub-id></element-citation></ref><ref id="B76-marinedrugs-18-00570"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gesheva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chausheva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Manoylov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Doumanova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Idakieva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tchorbanov</surname><given-names>A.</given-names></name></person-group><article-title>Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma</article-title><source>BMC Immunol.</source><year>2014</year><volume>15</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-014-0034-3</pub-id><pub-id pub-id-type="pmid">25168124</pub-id><pub-id pub-id-type="pmcid">PMC4164791</pub-id></element-citation></ref><ref id="B77-marinedrugs-18-00570"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kotiw</surname><given-names>M.</given-names></name></person-group><article-title>Brominated indoles from a marine mollusc inhibit inflammation in a murine model of acute lung injury</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0186904</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0186904</pub-id><pub-id pub-id-type="pmid">29073178</pub-id><pub-id pub-id-type="pmcid">PMC5658094</pub-id></element-citation></ref><ref id="B78-marinedrugs-18-00570"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Long</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Limax extract ameliorates cigarette smoke-induced chronic obstructive pulmonary disease in mice</article-title><source>Int. Immunopharmacol.</source><year>2018</year><volume>54</volume><fpage>210</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2017.11.004</pub-id><pub-id pub-id-type="pmid">29156356</pub-id></element-citation></ref><ref id="B79-marinedrugs-18-00570"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pons</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Michelot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frossard</surname><given-names>N.</given-names></name></person-group><article-title>The bronchorelaxant effect of helicidine, a <italic toggle="yes">Helix pomatia</italic> extract, involves prostaglandin E2 release</article-title><source>Pathol. Biol.</source><year>1999</year><volume>47</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1076/phbi.36.1.13.4622</pub-id><pub-id pub-id-type="pmid">10081783</pub-id></element-citation></ref><ref id="B80-marinedrugs-18-00570"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sergysels</surname><given-names>R.</given-names></name><name name-style="western"><surname>Art</surname><given-names>G.</given-names></name></person-group><article-title>A double-masked, placebo-controlled polysomnographic study of the antitussive effects of helicidine</article-title><source>Curr. Ther. Res. Clin. Exp.</source><year>2001</year><volume>62</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0011-393X(01)80040-0</pub-id></element-citation></ref><ref id="B81-marinedrugs-18-00570"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erspamer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Glasser</surname><given-names>A.</given-names></name></person-group><article-title>The pharmacological actions of murexine (urocanylcholine)</article-title><source>Br. J. Pharmacol. Chemother.</source><year>1957</year><volume>12</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1957.tb00117.x</pub-id><pub-id pub-id-type="pmid">13446370</pub-id><pub-id pub-id-type="pmcid">PMC1509659</pub-id></element-citation></ref><ref id="B82-marinedrugs-18-00570"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badiu</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Luque</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dumitrescu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Craciun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dinca</surname><given-names>D.</given-names></name></person-group><article-title>Amino acids from Mytilus galloprovincialis (L.) and Rapana venosa molluscs accelerate skin wounds healing via enhancement of dermal and epidermal neoformation</article-title><source>Protein J.</source><year>2010</year><volume>29</volume><fpage>81</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s10930-009-9225-9</pub-id><pub-id pub-id-type="pmid">20087635</pub-id></element-citation></ref><ref id="B83-marinedrugs-18-00570"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gesheva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chausheva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Doumanova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Idakieva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tchorbanov</surname><given-names>A.</given-names></name></person-group><article-title><italic toggle="yes">Helix pomatia</italic> hemocyanin - a novel bio-adjuvant for viral and bacterial antigens</article-title><source>Int. Immunopharmacol.</source><year>2015</year><volume>26</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.03.011</pub-id><pub-id pub-id-type="pmid">25799956</pub-id></element-citation></ref><ref id="B84-marinedrugs-18-00570"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Mueschenborn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Llosa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Construction and characterization of a <italic toggle="yes">Pseudomonas aeruginosa</italic> mucoid exopolysaccharide-alginate conjugate vaccine</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3875</fpage><lpage>3884</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.7.3875-3884.2003</pub-id><pub-id pub-id-type="pmid">12819072</pub-id><pub-id pub-id-type="pmcid">PMC162014</pub-id></element-citation></ref><ref id="B85-marinedrugs-18-00570"><label>85.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>A.M.</given-names></name></person-group><article-title>Clinical Pipeline: Marine Pharmacology</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline.xml">https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline.xml</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-30">(accessed on 30 June 2020)</date-in-citation></element-citation></ref><ref id="B86-marinedrugs-18-00570"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGivern</surname><given-names>J.G.</given-names></name></person-group><article-title>Ziconotide: A review of its pharmacology and use in the treatment of pain</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2007</year><volume>3</volume><fpage>69</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.2147/nedt.2007.3.1.69</pub-id><pub-id pub-id-type="pmid">19300539</pub-id><pub-id pub-id-type="pmcid">PMC2654521</pub-id></element-citation></ref><ref id="B87-marinedrugs-18-00570"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>L.J.</given-names></name></person-group><article-title>Brentuximab vedotin: A review in CD30-positive Hodgkin lymphoma</article-title><source>Drugs</source><year>2017</year><volume>77</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0705-5</pub-id><pub-id pub-id-type="pmid">28190142</pub-id><pub-id pub-id-type="pmcid">PMC7102329</pub-id></element-citation></ref><ref id="B88-marinedrugs-18-00570"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeks</surname><given-names>E.D.</given-names></name></person-group><article-title>Polatuzumab vedotin: First global approval</article-title><source>Drugs</source><year>2019</year><volume>79</volume><fpage>1467</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01175-0</pub-id><pub-id pub-id-type="pmid">31352604</pub-id><pub-id pub-id-type="pmcid">PMC6794237</pub-id></element-citation></ref><ref id="B89-marinedrugs-18-00570"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Balar</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Galsky</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Gartner</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Pinelli</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>2592</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01140</pub-id><pub-id pub-id-type="pmid">31356140</pub-id><pub-id pub-id-type="pmcid">PMC6784850</pub-id></element-citation></ref><ref id="B90-marinedrugs-18-00570"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nongmaithem</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Young</surname><given-names>F.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>V.</given-names></name><name name-style="western"><surname>Avila</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Are the traditional medical uses of muricidae molluscs substantiated by their pharmacological properties and bioactive compounds?</article-title><source>Mar. Drugs</source><year>2015</year><volume>13</volume><fpage>5237</fpage><lpage>5275</lpage><pub-id pub-id-type="doi">10.3390/md13085237</pub-id><pub-id pub-id-type="pmid">26295242</pub-id><pub-id pub-id-type="pmcid">PMC4557022</pub-id></element-citation></ref><ref id="B91-marinedrugs-18-00570"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnemain</surname><given-names>B.</given-names></name></person-group><article-title>Helix and drugs: Snails for western health care from antiquity to the present</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2005</year><volume>2</volume><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh057</pub-id><pub-id pub-id-type="pmcid">PMC1062150</pub-id><pub-id pub-id-type="pmid">15841274</pub-id></element-citation></ref><ref id="B92-marinedrugs-18-00570"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straus</surname><given-names>S.E.</given-names></name></person-group><article-title>Complementary and alternative medicine: Challenges and opportunities for American medicine</article-title><source>Acad. Med.</source><year>2000</year><volume>75</volume><fpage>572</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1097/00001888-200006000-00005</pub-id><pub-id pub-id-type="pmid">10875501</pub-id></element-citation></ref><ref id="B93-marinedrugs-18-00570"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cragg</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Cardellina</surname><given-names>J.H.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Newman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Snader</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McCloud</surname><given-names>T.G.</given-names></name></person-group><article-title>Ethnobotany and drug discovery: The experience of the US National Cancer Institute</article-title><source>Ciba Found. Symp.</source><year>1994</year><volume>185</volume><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">7736854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470514634.ch13</pub-id></element-citation></ref><ref id="B94-marinedrugs-18-00570"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.R.</given-names></name></person-group><article-title>The history of Ephedra (ma-huang)</article-title><source>J. R. Coll. Physicians Edinb.</source><year>2011</year><volume>41</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.4997/JRCPE.2011.116</pub-id><pub-id pub-id-type="pmid">21365072</pub-id></element-citation></ref><ref id="B95-marinedrugs-18-00570"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhukova</surname><given-names>N.V.</given-names></name></person-group><article-title>Fatty acids of marine mollusks: Impact of diet, bacterial symbiosis and biosynthetic potential</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>857</elocation-id><pub-id pub-id-type="doi">10.3390/biom9120857</pub-id><pub-id pub-id-type="pmid">31835867</pub-id><pub-id pub-id-type="pmcid">PMC6995604</pub-id></element-citation></ref><ref id="B96-marinedrugs-18-00570"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sofi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abbate</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gensini</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name></person-group><article-title>Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis</article-title><source>Am. J. Clin. Nutr.</source><year>2010</year><volume>92</volume><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2010.29673</pub-id><pub-id pub-id-type="pmid">20810976</pub-id></element-citation></ref><ref id="B97-marinedrugs-18-00570"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lordan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>C.</given-names></name></person-group><article-title>Marine bioactives as functional food ingredients: Potential to reduce the incidence of chronic diseases</article-title><source>Mar. Drugs</source><year>2011</year><volume>9</volume><fpage>1056</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.3390/md9061056</pub-id><pub-id pub-id-type="pmid">21747748</pub-id><pub-id pub-id-type="pmcid">PMC3131561</pub-id></element-citation></ref><ref id="B98-marinedrugs-18-00570"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kogevinas</surname><given-names>M.</given-names></name></person-group><article-title>Prenatal and childhood Mediterranean diet and the development of asthma and allergies in children</article-title><source>Public Health Nutr.</source><year>2009</year><volume>12</volume><fpage>1629</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1017/S1368980009990474</pub-id><pub-id pub-id-type="pmid">19689832</pub-id></element-citation></ref><ref id="B99-marinedrugs-18-00570"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorl&#237;-Aguilar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;n-Luj&#225;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Santigosa-Ayala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pi&#241;ol-Moreso</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Flores-Mateo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Basora-Gallis&#224;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arija-Val</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sol&#224;-Alberich</surname><given-names>R.</given-names></name></person-group><article-title>Effects of Mediterranean diet on lung function in smokers: A randomised, parallel and controlled protocol</article-title><source>BMC Public Health</source><year>2015</year><volume>15</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-015-1450-x</pub-id><pub-id pub-id-type="pmid">25636808</pub-id><pub-id pub-id-type="pmcid">PMC4328054</pub-id></element-citation></ref><ref id="B100-marinedrugs-18-00570"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hageman</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hooyenga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diersen-Schade</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Scalabrin</surname><given-names>D.M.F.</given-names></name><name name-style="western"><surname>Wichers</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Birch</surname><given-names>E.E.</given-names></name></person-group><article-title>The impact of dietary long-chain polyunsaturated fatty acids on respiratory illness in infants and children</article-title><source>Curr. Allergy Asthma Rep.</source><year>2012</year><volume>12</volume><fpage>564</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1007/s11882-012-0304-1</pub-id><pub-id pub-id-type="pmid">23001718</pub-id><pub-id pub-id-type="pmcid">PMC3492691</pub-id></element-citation></ref><ref id="B101-marinedrugs-18-00570"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Folsom</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Melnick</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tockman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Comstock</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Gennaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Sorlie</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Szklo</surname><given-names>M.</given-names></name></person-group><article-title>Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>331</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1056/NEJM199407283310403</pub-id><pub-id pub-id-type="pmid">8015569</pub-id></element-citation></ref><ref id="B102-marinedrugs-18-00570"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanjani</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Saksena</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dehghani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name></person-group><article-title>From ocean to bedside: The therapeutic potential of molluscan hemocyanins</article-title><source>Curr. Med. Chem.</source><year>2018</year><volume>25</volume><fpage>2292</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170502124227</pub-id><pub-id pub-id-type="pmid">28464782</pub-id></element-citation></ref><ref id="B103-marinedrugs-18-00570"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Markl</surname><given-names>J.</given-names></name></person-group><article-title>Keyhole limpet hemocyanin (KLH): A biomedical review</article-title><source>Micron</source><year>1999</year><volume>30</volume><fpage>597</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/S0968-4328(99)00036-0</pub-id><pub-id pub-id-type="pmid">10544506</pub-id></element-citation></ref><ref id="B104-marinedrugs-18-00570"><label>104.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.G.</given-names></name></person-group><source>Chinese Marine Materia Medica</source><publisher-name>Shanghai Scientific and Technical Publishers</publisher-name><publisher-loc>Shanghai, China</publisher-loc><publisher-name>China Ocean Press</publisher-name><publisher-loc>Beijing, China</publisher-loc><publisher-name>Chemical Industry Press</publisher-name><publisher-loc>Beijing, China</publisher-loc><year>2009</year><fpage>371</fpage></element-citation></ref><ref id="B105-marinedrugs-18-00570"><label>105.</label><element-citation publication-type="web"><article-title>WoRMS World Register of Marine Species</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.marinespecies.org/aphia.php?p=search">http://www.marinespecies.org/aphia.php?p=search</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B106-marinedrugs-18-00570"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asta Lakshmi</surname><given-names>S.</given-names></name></person-group><article-title>Wonder molluscs and their utilities</article-title><source>Int. J. Pharm. Sci. Rev. Res.</source><year>2011</year><volume>6</volume><fpage>30</fpage><lpage>33</lpage></element-citation></ref><ref id="B107-marinedrugs-18-00570"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neto</surname><given-names>N.A.L.</given-names></name><name name-style="western"><surname>Voeks</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>T.L.P.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>R.R.N.</given-names></name></person-group><article-title>Mollusks of Candombl&#233;: Symbolic and ritualistic importance</article-title><source>J. Ethnobiol. Ethnomed.</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">22420523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1746-4269-8-10</pub-id><pub-id pub-id-type="pmcid">PMC3325884</pub-id></element-citation></ref><ref id="B108-marinedrugs-18-00570"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hamer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mander</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mkhize</surname><given-names>N.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>F.</given-names></name></person-group><article-title>Invertebrate animals as a component of the traditional medicine trade in KwaZulu-Natal, South Africa</article-title><source>Afr. Invertebr.</source><year>2003</year><volume>44</volume><fpage>1</fpage><lpage>18</lpage></element-citation></ref><ref id="B109-marinedrugs-18-00570"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voultsiadou Eleni</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic properties and uses of marine invertebrates in the ancient Greek world and early Byzantium</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>130</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.04.041</pub-id><pub-id pub-id-type="pmid">20435126</pub-id></element-citation></ref><ref id="B110-marinedrugs-18-00570"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>Y.</given-names></name></person-group><article-title>Determination of chemical constituents of the marine pulmonate slug, <italic toggle="yes">Paraoncidium Reevesii</italic></article-title><source>Trop. J. Pharm. Res.</source><year>2014</year><volume>13</volume><fpage>2071</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v13i12.18</pub-id></element-citation></ref><ref id="B111-marinedrugs-18-00570"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.Z.</given-names></name></person-group><article-title>Antitumor effect of Limax in tumor-bearing mice</article-title><source>Chin. J. Mod. Dev. Tradit. Med.</source><year>1989</year><volume>9</volume><fpage>675</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">2611958</pub-id></element-citation></ref><ref id="B112-marinedrugs-18-00570"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barberis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bragazzi</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Galluzzo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>M.</given-names></name></person-group><article-title>The history of tuberculosis: From the first historical records to the isolation of Koch&#8217;s bacillus</article-title><source>J. Prev. Med. Hyg.</source><year>2017</year><volume>58</volume><fpage>E9</fpage><lpage>E12</lpage><pub-id pub-id-type="pmid">28515626</pub-id><pub-id pub-id-type="pmcid">PMC5432783</pub-id></element-citation></ref><ref id="B113-marinedrugs-18-00570"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>H.N.</given-names></name></person-group><article-title>The faunal drugstore: Animal-based remedies used in traditional medicines in Latin America</article-title><source>J. Ethnobiol. Ethnomed.</source><year>2011</year><volume>7</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1746-4269-7-9</pub-id><pub-id pub-id-type="pmid">21385357</pub-id><pub-id pub-id-type="pmcid">PMC3060860</pub-id></element-citation></ref><ref id="B114-marinedrugs-18-00570"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vijayakumaran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kathiroli</surname><given-names>S.</given-names></name></person-group><article-title>Marine organisms in Indian medicine and their future prospects</article-title><source>Nat. Prod. Radiance</source><year>2008</year><volume>7</volume><fpage>139</fpage><lpage>145</lpage></element-citation></ref><ref id="B115-marinedrugs-18-00570"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>P.</given-names></name></person-group><article-title>Ethnozoological practices among Naga tribes</article-title><source>Indian J. Tradit. Knowl.</source><year>2005</year><volume>4</volume><fpage>100</fpage><lpage>104</lpage></element-citation></ref><ref id="B116-marinedrugs-18-00570"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shilabin</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Kasanah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wedge</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Hamann</surname><given-names>M.T.</given-names></name></person-group><article-title>Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: Semisynthetic modifications and antifungal lead-exploration studies</article-title><source>J. Med. Chem.</source><year>2007</year><volume>50</volume><fpage>4340</fpage><lpage>4350</lpage><pub-id pub-id-type="doi">10.1021/jm061288r</pub-id><pub-id pub-id-type="pmid">17696332</pub-id><pub-id pub-id-type="pmcid">PMC4917214</pub-id></element-citation></ref><ref id="B117-marinedrugs-18-00570"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pond</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Mabeza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Seronay</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Concepcion</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Barrows</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Olivera</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.W.</given-names></name></person-group><article-title>Structure and activity of lobophorins from a turrid mollusk-associated Streptomyces sp.</article-title><source>J. Antibiot.</source><year>2014</year><volume>67</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/ja.2013.115</pub-id><pub-id pub-id-type="pmid">24220110</pub-id><pub-id pub-id-type="pmcid">PMC4470571</pub-id></element-citation></ref><ref id="B118-marinedrugs-18-00570"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brieger</surname><given-names>J.E.</given-names></name></person-group><article-title>Calcarea carbonica or Ostrea edulis?</article-title><source>Br. Homeopath. J.</source><year>1960</year><volume>49</volume><fpage>41</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0007-0785(60)80026-9</pub-id></element-citation></ref><ref id="B119-marinedrugs-18-00570"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramchandani</surname><given-names>N.M.</given-names></name></person-group><article-title>Homoeopathic treatment of upper respiratory tract infections in children: Evaluation of thirty case series</article-title><source>Complement. Ther. Clin. Pract.</source><year>2010</year><volume>16</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.ctcp.2009.09.008</pub-id><pub-id pub-id-type="pmid">20347842</pub-id></element-citation></ref><ref id="B120-marinedrugs-18-00570"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colin</surname><given-names>P.</given-names></name></person-group><article-title>Homeopathy and respiratory allergies: A series of 147 cases</article-title><source>Homeopathy</source><year>2006</year><volume>95</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.homp.2006.01.003</pub-id><pub-id pub-id-type="pmid">16569621</pub-id></element-citation></ref><ref id="B121-marinedrugs-18-00570"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>I.L.</given-names></name></person-group><article-title>Zootherapeutic practices among fishing communities in North and Northeast Brazil: A comparison</article-title><source>J. Ethnopharmacol.</source><year>2007</year><volume>111</volume><fpage>82</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2006.10.033</pub-id><pub-id pub-id-type="pmid">17118592</pub-id></element-citation></ref><ref id="B122-marinedrugs-18-00570"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer-Rochow</surname><given-names>V.B.</given-names></name></person-group><article-title>Therapeutic arthropods and other, largely terrestrial, folk-medicinally important invertebrates: A comparative survey and review</article-title><source>J. Ethnobiol. Ethnomed.</source><year>2017</year><volume>13</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s13002-017-0136-0</pub-id><pub-id pub-id-type="pmid">28173820</pub-id><pub-id pub-id-type="pmcid">PMC5296966</pub-id></element-citation></ref><ref id="B123-marinedrugs-18-00570"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alade</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ajibesin</surname><given-names>K.K.</given-names></name></person-group><article-title>Animals and animal products as medicines: A survey of Epie-Atissa and Ogbia people of Bayelsa State, Nigeria</article-title><source>J. Pharm. Pharmacogn. Res.</source><year>2018</year><volume>6</volume><fpage>483</fpage><lpage>502</lpage></element-citation></ref><ref id="B124-marinedrugs-18-00570"><label>124.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Meyerhof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobhy</surname><given-names>G.P.</given-names></name></person-group><source>The Abridged Version of &#8220;The Book of Simple Drugs&#8221;, of Ahmad Ibn Muhammad Al-Ghafiqi by Gregorius Abul-Farag</source><publisher-name>Al Ettemad Printing Press and Publising House</publisher-name><publisher-loc>Cairo, Egypt</publisher-loc><year>1932</year><fpage>224</fpage><lpage>228</lpage></element-citation></ref><ref id="B125-marinedrugs-18-00570"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabhakar</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.P.</given-names></name></person-group><article-title>Ethno-medicinal uses of some shell fishes by people of Kosi river basin of North-Bihar, India</article-title><source>Stud. Ethno Med.</source><year>2009</year><volume>3</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1080/09735070.2009.11886329</pub-id></element-citation></ref><ref id="B126-marinedrugs-18-00570"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nongmaithem</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Mouatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Volatile and bioactive compounds in opercula from Muricidae molluscs supports their use in ceremonial incense and traditional medicines</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-17551-3</pub-id><pub-id pub-id-type="pmid">29234065</pub-id><pub-id pub-id-type="pmcid">PMC5727037</pub-id></element-citation></ref><ref id="B127-marinedrugs-18-00570"><label>127.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lev</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zohar</surname><given-names>A.</given-names></name></person-group><source>Practical Materia Medica of the Medieval Eastern Mediterranean according to the Cairo Genizah</source><publisher-name>Brill Online Books and Journals</publisher-name><publisher-loc>Leiden, The Netherlands</publisher-loc><year>2008</year><volume>Volume 7</volume></element-citation></ref><ref id="B128-marinedrugs-18-00570"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.J.</given-names></name></person-group><article-title>Ethnozoological study of medicinal animals on Jeju Island, Korea</article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>146</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.11.011</pub-id><pub-id pub-id-type="pmid">23266277</pub-id></element-citation></ref><ref id="B129-marinedrugs-18-00570"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinlampianga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A.C.</given-names></name></person-group><article-title>Ethnozoological diversity of Northeast India: Empirical learning with traditional knowledge holders of Mizoram and Arunachal Pradesh</article-title><source>Indian J. Tradit. Knowl.</source><year>2013</year><volume>12</volume><fpage>18</fpage><lpage>30</lpage></element-citation></ref><ref id="B130-marinedrugs-18-00570"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>I.L.</given-names></name></person-group><article-title>Zootherapy goes to town: The use of animal-based remedies in urban areas of NE and N Brazil</article-title><source>J. Ethnopharmacol.</source><year>2007</year><volume>113</volume><fpage>541</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2007.07.015</pub-id><pub-id pub-id-type="pmid">17719192</pub-id></element-citation></ref><ref id="B131-marinedrugs-18-00570"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McHugh</surname><given-names>J.</given-names></name></person-group><article-title>Blattes de byzance in India: Mollusk opercula and the history of perfumery</article-title><source>J. R. Asiat. Soc.</source><year>2013</year><volume>23</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1017/S1356186312000727</pub-id></element-citation></ref><ref id="B132-marinedrugs-18-00570"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cragg</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>Natural products: A continuing source of novel drug leads</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>2013</year><volume>1830</volume><fpage>3670</fpage><lpage>3695</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2013.02.008</pub-id><pub-id pub-id-type="pmcid">PMC3672862</pub-id><pub-id pub-id-type="pmid">23428572</pub-id></element-citation></ref><ref id="B133-marinedrugs-18-00570"><label>133.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>HPUS</collab></person-group><source>Homeopathic Materia Medica of the United States</source><edition>1st ed.</edition><publisher-name>Duncan Brothers Publishers</publisher-name><publisher-loc>Chicago, IL, USA</publisher-loc><year>1878</year></element-citation></ref><ref id="B134-marinedrugs-18-00570"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Immanuel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thaddaeus</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Usha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramasubburayan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palavesam</surname><given-names>A.</given-names></name></person-group><article-title>Antipyretic, wound healing and antimicrobial activity of processed shell of the marine mollusc <italic toggle="yes">Cypraea moneta</italic></article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2012</year><volume>2</volume><issue>Suppl. S3</issue><fpage>S1643</fpage><lpage>S1646</lpage><pub-id pub-id-type="doi">10.1016/S2221-1691(12)60469-9</pub-id></element-citation></ref><ref id="B135-marinedrugs-18-00570"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rinaudo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jellouli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nasri</surname><given-names>M.</given-names></name></person-group><article-title>Characterization and in vitro evaluation of cytotoxicity, antimicrobial and antioxidant activities of chitosans extracted from three different marine sources</article-title><source>Appl. Biochem. Biotechnol.</source><year>2015</year><volume>177</volume><fpage>18</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s12010-015-1724-x</pub-id><pub-id pub-id-type="pmid">26150381</pub-id></element-citation></ref><ref id="B136-marinedrugs-18-00570"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanmugam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kathiresan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>L.</given-names></name></person-group><article-title>Preparation, characterization and antibacterial activity of chitosan and phosphorylated chitosan from cuttlebone of <italic toggle="yes">Sepia kobiensis</italic> (Hoyle, 1885)</article-title><source>Biotechnol. Rep.</source><year>2016</year><volume>9</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.btre.2015.10.007</pub-id><pub-id pub-id-type="pmcid">PMC5394631</pub-id><pub-id pub-id-type="pmid">28507912</pub-id></element-citation></ref><ref id="B137-marinedrugs-18-00570"><label>137.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Oakes</surname><given-names>F.R.</given-names></name></person-group><article-title>Non-Lethal Method for Extracting Crude Hemocyanin from Gastropod Molluscs</article-title><source>U.S. Patent</source><patent>No.6852338B2</patent><year>2005</year><day>8</day><month>2</month></element-citation></ref><ref id="B138-marinedrugs-18-00570"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quevauviller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mainil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcet</surname><given-names>S.</given-names></name></person-group><article-title>Le mucus d&#8217;<italic toggle="yes">H&#233;lix pomatia</italic> L.-pr&#233;paration, composition, propri&#233;t&#233;s th&#233;rapeutiques et pharmacodynamiques</article-title><source>Rev. Pathol. Gen. Physiol. Clin.</source><year>1953</year><volume>653</volume><fpage>1514</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">13156274</pub-id></element-citation></ref><ref id="B139-marinedrugs-18-00570"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yie</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Tchou-Wong</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Rom</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.C.</given-names></name></person-group><article-title>Selective p38 activation in human non-small cell lung cancer</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2002</year><volume>26</volume><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.26.5.4689</pub-id><pub-id pub-id-type="pmid">11970907</pub-id></element-citation></ref><ref id="B140-marinedrugs-18-00570"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G.Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.K.</given-names></name></person-group><article-title>Effect of Limax lyophilized powder on bronchial asthma</article-title><source>J. Chin. Med. Mater.</source><year>2011</year><volume>34</volume><fpage>1086</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">22066405</pub-id></element-citation></ref><ref id="B141-marinedrugs-18-00570"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Natural product research in the Australian marine invertebrate <italic toggle="yes">Dicathais Orbita</italic></article-title><source>Mar. Drugs</source><year>2013</year><volume>11</volume><fpage>1370</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.3390/md11041370</pub-id><pub-id pub-id-type="pmid">23612370</pub-id><pub-id pub-id-type="pmcid">PMC3705410</pub-id></element-citation></ref><ref id="B142-marinedrugs-18-00570"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roseghini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Severini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Erspamer</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Erspamer</surname><given-names>V.</given-names></name></person-group><article-title>Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily</article-title><source>Toxicon</source><year>1996</year><volume>34</volume><fpage>33</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(95)00104-2</pub-id><pub-id pub-id-type="pmid">8835333</pub-id></element-citation></ref><ref id="B143-marinedrugs-18-00570"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Sex-specific Tyrian purple genesis: Precursor and pigment distribution in the reproductive system of the marine mollusc, <italic toggle="yes">Dicathais Orbita</italic></article-title><source>J. Chem. Ecol.</source><year>2008</year><volume>34</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s10886-007-9402-2</pub-id><pub-id pub-id-type="pmid">18075711</pub-id></element-citation></ref><ref id="B144-marinedrugs-18-00570"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooksey</surname><given-names>C.J.</given-names></name></person-group><article-title>Tyrian purple: 6, 6&#8242;-dibromoindigo and related compounds</article-title><source>Molecules</source><year>2001</year><volume>6</volume><fpage>736</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.3390/60900736</pub-id></element-citation></ref><ref id="B145-marinedrugs-18-00570"><label>145.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>K.C.</given-names></name></person-group><source>The Elder Pliny&#8217;s Chapters on Chemical Subjects</source><publisher-name>E. Arnold &amp; Company</publisher-name><publisher-loc>London, UK</publisher-loc><year>1932</year></element-citation></ref><ref id="B146-marinedrugs-18-00570"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>V.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Young</surname><given-names>F.</given-names></name></person-group><article-title>Marine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cells</article-title><source>Mar. Drugs</source><year>2012</year><volume>10</volume><fpage>64</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3390/md10010064</pub-id><pub-id pub-id-type="pmid">22363221</pub-id><pub-id pub-id-type="pmcid">PMC3280530</pub-id></element-citation></ref><ref id="B147-marinedrugs-18-00570"><label>147.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeelian</surname><given-names>B.</given-names></name></person-group><article-title>In Vitro and In Vivo Testing of Purified Muricid Mollusc Extract on Colorectal Cancer</article-title><source>Ph.D. Thesis</source><publisher-name>Flinders University</publisher-name><publisher-loc>Adelaide, Australia</publisher-loc><year>2014</year></element-citation></ref><ref id="B148-marinedrugs-18-00570"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sklirou</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Gaboriaud-Kolar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Papassideri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skaltsounis</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Trougakos</surname><given-names>I.P.</given-names></name></person-group><article-title>6-bromo-indirubin-3&#8242;-oxime (6BIO), a Glycogen synthase kinase-3&#946; inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>11713</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11662-7</pub-id><pub-id pub-id-type="pmid">28916781</pub-id><pub-id pub-id-type="pmcid">PMC5601901</pub-id></element-citation></ref><ref id="B149-marinedrugs-18-00570"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.R.</given-names></name></person-group><article-title>Tyrian purple precursors in the egg masses of the Australian muricid, <italic toggle="yes">Dicathais orbita</italic>: A possible defensive role</article-title><source>J. Chem. Ecol.</source><year>2000</year><volume>26</volume><fpage>1037</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1023/A:1005441116095</pub-id></element-citation></ref><ref id="B150-marinedrugs-18-00570"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gesheva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Idakieva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kerekov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nikolova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Doumanova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tchorbanov</surname><given-names>A.</given-names></name></person-group><article-title>Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins</article-title><source>Fish Shellfish Immunol.</source><year>2011</year><volume>30</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2010.09.018</pub-id><pub-id pub-id-type="pmid">20887791</pub-id></element-citation></ref><ref id="B151-marinedrugs-18-00570"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kotiw</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Correlation between fatty acid profile and anti-inflammatory activity in common Australian seafood by-products</article-title><source>Mar. Drugs</source><year>2019</year><volume>17</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.3390/md17030155</pub-id><pub-id pub-id-type="pmid">30845724</pub-id><pub-id pub-id-type="pmcid">PMC6471488</pub-id></element-citation></ref><ref id="B152-marinedrugs-18-00570"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>P.D.</given-names></name></person-group><article-title>The Scaphopoda</article-title><source>Adv. Mar. Biol.</source><year>2002</year><volume>42</volume><fpage>137</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">12094723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-2881(02)42014-7</pub-id></element-citation></ref><ref id="B153-marinedrugs-18-00570"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Toledo-Piza</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Negri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mendonca</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C.A.</given-names></name></person-group><article-title>Polyunsaturated fatty acids from <italic toggle="yes">Phyllocaulis boraceiensis</italic> mucus block the replication of influenza virus</article-title><source>Arch. Microbiol.</source><year>2018</year><volume>200</volume><fpage>961</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1007/s00203-018-1507-1</pub-id><pub-id pub-id-type="pmid">29616305</pub-id></element-citation></ref><ref id="B154-marinedrugs-18-00570"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Toledo-Piza</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Negri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Namiyama</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tonelotto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villar</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Rofatto</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Mendonca</surname><given-names>R.Z.</given-names></name></person-group><article-title>The antiviral effect of mollusk mucus on measles virus</article-title><source>Antivir. Res.</source><year>2016</year><volume>134</volume><fpage>172</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.09.005</pub-id><pub-id pub-id-type="pmid">27623346</pub-id></element-citation></ref><ref id="B155-marinedrugs-18-00570"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szab&#243;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amesbury</surname><given-names>J.R.</given-names></name></person-group><article-title>Molluscs in a world of islands: The use of shellfish as a food resource in the tropical island Asia-Pacific region</article-title><source>Quat. Int.</source><year>2011</year><volume>239</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.quaint.2011.02.033</pub-id></element-citation></ref><ref id="B156-marinedrugs-18-00570"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dortch</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kendrick</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>K.</given-names></name></person-group><article-title>Aboriginal mollusc exploitation in southwestern Australia</article-title><source>Archaeol. Ocean.</source><year>1984</year><volume>19</volume><fpage>81</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1002/j.1834-4453.1984.tb00088.x</pub-id></element-citation></ref><ref id="B157-marinedrugs-18-00570"><label>157.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bodeker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.-K.</given-names></name></person-group><source>WHO Global Atlas of Traditional, Complementary and Alternative Medicine</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Kobe, Japan</publisher-loc><year>2005</year><volume>Volume 1</volume><fpage>347</fpage></element-citation></ref><ref id="B158-marinedrugs-18-00570"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allaertaert</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Villet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sauve</surname><given-names>L.</given-names></name></person-group><article-title>Observational study on the dispensing of cough syrups to children with acute cough by community pharmacists in France</article-title><source>Minerva Pediatr.</source><year>2018</year><volume>70</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">28211646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23736/S0026-4946.17.04752-1</pub-id></element-citation></ref><ref id="B159-marinedrugs-18-00570"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fung</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Linn</surname><given-names>Y.C.</given-names></name></person-group><article-title>Developing traditional chinese medicine in the era of evidence-based medicine: Current evidences and challenges</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2015</year><volume>2015</volume><fpage>425037</fpage><pub-id pub-id-type="doi">10.1155/2015/425037</pub-id><pub-id pub-id-type="pmcid">PMC4407626</pub-id><pub-id pub-id-type="pmid">25949261</pub-id></element-citation></ref><ref id="B160-marinedrugs-18-00570"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morice</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kardos</surname><given-names>P.</given-names></name></person-group><article-title>Comprehensive evidence-based review on European antitussives</article-title><source>BMJ Open Respir. Res.</source><year>2016</year><volume>3</volume><fpage>e000137</fpage><pub-id pub-id-type="doi">10.1136/bmjresp-2016-000137</pub-id><pub-id pub-id-type="pmcid">PMC4985807</pub-id><pub-id pub-id-type="pmid">27547407</pub-id></element-citation></ref><ref id="B161-marinedrugs-18-00570"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roch</surname><given-names>P.</given-names></name></person-group><article-title>Defense mechanisms and disease prevention in farmed marine invertebrates</article-title><source>Aquaculture</source><year>1999</year><volume>172</volume><fpage>125</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/S0044-8486(98)00439-6</pub-id></element-citation></ref><ref id="B162-marinedrugs-18-00570"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Der Knaap</surname><given-names>W.</given-names></name><name name-style="western"><surname>No&#235;l</surname><given-names>T.</given-names></name></person-group><article-title>Present knowledge on the molecular basis of cytotoxicity, antibacterial activity and stress response in marine bivalves</article-title><source>Ital. J. Zool.</source><year>1996</year><volume>63</volume><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1080/11250009609356151</pub-id></element-citation></ref><ref id="B163-marinedrugs-18-00570"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z.</given-names></name></person-group><article-title>Potential reasons and controlling strategies of mollusk dramatic death in China</article-title><source>Chin. Fish.</source><year>1999</year><volume>9</volume><fpage>34</fpage><lpage>39</lpage></element-citation></ref><ref id="B164-marinedrugs-18-00570"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zannella</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mosca</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Franci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Folliero</surname><given-names>V.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiscar</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>M.</given-names></name></person-group><article-title>Microbial diseases of bivalve mollusks: Infections, immunology and antimicrobial defense</article-title><source>Mar. Drugs</source><year>2017</year><volume>15</volume><elocation-id>188</elocation-id><pub-id pub-id-type="doi">10.3390/md15060182</pub-id><pub-id pub-id-type="pmid">28629124</pub-id><pub-id pub-id-type="pmcid">PMC5484132</pub-id></element-citation></ref><ref id="B165-marinedrugs-18-00570"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yum</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.J.</given-names></name></person-group><article-title>Recurrent Pseudomonas aeruginosa infection in chronic lung diseases: Relapse or reinfection?</article-title><source>Tuberc. Respir. Dis.</source><year>2014</year><volume>77</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.4046/trd.2014.77.4.172</pub-id><pub-id pub-id-type="pmcid">PMC4217033</pub-id><pub-id pub-id-type="pmid">25368663</pub-id></element-citation></ref><ref id="B166-marinedrugs-18-00570"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Malkowski</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Varney</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Intranasal peptide-based fpva-klh conjugate vaccine protects mice from <italic toggle="yes">Pseudomonas aeruginosa</italic> acute murine pneumonia</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fimmu.2019.02497</pub-id><pub-id pub-id-type="pmcid">PMC6819369</pub-id><pub-id pub-id-type="pmid">31708925</pub-id></element-citation></ref><ref id="B167-marinedrugs-18-00570"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Roch</surname><given-names>P.</given-names></name></person-group><article-title>Myticin, a novel cysteine-rich antimicrobial peptide isolated from haemocytes and plasma of the mussel <italic toggle="yes">Mytilus galloprovincialis</italic></article-title><source>Eur. J. Biochem.</source><year>1999</year><volume>265</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00654.x</pub-id><pub-id pub-id-type="pmid">10491159</pub-id></element-citation></ref><ref id="B168-marinedrugs-18-00570"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domeneghetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Franzoi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>N.</given-names></name><name name-style="western"><surname>Norante</surname><given-names>R.</given-names></name><name name-style="western"><surname>El Halfawy</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Mammi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bellanda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Venier</surname><given-names>P.</given-names></name></person-group><article-title>Structural and antimicrobial features of peptides related to Myticin C, a special defense molecule from the Mediterranean mussel <italic toggle="yes">Mytilus galloprovincialis</italic></article-title><source>J. Agric. Food Chem.</source><year>2015</year><volume>63</volume><fpage>9251</fpage><lpage>9259</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.5b03491</pub-id><pub-id pub-id-type="pmid">26444944</pub-id></element-citation></ref><ref id="B169-marinedrugs-18-00570"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elshahawi</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Trindade-Silva</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Hanora</surname><given-names>A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Vizzoni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schrago</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Concepcion</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Distel</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Boronated tartrolon antibiotic produced by symbiotic cellulose-degrading bacteria in shipworm gills</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>E295</fpage><lpage>E304</lpage><pub-id pub-id-type="doi">10.1073/pnas.1213892110</pub-id><pub-id pub-id-type="pmid">23288898</pub-id><pub-id pub-id-type="pmcid">PMC3557025</pub-id></element-citation></ref><ref id="B170-marinedrugs-18-00570"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maselli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salzano</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Scaloni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maione</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falanga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naviglio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Cosmo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>S.</given-names></name></person-group><article-title>OctoPartenopin: Identification and preliminary characterization of a novel antimicrobial peptide from the suckers of <italic toggle="yes">Octopus vulgaris</italic></article-title><source>Mar. Drugs</source><year>2020</year><volume>18</volume><elocation-id>380</elocation-id><pub-id pub-id-type="doi">10.3390/md18080380</pub-id><pub-id pub-id-type="pmcid">PMC7460285</pub-id><pub-id pub-id-type="pmid">32717885</pub-id></element-citation></ref><ref id="B171-marinedrugs-18-00570"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karuso</surname><given-names>P.</given-names></name></person-group><article-title>Isolation and total synthesis of two novel metabolites from the fissurellid mollusc <italic toggle="yes">Scutus antipodes</italic></article-title><source>Tetrahedron Lett.</source><year>2017</year><volume>58</volume><fpage>1020</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2017.01.096</pub-id></element-citation></ref><ref id="B172-marinedrugs-18-00570"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marongiu</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Obino</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gavagnin</surname><given-names>M.</given-names></name><name name-style="western"><surname>La Colla</surname><given-names>P.</given-names></name></person-group><article-title>Antimicrobial and antiviral activity of xylosyl-methylthio-adenosine, a naturally occurring analogue of methylthio-adenosine from <italic toggle="yes">Doris verrucosa</italic></article-title><source>Experientia</source><year>1991</year><volume>47</volume><fpage>1228</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1007/BF01918391</pub-id><pub-id pub-id-type="pmid">1765135</pub-id></element-citation></ref><ref id="B173-marinedrugs-18-00570"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chellaram</surname><given-names>C.</given-names></name><name name-style="western"><surname>Edward</surname><given-names>J.</given-names></name></person-group><article-title>Anti-inflammatory potential of coral reef associated gastropod, <italic toggle="yes">Drupa Margariticola</italic></article-title><source>Indian J. Sci. Technol.</source><year>2009</year><volume>2</volume><fpage>75</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.17485/ijst/2009/v2i2.12</pub-id></element-citation></ref><ref id="B174-marinedrugs-18-00570"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitt</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dedi</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Taylor-Harris</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>A.</given-names></name></person-group><article-title>Antimicrobial properties of mucus from the brown garden snail <italic toggle="yes">Helix aspersa</italic></article-title><source>Br. J. Biomed. Sci.</source><year>2015</year><volume>72</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1080/09674845.2015.11665749</pub-id><pub-id pub-id-type="pmid">26738399</pub-id></element-citation></ref><ref id="B175-marinedrugs-18-00570"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Periyasamy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balakrishnan</surname><given-names>S.</given-names></name></person-group><article-title>Antimicrobial activities of the tissue extracts of <italic toggle="yes">Babylonia spirata</italic> Linnaeus, 1758 (Mollusca: Gastropoda) from Thazhanguda, southeast coast of India</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2012</year><volume>2</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S2221-1691(11)60186-X</pub-id><pub-id pub-id-type="pmid">23569831</pub-id><pub-id pub-id-type="pmcid">PMC3609203</pub-id></element-citation></ref><ref id="B176-marinedrugs-18-00570"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Tun</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Forteza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haygood</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Concepcion</surname><given-names>G.P.</given-names></name></person-group><article-title>Synergistic anti-methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) activity and absolute stereochemistry of 7,8-dideoxygriseorhodin C</article-title><source>J. Antibiot.</source><year>2020</year><volume>73</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/s41429-019-0275-8</pub-id><pub-id pub-id-type="pmcid">PMC7125055</pub-id><pub-id pub-id-type="pmid">31992865</pub-id></element-citation></ref><ref id="B177-marinedrugs-18-00570"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Bedi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sadikot</surname><given-names>R.T.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> biofilms: Host response and clinical implications in lung infections</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2018</year><volume>58</volume><fpage>428</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2017-0321TR</pub-id><pub-id pub-id-type="pmid">29372812</pub-id><pub-id pub-id-type="pmcid">PMC5894500</pub-id></element-citation></ref><ref id="B178-marinedrugs-18-00570"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gasu</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Ahor</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Borquaye</surname><given-names>L.S.</given-names></name></person-group><article-title>Peptide mix from <italic toggle="yes">Olivancillaria hiatula</italic> interferes with cell-to-cell communication in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>BioMed Res. Int.</source><year>2019</year><volume>2019</volume><pub-id pub-id-type="doi">10.1155/2019/5313918</pub-id><pub-id pub-id-type="pmcid">PMC6778971</pub-id><pub-id pub-id-type="pmid">31662981</pub-id></element-citation></ref><ref id="B179-marinedrugs-18-00570"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gasu</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Ahor</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Borquaye</surname><given-names>L.S.</given-names></name></person-group><article-title>Peptide extract from <italic toggle="yes">Olivancillaria hiatula</italic> exhibits broad-spectrum antibacterial activity</article-title><source>BioMed Res. Int.</source><year>2018</year><volume>2018</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1155/2018/6010572</pub-id><pub-id pub-id-type="pmcid">PMC6323461</pub-id><pub-id pub-id-type="pmid">30671464</pub-id></element-citation></ref><ref id="B180-marinedrugs-18-00570"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishwarya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vaseeharan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Iswarya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karthikeyan</surname><given-names>S.</given-names></name></person-group><article-title>Haemolytic and antibiofilm properties of haemocyanin purified from the haemolymph of Indian white shrimp <italic toggle="yes">Fenneropenaeus indicus</italic></article-title><source>Fish Shellfish Immunol.</source><year>2016</year><volume>59</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2016.10.043</pub-id><pub-id pub-id-type="pmid">27815202</pub-id></element-citation></ref><ref id="B181-marinedrugs-18-00570"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishwarya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Iswarya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thangaviji</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sivakamavalli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Thangaraj</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Vaseeharan</surname><given-names>B.</given-names></name></person-group><article-title>Immunological and antibiofilm property of haemocyanin purified from grooved tiger shrimp (<italic toggle="yes">Penaeus semisulcatus</italic>): An in vitro and in silico approach</article-title><source>Microb. Pathog.</source><year>2020</year><volume>147</volume><fpage>104253</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104253</pub-id><pub-id pub-id-type="pmid">32592822</pub-id></element-citation></ref><ref id="B182-marinedrugs-18-00570"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishwarya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vaseeharan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jayakumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramasubramanian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Govindarajan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Khaled</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Al-anbr</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Benelli</surname><given-names>G.</given-names></name></person-group><article-title>Bio-mining drugs from the sea: High antibiofilm properties of haemocyanin purified from the haemolymph of flower crab <italic toggle="yes">Portunus pelagicus</italic> (L.) (Decapoda: Portunidae)</article-title><source>Aquaculture</source><year>2018</year><volume>489</volume><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2018.02.014</pub-id></element-citation></ref><ref id="B183-marinedrugs-18-00570"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Poll</surname><given-names>T.</given-names></name><name name-style="western"><surname>Opal</surname><given-names>S.M.</given-names></name></person-group><article-title>Pathogenesis, treatment, and prevention of pneumococcal pneumonia</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>1543</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61114-4</pub-id><pub-id pub-id-type="pmid">19880020</pub-id></element-citation></ref><ref id="B184-marinedrugs-18-00570"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chellaram</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sreenivasan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Jonesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Edward</surname><given-names>J.K.P.</given-names></name></person-group><article-title>In vitro antibiotic bustle of coral reef associated gastropod, <italic toggle="yes">Drupa Margariticola</italic> (Broderip, 1832) of tuticorin coastal waters, Southeastern India</article-title><source>Biotechnology</source><year>2009</year><volume>8</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.3923/biotech.2009.456.461</pub-id></element-citation></ref><ref id="B185-marinedrugs-18-00570"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subhapradha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Krishnamoorthy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>A.</given-names></name></person-group><article-title>In vitro evaluation of antimicrobial activity of methanolic extract from selected species of Cephalopods on clinical isolates</article-title><source>Afr. J. Microbiol. Res.</source><year>2011</year><volume>5</volume><fpage>3884</fpage><lpage>3889</lpage></element-citation></ref><ref id="B186-marinedrugs-18-00570"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Defres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marwick</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nathwani</surname><given-names>D.</given-names></name></person-group><article-title>MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia</article-title><source>Eur. Respir. J.</source><year>2009</year><volume>34</volume><fpage>1470</fpage><pub-id pub-id-type="doi">10.1183/09031936.00122309</pub-id><pub-id pub-id-type="pmid">19948913</pub-id></element-citation></ref><ref id="B187-marinedrugs-18-00570"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notariale</surname><given-names>R.</given-names></name><name name-style="western"><surname>Basile</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Cacciapuoti</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Aliberti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gesuele</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Ruberto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sorbo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tenore</surname><given-names>G.C.</given-names></name><etal/></person-group><article-title>Protamine-like proteins have bactericidal activity: The first evidence in <italic toggle="yes">Mytilus galloprovincialis</italic></article-title><source>Acta Biochim. Pol.</source><year>2018</year><volume>65</volume><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.18388/abp.2018_2638</pub-id><pub-id pub-id-type="pmid">30447153</pub-id></element-citation></ref><ref id="B188-marinedrugs-18-00570"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.L.</given-names></name></person-group><article-title>Sialic acid-binding lectins (SABLs) from Solen grandis function as PRRs ensuring immune recognition and bacterial clearance</article-title><source>Fish Shellfish Immunol.</source><year>2018</year><volume>72</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2017.11.026</pub-id><pub-id pub-id-type="pmid">29146448</pub-id></element-citation></ref><ref id="B189-marinedrugs-18-00570"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cilia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fratini</surname><given-names>F.</given-names></name></person-group><article-title>Antimicrobial properties of terrestrial snail and slug mucus</article-title><source>J. Complement. Integr. Med.</source><year>2018</year><volume>15</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1515/jcim-2017-0168</pub-id><pub-id pub-id-type="pmid">29596054</pub-id></element-citation></ref><ref id="B190-marinedrugs-18-00570"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Destoumieux-Garzon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vidal-Dupiol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mitta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gueguen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bachere</surname><given-names>E.</given-names></name></person-group><article-title>Antimicrobial peptides in marine invertebrate health and disease</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2016</year><volume>371</volume><pub-id pub-id-type="doi">10.1098/rstb.2015.0300</pub-id><pub-id pub-id-type="pmcid">PMC4874397</pub-id><pub-id pub-id-type="pmid">27160602</pub-id></element-citation></ref><ref id="B191-marinedrugs-18-00570"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoang</surname><given-names>V.L.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>Antimicrobial peptides from marine sources</article-title><source>Curr. Protein Pept. Sci.</source><year>2013</year><volume>14</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.2174/13892037113149990037</pub-id><pub-id pub-id-type="pmid">23721311</pub-id></element-citation></ref><ref id="B192-marinedrugs-18-00570"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazcano-P&#233;rez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rom&#225;n-Gonz&#225;lez</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Puig</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arregu&#237;n-Espinosa</surname><given-names>R.</given-names></name></person-group><article-title>Bioactive peptides from marine organisms: A short overview</article-title><source>Protein Pept. Lett.</source><year>2012</year><volume>19</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.2174/092986612800793208</pub-id><pub-id pub-id-type="pmid">22489781</pub-id></element-citation></ref><ref id="B193-marinedrugs-18-00570"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ageitos</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>S&#225;nchez-P&#233;rez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calo-Mata</surname><given-names>P.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>T.G.</given-names></name></person-group><article-title>Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria</article-title><source>Biochem. Pharmacol.</source><year>2017</year><volume>133</volume><fpage>117</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.018</pub-id><pub-id pub-id-type="pmid">27663838</pub-id></element-citation></ref><ref id="B194-marinedrugs-18-00570"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tincu</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S.W.</given-names></name></person-group><article-title>Antimicrobial peptides from marine invertebrates</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>3645</fpage><lpage>3654</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.10.3645-3654.2004</pub-id><pub-id pub-id-type="pmid">15388415</pub-id><pub-id pub-id-type="pmcid">PMC521913</pub-id></element-citation></ref><ref id="B195-marinedrugs-18-00570"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sable</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parajuli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jois</surname><given-names>S.</given-names></name></person-group><article-title>Peptides, peptidomimetics, and polypeptides from marine sources: A wealth of natural sources for pharmaceutical applications</article-title><source>Mar. Drugs</source><year>2017</year><volume>15</volume><elocation-id>124</elocation-id><pub-id pub-id-type="doi">10.3390/md15040124</pub-id><pub-id pub-id-type="pmcid">PMC5408270</pub-id><pub-id pub-id-type="pmid">28441741</pub-id></element-citation></ref><ref id="B196-marinedrugs-18-00570"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carriel-Gomes</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kratz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>V.D.M.</given-names></name><name name-style="western"><surname>Barardi</surname><given-names>C.R.M.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>C.M.O.</given-names></name></person-group><article-title>Evaluation of antiviral activity in hemolymph from oysters <italic toggle="yes">Crassostrea rhizophorae</italic> and <italic toggle="yes">Crassostrea gigas</italic></article-title><source>Aquat. Living Resour.</source><year>2006</year><volume>19</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1051/alr:2006017</pub-id></element-citation></ref><ref id="B197-marinedrugs-18-00570"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolashka-Angelova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>B.</given-names></name><name name-style="western"><surname>Velkova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heilen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sandra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nikolaeva-Glomb</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dolashki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galabov</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Van Beeumen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stevanovic</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of glycosylated sites in <italic toggle="yes">Rapana</italic> hemocyanin by mass spectrometry and gene sequence, and their antiviral effect</article-title><source>Bioconjugate Chem.</source><year>2009</year><volume>20</volume><fpage>1315</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1021/bc900034k</pub-id><pub-id pub-id-type="pmid">19499947</pub-id></element-citation></ref><ref id="B198-marinedrugs-18-00570"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swaminathan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Dear</surname><given-names>K.</given-names></name><name name-style="western"><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Keyhole limpet haemocyanin-a model antigen for human immunotoxicological studies</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>78</volume><fpage>1135</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1111/bcp.12422</pub-id><pub-id pub-id-type="pmid">24833186</pub-id><pub-id pub-id-type="pmcid">PMC4243888</pub-id></element-citation></ref><ref id="B199-marinedrugs-18-00570"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Matsuno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.R.I.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kishimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Crystal Structure of the 3.8-MDa Respiratory Supermolecule Hemocyanin at 3.0 &#197; Resolution</article-title><source>Structure</source><year>2015</year><volume>23</volume><fpage>2204</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.09.008</pub-id><pub-id pub-id-type="pmid">26602184</pub-id></element-citation></ref><ref id="B200-marinedrugs-18-00570"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name></person-group><article-title>High-value compounds from the molluscs of marine and estuarine ecosystems as prospective functional food ingredients: An overview</article-title><source>Food Res. Int.</source><year>2020</year><volume>137</volume><fpage>109637</fpage><pub-id pub-id-type="doi">10.1016/j.foodres.2020.109637</pub-id><pub-id pub-id-type="pmid">33233216</pub-id><pub-id pub-id-type="pmcid">PMC7457972</pub-id></element-citation></ref><ref id="B201-marinedrugs-18-00570"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chernov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kasuya</surname><given-names>H.</given-names></name></person-group><article-title>Potential role of zinc supplementation in prophylaxis and treatment of COVID-19</article-title><source>Med. Hypotheses</source><year>2020</year><volume>144</volume><fpage>109848</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2020.109848</pub-id><pub-id pub-id-type="pmid">32512490</pub-id><pub-id pub-id-type="pmcid">PMC7247509</pub-id></element-citation></ref><ref id="B202-marinedrugs-18-00570"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Te Velthuis</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>van den Worm</surname><given-names>S.H.E.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><article-title>Zn<sup>2+</sup> inhibits coronavirus and arterivirus rna polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1001176</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001176</pub-id><pub-id pub-id-type="pmid">21079686</pub-id><pub-id pub-id-type="pmcid">PMC2973827</pub-id></element-citation></ref><ref id="B203-marinedrugs-18-00570"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wessels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rolles</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rink</surname><given-names>L.</given-names></name></person-group><article-title>The potential impact of zinc supplementation on COVID-19 pathogenesis</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1712</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01712</pub-id><pub-id pub-id-type="pmid">32754164</pub-id><pub-id pub-id-type="pmcid">PMC7365891</pub-id></element-citation></ref><ref id="B204-marinedrugs-18-00570"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Meguid</surname><given-names>M.M.</given-names></name></person-group><article-title>Metabolic alterations during inflammation and its modulation by central actions of omega-3 fatty acids</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><year>2003</year><volume>6</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1097/01.mco.0000078981.18774.5e</pub-id><pub-id pub-id-type="pmid">12806215</pub-id></element-citation></ref><ref id="B205-marinedrugs-18-00570"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>S.</given-names></name></person-group><article-title>Dietary fat and asthma: Is there a connection?</article-title><source>Eur. Respir. J.</source><year>1997</year><volume>10</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1183/09031936.97.10010006</pub-id><pub-id pub-id-type="pmid">9032484</pub-id></element-citation></ref><ref id="B206-marinedrugs-18-00570"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calder</surname><given-names>P.C.</given-names></name></person-group><article-title>Very long-chain n-3 fatty acids and human health: Fact, fiction and the future</article-title><source>Proc. Nutr. Soc.</source><year>2018</year><volume>77</volume><fpage>52</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1017/S0029665117003950</pub-id><pub-id pub-id-type="pmid">29039280</pub-id></element-citation></ref><ref id="B207-marinedrugs-18-00570"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mickleborough</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Shei</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wilhite</surname><given-names>D.P.</given-names></name></person-group><article-title>Marine lipid fraction PCSO-524&#8482; (Lyprinol<sup>&#174;</sup>/Omega XL<sup>&#174;</sup>) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma</article-title><source>Respir. Med.</source><year>2013</year><volume>107</volume><fpage>1152</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2013.04.010</pub-id><pub-id pub-id-type="pmid">23660397</pub-id></element-citation></ref><ref id="B208-marinedrugs-18-00570"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Hazlewood</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Hansbro</surname><given-names>P.M.</given-names></name></person-group><article-title>Lyprinol reduces inflammation and improves lung function in a mouse model of allergic airways disease</article-title><source>Clin. Exp. Allergy</source><year>2010</year><volume>40</volume><fpage>1785</fpage><lpage>1793</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2010.03503.x</pub-id><pub-id pub-id-type="pmid">20412134</pub-id></element-citation></ref><ref id="B209-marinedrugs-18-00570"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leutenegger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wheat</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of children&#8217;s asthma with a lipid extract of the new Zealand green lipped mussel (<italic toggle="yes">Perna canaliculus</italic>) (Lyprinol<sup>&#174;</sup>)&#8212;A double blind, randomized controlled trial in children with moderate to serve chronic obstructive asthma</article-title><source>Internet J. Asthma Allergy Immunol.</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="B210-marinedrugs-18-00570"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emelyanov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fedoseev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krasnoschekova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abulimity</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trendeleva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>P.J.</given-names></name></person-group><article-title>Treatment of asthma with lipid extract of New Zealand green-lipped mussel: A randomised clinical trial</article-title><source>Eur. Respir. J.</source><year>2002</year><volume>20</volume><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1183/09031936.02.02632001</pub-id><pub-id pub-id-type="pmid">12358334</pub-id></element-citation></ref><ref id="B211-marinedrugs-18-00570"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thien</surname><given-names>F.C.K.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>M.J.</given-names></name></person-group><article-title>Dietary marine fatty acids (fish oil) for asthma in adults and children</article-title><source>Cochrane Database Syst. Rev.</source><year>2000</year><volume>2000</volume><fpage>CD001283</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001283</pub-id><pub-id pub-id-type="pmid">12137622</pub-id></element-citation></ref><ref id="B212-marinedrugs-18-00570"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kotiw</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mouatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Anti-inflammatory activity and structure-activity relationships of brominated indoles from a marine mollusc</article-title><source>Mar. Drugs</source><year>2017</year><volume>15</volume><elocation-id>133</elocation-id><pub-id pub-id-type="doi">10.3390/md15050133</pub-id><pub-id pub-id-type="pmcid">PMC5450539</pub-id><pub-id pub-id-type="pmid">28481239</pub-id></element-citation></ref><ref id="B213-marinedrugs-18-00570"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazbeck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>G.S.</given-names></name></person-group><article-title>Combined effects of muricid extract and 5-fluorouracil on intestinal toxicity in rats</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1155/2015/170858</pub-id><pub-id pub-id-type="pmcid">PMC4444572</pub-id><pub-id pub-id-type="pmid">26074985</pub-id></element-citation></ref><ref id="B214-marinedrugs-18-00570"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeelian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Le Leu</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>6-Bromoisatin found in muricid mollusc extracts inhibits colon cancer cell proliferation and induces apoptosis, preventing early stage tumor formation in a colorectal cancer rodent model</article-title><source>Mar. Drugs</source><year>2014</year><volume>12</volume><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.3390/md12010017</pub-id><pub-id pub-id-type="pmid">24368567</pub-id><pub-id pub-id-type="pmcid">PMC3917258</pub-id></element-citation></ref><ref id="B215-marinedrugs-18-00570"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westley</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>McIver</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Le Leu</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Gastrointestinal and hepatotoxicity assessment of an anticancer extract from muricid molluscs</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2013</year><volume>2013</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2013/837370</pub-id><pub-id pub-id-type="pmid">23690858</pub-id><pub-id pub-id-type="pmcid">PMC3652158</pub-id></element-citation></ref><ref id="B216-marinedrugs-18-00570"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joung</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>P.J.</given-names></name></person-group><article-title>Anti-inflammatory effects of extract from <italic toggle="yes">Haliotis discus hannai</italic> fermented with <italic toggle="yes">Cordyceps militaris</italic> mycelia in RAW264.7 macrophages through TRIF-dependent signaling pathway</article-title><source>Fish Shellfish Immunol.</source><year>2014</year><volume>38</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2014.03.018</pub-id><pub-id pub-id-type="pmid">24657261</pub-id></element-citation></ref><ref id="B217-marinedrugs-18-00570"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Z.-J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I.L.W.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W.-K.</given-names></name></person-group><article-title>The antioxidant and anti-inflammatory effects of abalone intestine digest, <italic toggle="yes">Haliotis discus hannai</italic> in RAW 264.7 macrophages</article-title><source>Biotechnol. Bioprocess Eng.</source><year>2012</year><volume>17</volume><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1007/s12257-011-0544-2</pub-id></element-citation></ref><ref id="B218-marinedrugs-18-00570"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.H.</given-names></name></person-group><article-title>Anti-inflammatory and burn injury wound healing properties of the shell of <italic toggle="yes">Haliotis diversicolor</italic></article-title><source>BMC Complement. Altern. Med.</source><year>2016</year><volume>16</volume><elocation-id>487</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-016-1473-6</pub-id><pub-id pub-id-type="pmid">27894302</pub-id><pub-id pub-id-type="pmcid">PMC5126830</pub-id></element-citation></ref><ref id="B219-marinedrugs-18-00570"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>R.</given-names></name></person-group><article-title>Indian freshwater edible snail <italic toggle="yes">Bellamya bengalensis</italic> lipid extract prevents T cell mediated hypersensitivity and inhibits LPS induced macrophage activation</article-title><source>J. Ethnopharmacol.</source><year>2014</year><volume>157</volume><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.09.009</pub-id><pub-id pub-id-type="pmid">25291010</pub-id></element-citation></ref><ref id="B220-marinedrugs-18-00570"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.H.S.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.C.</given-names></name></person-group><article-title>Manufacture and characterization of anti-inflammatory liposomes from jumbo flying squid (<italic toggle="yes">Dosidicus gigas</italic>) skin phospholipid extraction</article-title><source>Food Funct.</source><year>2018</year><volume>9</volume><fpage>3986</fpage><lpage>3996</lpage><pub-id pub-id-type="doi">10.1039/C8FO00767E</pub-id><pub-id pub-id-type="pmid">29974091</pub-id></element-citation></ref><ref id="B221-marinedrugs-18-00570"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Taveira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valent&#227;o</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>P.B.</given-names></name></person-group><article-title>Fatty acids from edible sea hares: Anti-inflammatory capacity in LPS-stimulated RAW 264.7 cells involves iNOS modulation</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>8981</fpage><lpage>8987</lpage><pub-id pub-id-type="doi">10.1039/C4RA14333G</pub-id></element-citation></ref><ref id="B222-marinedrugs-18-00570"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Son</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.H.</given-names></name></person-group><article-title>Indirubin-3&#8242;-oxime inhibits inflammatory activation of rat brain microglia</article-title><source>Neurosci. Lett.</source><year>2011</year><volume>487</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2010.10.009</pub-id><pub-id pub-id-type="pmid">20946938</pub-id></element-citation></ref><ref id="B223-marinedrugs-18-00570"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>G.M.</given-names></name></person-group><article-title>Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-&#954;B and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells</article-title><source>Inflamm. Res.</source><year>2012</year><volume>61</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1007/s00011-011-0413-7</pub-id><pub-id pub-id-type="pmid">22187016</pub-id></element-citation></ref><ref id="B224-marinedrugs-18-00570"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Y.</given-names></name></person-group><article-title>Indirubin inhibits ATP-induced phagocytosis attenuation, ROS production and cell death of macrophages</article-title><source>Yao Xue Xue Bao</source><year>2012</year><volume>47</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22493804</pub-id></element-citation></ref><ref id="B225-marinedrugs-18-00570"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name></person-group><article-title>Polyether macrocyclic polyketide from the muricid gastropod <italic toggle="yes">Chicoreus ramosus</italic> attenuates pro-inflammatory 5-lipoxygenase</article-title><source>Med. Chem. Res.</source><year>2020</year><volume>29</volume><fpage>1976</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.1007/s00044-020-02614-4</pub-id></element-citation></ref><ref id="B226-marinedrugs-18-00570"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>S.</given-names></name></person-group><article-title>First report of antioxidant 1H-benzochromenone from muricid gastropod <italic toggle="yes">Chicoreus ramosus</italic> as dual inhibitors of pro-inflammatory 5-lipoxygenase and carbolytic enzymes</article-title><source>Nat. Prod. Res.</source><year>2019</year><pub-id pub-id-type="doi">10.1080/14786419.2019.1647428</pub-id><pub-id pub-id-type="pmid">31507218</pub-id></element-citation></ref><ref id="B227-marinedrugs-18-00570"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name></person-group><article-title>An unreported bis-abeo cembrane-type diterpenoid with antioxidative and anti-lipoxygenase activities from the muricid gastropod mollusc <italic toggle="yes">Chicoreus ramosus</italic></article-title><source>Nat. Prod. Res.</source><year>2018</year><volume>34</volume><fpage>1678</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1080/14786419.2018.1527833</pub-id><pub-id pub-id-type="pmid">30580610</pub-id></element-citation></ref><ref id="B228-marinedrugs-18-00570"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name></person-group><article-title>Polygalactan from bivalve <italic toggle="yes">Crassostrea madrasensis</italic> attenuates nuclear factor-&#954;B activation and cytokine production in lipopolysaccharide-activated macrophage</article-title><source>Carbohydr. Polym.</source><year>2020</year><volume>249</volume><fpage>116817</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.116817</pub-id><pub-id pub-id-type="pmid">32933665</pub-id></element-citation></ref><ref id="B229-marinedrugs-18-00570"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name></person-group><article-title>Characterization and bioactive potentials of secondary metabolites from mollusks <italic toggle="yes">Crassostrea madrasensis</italic> and <italic toggle="yes">Amphioctopus marginatus</italic></article-title><source>Nat. Prod. Res.</source><year>2019</year><volume>33</volume><fpage>3190</fpage><lpage>3202</lpage><pub-id pub-id-type="doi">10.1080/14786419.2018.1466131</pub-id><pub-id pub-id-type="pmid">29683354</pub-id></element-citation></ref><ref id="B230-marinedrugs-18-00570"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chakkalakal</surname><given-names>S.J.</given-names></name></person-group><article-title>Antioxidant and antiinflammatory secondary metabolites from the Asian green mussel <italic toggle="yes">Perna viridis</italic></article-title><source>J. Food Biochem.</source><year>2019</year><volume>43</volume><fpage>e12736</fpage><pub-id pub-id-type="doi">10.1111/jfbc.12736</pub-id><pub-id pub-id-type="pmid">31353543</pub-id></element-citation></ref><ref id="B231-marinedrugs-18-00570"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name></person-group><article-title>The inhibitory effect of a novel polypeptide fraction from <italic toggle="yes">Arca subcrenata</italic> on cancer-related inflammation in human cervical cancer HeLa cells</article-title><source>Sci. World J.</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/768938</pub-id><pub-id pub-id-type="pmcid">PMC3934088</pub-id><pub-id pub-id-type="pmid">24683359</pub-id></element-citation></ref><ref id="B232-marinedrugs-18-00570"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>K.</given-names></name></person-group><article-title>Antioxidative and anti-inflammatory pyranoids and isochromenyl analogues from Corbiculid bivalve clam, <italic toggle="yes">Villorita cyprinoides</italic></article-title><source>Food Chem.</source><year>2018</year><volume>251</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2018.01.059</pub-id><pub-id pub-id-type="pmid">29426418</pub-id></element-citation></ref><ref id="B233-marinedrugs-18-00570"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name></person-group><article-title>Anti-osteoarthritis, anti-nociception, anti-inflammatory activities of isolated fraction of flesh extract <italic toggle="yes">Viviparous bengalensis</italic> in experimental model</article-title><source>Int. J. Curr. Res. Acad. Rev.</source><year>2015</year><volume>3</volume><fpage>66</fpage><lpage>87</lpage></element-citation></ref><ref id="B234-marinedrugs-18-00570"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name></person-group><article-title>Anti-osteoporosis activity of fresh water snail (<italic toggle="yes">Viviparous bengalensis</italic>) flesh extracted protein fraction vb-p4 in rat models</article-title><source>Int. J. Curr. Res. Biosci. Plant Biol.</source><year>2002</year><volume>2</volume><fpage>60</fpage><lpage>72</lpage></element-citation></ref><ref id="B235-marinedrugs-18-00570"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.C.D.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name></person-group><article-title>Anti-osteoporosis and anti-osteoarthritis activity of fresh water snail (<italic toggle="yes">Viviparous bengalensis</italic>) flesh extract in experimental animal model</article-title><source>Open J. Rheumatol. Autoimmune Dis.</source><year>2013</year><volume>3</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.4236/ojra.2013.31003</pub-id></element-citation></ref><ref id="B236-marinedrugs-18-00570"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akerkar</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Ponkshe</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Indap</surname><given-names>M.M.</given-names></name></person-group><article-title>Evaluation of immunomodulatory activity of extracts from marine animals</article-title><source>Indian J. Mar. Sci.</source><year>2009</year><volume>38</volume><fpage>22</fpage><lpage>27</lpage></element-citation></ref><ref id="B237-marinedrugs-18-00570"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponkshe</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Indap</surname><given-names>M.M.</given-names></name></person-group><article-title>In vivo and in vitro evaluation for immunomodulatory activity of three marine animal extracts with reference to phagocytosis</article-title><source>Indian J. Exp. Biol.</source><year>2002</year><volume>40</volume><fpage>1399</fpage><lpage>1402</lpage><pub-id pub-id-type="pmid">12974404</pub-id></element-citation></ref><ref id="B238-marinedrugs-18-00570"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chellaram</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>T.P.P.</given-names></name><name name-style="western"><surname>Kuberan</surname><given-names>G.</given-names></name><name name-style="western"><surname>John</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Priya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>B.A.</given-names></name></person-group><article-title>Anti-inflammatory and analgesic effects of coral reef associated gastropod, <italic toggle="yes">Trochus tentorium</italic> from Tuticorin coastal waters, Southeastern India</article-title><source>Afr. J. Biotechnol.</source><year>2012</year><volume>11</volume><fpage>14621</fpage><lpage>14626</lpage></element-citation></ref><ref id="B239-marinedrugs-18-00570"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santhi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sivakumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thangathirupathi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thilaga</surname><given-names>R.</given-names></name></person-group><article-title>Analgesic, anti-pyretic and anti-inflammatory activities of chloroform extract of prosobranch mollusc <italic toggle="yes">Purpura Persica</italic></article-title><source>Int. J. Pharm. Biol. Sci.</source><year>2011</year><volume>5</volume><fpage>9</fpage><lpage>15</lpage></element-citation></ref><ref id="B240-marinedrugs-18-00570"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santhi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sivakumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thilaga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thangathirupathi</surname><given-names>A.</given-names></name></person-group><article-title>Analgesic, antipyretic and anti inflammatory activities of column fraction of <italic toggle="yes">Babylonia zeylanica</italic> (Bruguiere, 1789) in albino rats</article-title><source>Int. J. Pharm. Biol. Sci.</source><year>2012</year><volume>2</volume><fpage>151</fpage><lpage>159</lpage></element-citation></ref><ref id="B241-marinedrugs-18-00570"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>George</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Senan</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sherief</surname><given-names>P.</given-names></name></person-group><article-title>Effect of feeding cuttlefish liver oil on immune function, inflammatory response and platelet aggregation in rats</article-title><source>Curr. Sci.</source><year>2005</year><volume>88</volume><fpage>507</fpage><lpage>510</lpage></element-citation></ref><ref id="B242-marinedrugs-18-00570"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name></person-group><article-title>Zhikang capsule ameliorates dextran sodium sulfate-induced colitis by inhibition of inflammation, apoptosis, oxidative stress and MyD88-dependent TLR4 signaling pathway</article-title><source>J. Ethnopharmacol.</source><year>2016</year><volume>192</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.07.055</pub-id><pub-id pub-id-type="pmid">27452656</pub-id></element-citation></ref><ref id="B243-marinedrugs-18-00570"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Das</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>R.</given-names></name></person-group><article-title>Prevention of the progression of adjuvant induced arthritis by oral supplementation of Indian fresh water mussel (<italic toggle="yes">Lamellidens marginalis</italic>) aqueous extract in experimental rats</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>132</volume><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.08.036</pub-id><pub-id pub-id-type="pmid">20728518</pub-id></element-citation></ref><ref id="B244-marinedrugs-18-00570"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swapna</surname><given-names>P.</given-names></name></person-group><article-title>Anti Inflammatory, wound healing and analgesic activities of fresh water mollusc <italic toggle="yes">Parreysia cylindrica</italic> in albino rats</article-title><source>Indian J. Appl. Res.</source><year>2015</year><volume>5</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.36106/ijar</pub-id></element-citation></ref><ref id="B245-marinedrugs-18-00570"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Anti-inflammatory activity and mechanism of a lipid extract from hard-shelled mussel (<italic toggle="yes">Mytilus coruscus</italic>) on chronic arthritis in rats</article-title><source>Mar. Drugs</source><year>2014</year><volume>12</volume><fpage>568</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.3390/md12020568</pub-id><pub-id pub-id-type="pmid">24473164</pub-id><pub-id pub-id-type="pmcid">PMC3944504</pub-id></element-citation></ref><ref id="B246-marinedrugs-18-00570"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsujikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Satake</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>M.</given-names></name></person-group><article-title>Studies on biological activities of melanin from marine animals. V. Anti-inflammatory activity of low-molecular-weight melanoprotein from squid (Fr. SM II)</article-title><source>Chem. Pharm. Bull.</source><year>1987</year><volume>35</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1248/cpb.35.1144</pub-id><pub-id pub-id-type="pmid">3607938</pub-id></element-citation></ref><ref id="B247-marinedrugs-18-00570"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name></person-group><article-title>A novel tumor necrosis factor in the Pacific oyster <italic toggle="yes">Crassostrea gigas</italic> mediates the antibacterial response by triggering the synthesis of lysozyme and nitric oxide</article-title><source>Fish Shellfish Immunol.</source><year>2020</year><volume>98</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2019.12.073</pub-id><pub-id pub-id-type="pmid">31881330</pub-id></element-citation></ref><ref id="B248-marinedrugs-18-00570"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaugule</surname><given-names>S.</given-names></name><name name-style="western"><surname>More</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rane</surname><given-names>G.</given-names></name><name name-style="western"><surname>Indap</surname><given-names>M.</given-names></name></person-group><article-title>Methanolic extract of <italic toggle="yes">Euchelus asper</italic> exhibits in-ovo anti-angiogenic and in vitro anti-proliferative activities</article-title><source>Biol. Res.</source><year>2017</year><volume>50</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s40659-017-0147-2</pub-id><pub-id pub-id-type="pmid">29233192</pub-id><pub-id pub-id-type="pmcid">PMC5726033</pub-id></element-citation></ref><ref id="B249-marinedrugs-18-00570"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meivelu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seedevi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vairamani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>A.</given-names></name></person-group><article-title>Exploring the chemical composition and anticancer potential of oil from squid (<italic toggle="yes">Loligo duvauceli</italic>) liver waste from fish processing industry</article-title><source>Waste Biomass Valorization</source><year>2019</year><volume>10</volume><fpage>2967</fpage><lpage>2973</lpage><pub-id pub-id-type="doi">10.1007/s12649-018-0304-z</pub-id></element-citation></ref><ref id="B250-marinedrugs-18-00570"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name></person-group><article-title>Apple snails polysaccharide extraction and pharmacological potential study in vitro</article-title><source>Appl. Mech. Mat.</source><year>2014</year><volume>651</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.4028/www.scientific.net/AMM.651-653.207</pub-id></element-citation></ref><ref id="B251-marinedrugs-18-00570"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name></person-group><article-title>Antitumor and immune regulation activities of the extracts of some Chinese marine invertebrates</article-title><source>Chin. J. Oceanol. Limnol.</source><year>2005</year><volume>23</volume><fpage>110</fpage><lpage>117</lpage></element-citation></ref><ref id="B252-marinedrugs-18-00570"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name></person-group><article-title>A novel polypeptide from <italic toggle="yes">Meretrix meretrix</italic> Linnaeus inhibits the growth of human lung adenocarcinoma</article-title><source>Exp. Biol. Med.</source><year>2012</year><volume>237</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1258/ebm.2012.011337</pub-id><pub-id pub-id-type="pmid">22522344</pub-id></element-citation></ref><ref id="B253-marinedrugs-18-00570"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shilabin</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hamann</surname><given-names>M.T.</given-names></name></person-group><article-title>In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities</article-title><source>Bioorg. Med. Chem.</source><year>2007</year><volume>19</volume><fpage>6628</fpage><lpage>6632</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.06.050</pub-id><pub-id pub-id-type="pmid">21839640</pub-id><pub-id pub-id-type="pmcid">PMC3523750</pub-id></element-citation></ref><ref id="B254-marinedrugs-18-00570"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalemkerian</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Adil</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rosati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khoulani</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Pettit</surname><given-names>G.R.</given-names></name></person-group><article-title>Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification</article-title><source>Cancer Chemother. Pharmacol.</source><year>1999</year><volume>43</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1007/s002800050931</pub-id><pub-id pub-id-type="pmid">10321512</pub-id></element-citation></ref><ref id="B255-marinedrugs-18-00570"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Natsume</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamaoki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyasaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gondo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakakibara</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Antitumor activity of TZT-1027, a novel dolastatin 10 derivative</article-title><source>Jap. J. Cancer Res.</source><year>1997</year><volume>88</volume><fpage>316</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.1997.tb00383.x</pub-id><pub-id pub-id-type="pmid">9140117</pub-id><pub-id pub-id-type="pmcid">PMC5921373</pub-id></element-citation></ref><ref id="B256-marinedrugs-18-00570"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janmaat</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kruyt</surname><given-names>F.A.E.</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G.</given-names></name></person-group><article-title>Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling</article-title><source>Mol. Pharmacol.</source><year>2005</year><volume>68</volume><fpage>502</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1124/mol.105.011361</pub-id><pub-id pub-id-type="pmid">15908515</pub-id></element-citation></ref><ref id="B257-marinedrugs-18-00570"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciavatta</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casapullo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gavagnin</surname><given-names>M.</given-names></name></person-group><article-title>Kahalalide F analogues from the mucous secretion of Indian sacoglossan mollusc <italic toggle="yes">Elysia ornata</italic></article-title><source>Tetrahedron</source><year>2016</year><volume>72</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2015.12.003</pub-id></element-citation></ref><ref id="B258-marinedrugs-18-00570"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teixid&#243;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arguelaguet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pons</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aracil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Somoza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mar&#233;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ram&#243;n</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cajal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Losa</surname><given-names>J.</given-names></name></person-group><article-title>ErbB3 expression predicts sensitivity to elisidepsin treatment: In vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines</article-title><source>Int. J. Oncol.</source><year>2012</year><volume>41</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">22485250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2012.1425</pub-id></element-citation></ref><ref id="B259-marinedrugs-18-00570"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Oaknin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cuadra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coronado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Soto-Matos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cullell-Young</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors</article-title><source>Cancer Chemother. Pharmacol.</source><year>2012</year><volume>70</volume><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1007/s00280-012-1951-6</pub-id><pub-id pub-id-type="pmid">22926637</pub-id></element-citation></ref><ref id="B260-marinedrugs-18-00570"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ciruelos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nieto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>1116</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4366</pub-id><pub-id pub-id-type="pmid">18281545</pub-id></element-citation></ref><ref id="B261-marinedrugs-18-00570"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamann</surname><given-names>M.T.</given-names></name></person-group><article-title>Technology evaluation: Kahalalide F, PharmaMar</article-title><source>Curr. Opin. Mol. Ther.</source><year>2004</year><volume>6</volume><fpage>657</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">15663330</pub-id><pub-id pub-id-type="pmcid">PMC4941207</pub-id></element-citation></ref><ref id="B262-marinedrugs-18-00570"><label>262.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><collab>PharmaMar</collab></person-group><article-title>PharmaMar reports new data on Kahalalide-F and Aplidin(R) at ESMO congress</article-title><source>Proceedings of the 31st European Society for Medical Oncology Congress (ESMO)</source><conf-loc>Istanbul, Turkey</conf-loc><conf-date>29 September&#8211;3 October 2006</conf-date></element-citation></ref><ref id="B263-marinedrugs-18-00570"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Aracil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez-Soler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models</article-title><source>Eur. J. Cancer</source><year>2009</year><volume>45</volume><fpage>1855</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.03.003</pub-id><pub-id pub-id-type="pmid">19346126</pub-id><pub-id pub-id-type="pmcid">PMC2700178</pub-id></element-citation></ref><ref id="B264-marinedrugs-18-00570"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poncet</surname><given-names>J.</given-names></name></person-group><article-title>The dolastatins, a family of promising antineoplastic agents</article-title><source>Curr. Pharm. Des.</source><year>1999</year><volume>5</volume><fpage>139</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10066887</pub-id></element-citation></ref><ref id="B265-marinedrugs-18-00570"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cortes-Funes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Casado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lopez-Martin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuadra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coronado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matos-Pita</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors</article-title><source>Cancer Chemother. Pharmacol.</source><year>2013</year><volume>72</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2170-5</pub-id><pub-id pub-id-type="pmid">23645288</pub-id></element-citation></ref><ref id="B266-marinedrugs-18-00570"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Valentao</surname><given-names>P.</given-names></name></person-group><article-title>Chemical diversity and biological properties of secondary metabolites from sea hares of <italic toggle="yes">Aplysia</italic> genus</article-title><source>Mar Drugs</source><year>2016</year><volume>14</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.3390/md14020039</pub-id><pub-id pub-id-type="pmcid">PMC4771992</pub-id><pub-id pub-id-type="pmid">26907303</pub-id></element-citation></ref><ref id="B267-marinedrugs-18-00570"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.-j.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.-S.</given-names></name></person-group><article-title>Two patients of acute liver damage following the ingestion of a sea hare eggs</article-title><source>J. Agric. Med. Comm. Health</source><year>2005</year><volume>30</volume><fpage>241</fpage><lpage>249</lpage></element-citation></ref><ref id="B268-marinedrugs-18-00570"><label>268.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jamil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kasi</surname><given-names>A.</given-names></name></person-group><source>Cancer: Metastasis to the Lung</source><publisher-name>NCBI, StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B269-marinedrugs-18-00570"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riihim&#228;ki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hemminki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fallah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sundquist</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sundquist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hemminki</surname><given-names>K.</given-names></name></person-group><article-title>Metastatic sites and survival in lung cancer</article-title><source>Lung Cancer</source><year>2014</year><volume>86</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2014.07.020</pub-id><pub-id pub-id-type="pmid">25130083</pub-id></element-citation></ref><ref id="B270-marinedrugs-18-00570"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Helman</surname><given-names>L.J.</given-names></name></person-group><article-title>The molecular biology of pulmonary metastasis</article-title><source>Thorac. Surg. Clin.</source><year>2006</year><volume>16</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.thorsurg.2005.12.003</pub-id><pub-id pub-id-type="pmid">16805200</pub-id></element-citation></ref><ref id="B271-marinedrugs-18-00570"><label>271.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Punt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stranford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>J.</given-names></name></person-group><source>Kuby Immunology</source><edition>8th ed.</edition><publisher-name>Macmillan Learning</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2018</year><fpage>880</fpage></element-citation></ref><ref id="B272-marinedrugs-18-00570"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizarro-Bauerle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sosoniuk-Roche</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vallejos</surname><given-names>G.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Salazar-Onfray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aguilar-Guzm&#225;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.I.</given-names></name></person-group><article-title>Molluskan hemocyanins activate the classical pathway of the human complement system through natural antibodies</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00188</pub-id><pub-id pub-id-type="pmid">28286504</pub-id><pub-id pub-id-type="pmcid">PMC5323374</pub-id></element-citation></ref><ref id="B273-marinedrugs-18-00570"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kellar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name></person-group><article-title>Preclinical murine models for lung cancer: Clinical trial applications</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>621324</fpage><pub-id pub-id-type="doi">10.1155/2015/621324</pub-id><pub-id pub-id-type="pmid">26064932</pub-id><pub-id pub-id-type="pmcid">PMC4433653</pub-id></element-citation></ref><ref id="B274-marinedrugs-18-00570"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Borsig</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vlodavsky</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pavao</surname><given-names>M.S.G.</given-names></name></person-group><article-title>Antitumor properties of a new non-anticoagulant heparin analog from the mollusk <italic toggle="yes">Nodipecten nodosus: Effect</italic> on P-selectin, heparanase, metastasis and cellular recruitment</article-title><source>Glycobiology</source><year>2015</year><volume>25</volume><fpage>386</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwu119</pub-id><pub-id pub-id-type="pmid">25367817</pub-id></element-citation></ref><ref id="B275-marinedrugs-18-00570"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>de Paiva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Porcionatto</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nader</surname><given-names>H.B.</given-names></name></person-group><article-title>Isolation and characterization of a heparin with high anticoagulant activity from <italic toggle="yes">Anomalocardia brasiliana</italic></article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>1985</year><volume>843</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(85)90041-8</pub-id><pub-id pub-id-type="pmid">4063384</pub-id></element-citation></ref><ref id="B276-marinedrugs-18-00570"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Tersariol</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Toma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Porcionatto</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Nader</surname><given-names>H.B.</given-names></name></person-group><article-title>Structure of heparan sulfate: Identification of variable and constant oligosaccharide domains in eight heparan sulfates of different origins</article-title><source>Cell Mol. Biol.</source><year>1998</year><volume>44</volume><fpage>417</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">9620437</pub-id></element-citation></ref><ref id="B277-marinedrugs-18-00570"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>A.</given-names></name></person-group><article-title>Extraction of heparin and heparin-like substance from marine mesogastropod mollusc <italic toggle="yes">Turritella attenuata</italic> (Lamarck, 1779)</article-title><source>Indian J. Exp. Biol.</source><year>2004</year><volume>42</volume><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">15233481</pub-id></element-citation></ref><ref id="B278-marinedrugs-18-00570"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pejler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Danielsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bj&#246;rk</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lindahl</surname><given-names>U.</given-names></name><name name-style="western"><surname>Nader</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>C.</given-names></name></person-group><article-title>Structure and antithrombin-binding properties of heparin isolated from the clams <italic toggle="yes">Anomalocardia brasiliana</italic> and <italic toggle="yes">Tivela mactroides</italic></article-title><source>J. Biol. Chem.</source><year>1987</year><volume>262</volume><fpage>11413</fpage><lpage>11421</lpage><pub-id pub-id-type="pmid">3624220</pub-id></element-citation></ref><ref id="B279-marinedrugs-18-00570"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeelian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Purified brominated indole derivatives from <italic toggle="yes">Dicathais orbita</italic> induce apoptosis and cell cycle arrest in colorectal cancer cell lines</article-title><source>Mar. Drugs</source><year>2013</year><volume>11</volume><fpage>3802</fpage><lpage>3822</lpage><pub-id pub-id-type="doi">10.3390/md11103802</pub-id><pub-id pub-id-type="pmid">24152558</pub-id><pub-id pub-id-type="pmcid">PMC3826136</pub-id></element-citation></ref><ref id="B280-marinedrugs-18-00570"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>McIver</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Bioactivity of the Murex homeopathic remedy and of extracts from an Australian muricid mollusc against human cancer cells</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2011</year><volume>2011</volume><fpage>3802</fpage><lpage>3822</lpage><pub-id pub-id-type="doi">10.1093/ecam/nep042</pub-id><pub-id pub-id-type="pmcid">PMC3137770</pub-id><pub-id pub-id-type="pmid">19491143</pub-id></element-citation></ref><ref id="B281-marinedrugs-18-00570"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolaou</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Liapis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Evdokiou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Constantinou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Magiatis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skaltsounis</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Koumas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Costeas</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Constantinou</surname><given-names>A.I.</given-names></name></person-group><article-title>Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2012</year><volume>425</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.07.053</pub-id><pub-id pub-id-type="pmid">22820195</pub-id></element-citation></ref><ref id="B282-marinedrugs-18-00570"><label>282.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>V.</given-names></name><name name-style="western"><surname>Young</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Muricidae Extracts on Estrogen-Sensitive Breast Cancer and the Steroidogenic Pathway</article-title><publisher-name>Flinders University</publisher-name><publisher-loc>Adelaide, Australia</publisher-loc><comment>Unpublished Work</comment><year>2013</year></element-citation></ref><ref id="B283-marinedrugs-18-00570"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.-U.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Letters</surname><given-names>M.C.</given-names></name></person-group><article-title>Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2010</year><volume>20</volume><fpage>2033</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.01.039</pub-id><pub-id pub-id-type="pmid">20153646</pub-id></element-citation></ref><ref id="B284-marinedrugs-18-00570"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyairi</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis of methoxy-and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>5370</fpage><lpage>5373</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.07.011</pub-id><pub-id pub-id-type="pmid">21802947</pub-id></element-citation></ref><ref id="B285-marinedrugs-18-00570"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scuto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Polychronopoulos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Magiatis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skaltsounis</surname><given-names>L.</given-names></name></person-group><article-title>6-Bromoindirubin-3&#8242;-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells</article-title><source>J. Cancer Res.</source><year>2011</year><volume>71</volume><fpage>3972</fpage><lpage>3979</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3852</pub-id><pub-id pub-id-type="pmcid">PMC3107399</pub-id><pub-id pub-id-type="pmid">21610112</pub-id></element-citation></ref><ref id="B286-marinedrugs-18-00570"><label>286.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fiebig</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>J.</given-names></name></person-group><article-title>In vivo anti-tumor activity of indirubins</article-title><source>Indirubin: The red shade of Indigo</source><person-group person-group-type="editor"><name name-style="western"><surname>Meijer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guyard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Skaltsounis</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Eisenbrand</surname><given-names>G.</given-names></name></person-group><publisher-name>Life In Progress Editions</publisher-name><publisher-loc>Roscoff, France</publisher-loc><year>2006</year></element-citation></ref><ref id="B287-marinedrugs-18-00570"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westley</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>McIver</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Le Leu</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name></person-group><article-title>Enhanced acute apoptotic response to azoxymethane-induced DNA damage in the rodent colonic epithelium by Tyrian purple precursors: A potential colorectal cancer chemopreventative</article-title><source>Cancer Biol. Ther.</source><year>2010</year><volume>9</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.5.10887</pub-id><pub-id pub-id-type="pmid">20150770</pub-id></element-citation></ref><ref id="B288-marinedrugs-18-00570"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudd</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chahal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guinan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>O.J.R.</given-names></name><name name-style="western"><surname>Esmaeelian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krysinska</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pogson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Voelcker</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C.A.</given-names></name></person-group><article-title>Mapping insoluble indole metabolites in the gastrointestinal environment of a murine colorectal cancer model using desorption/ionisation on porous silicon imaging</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><pub-id pub-id-type="doi">10.1038/s41598-019-48533-2</pub-id><pub-id pub-id-type="pmid">31451756</pub-id><pub-id pub-id-type="pmcid">PMC6710270</pub-id></element-citation></ref><ref id="B289-marinedrugs-18-00570"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>V.</given-names></name><name name-style="western"><surname>Benkendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Young</surname><given-names>F.</given-names></name></person-group><article-title>An in vitro high-throughput assay for screening reproductive and toxic effects of anticancer compounds</article-title><source>Biotechnol. Appl. Biochem.</source><year>2014</year><volume>61</volume><fpage>582</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1002/bab.1199</pub-id><pub-id pub-id-type="pmid">24650341</pub-id></element-citation></ref><ref id="B290-marinedrugs-18-00570"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karthik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manigandan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>R.</given-names></name></person-group><article-title>Toxicity, teratogenicity and antibacterial activity of posterior salivary gland (PSG) toxin from the cuttlefish <italic toggle="yes">Sepia pharaonis</italic> (Ehrenberg, 1831)</article-title><source>J. Chromatogr. B Analyt. Technol. Biomed Life Sci.</source><year>2017</year><volume>1064</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2017.08.045</pub-id><pub-id pub-id-type="pmid">28892742</pub-id></element-citation></ref><ref id="B291-marinedrugs-18-00570"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karthik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ebenezar</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Sivamalai</surname><given-names>T.</given-names></name></person-group><article-title>Isolation, purification and characterization of avian antimicrobial glycopeptide from the posterior salivary gland of <italic toggle="yes">Sepia pharaonis</italic></article-title><source>Appl. Biochem. Biotechnol.</source><year>2014</year><volume>175</volume><fpage>1507</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1007/s12010-014-1370-8</pub-id><pub-id pub-id-type="pmid">25410800</pub-id></element-citation></ref><ref id="B292-marinedrugs-18-00570"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name></person-group><article-title>A novel cysteine-rich antimicrobial peptide from the mucus of the snail of <italic toggle="yes">Achatina fulica</italic></article-title><source>Peptides</source><year>2013</year><volume>39</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2012.09.001</pub-id><pub-id pub-id-type="pmid">23103587</pub-id></element-citation></ref><ref id="B293-marinedrugs-18-00570"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J.P.</given-names></name></person-group><article-title>Macrocyclic antimicrobial peptides engineered from &#969;-conotoxin</article-title><source>Curr. Pharm. Des.</source><year>2017</year><volume>23</volume><fpage>2131</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.2174/1381612822666161027120518</pub-id><pub-id pub-id-type="pmid">28245769</pub-id><pub-id pub-id-type="pmcid">PMC5470054</pub-id></element-citation></ref><ref id="B294-marinedrugs-18-00570"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolashka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moshtanska</surname><given-names>V.</given-names></name><name name-style="western"><surname>Borisova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dolashki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stevanovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimanov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Voelter</surname><given-names>W.</given-names></name></person-group><article-title>Antimicrobial proline-rich peptides from the hemolymph of marine snail <italic toggle="yes">Rapana venosa</italic></article-title><source>Peptides</source><year>2011</year><volume>32</volume><fpage>1477</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2011.05.001</pub-id><pub-id pub-id-type="pmid">21703315</pub-id></element-citation></ref><ref id="B295-marinedrugs-18-00570"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitaab</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ranaei Siadat</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Pazooki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sefidbakht</surname><given-names>Y.</given-names></name></person-group><article-title>Antibacterial and molecular dynamics study of the Dolabellanin B2 isolated from sea slug, <italic toggle="yes">Peronia peronii</italic></article-title><source>Biosci. Biotechnol. Res. Asia</source><year>2015</year><volume>12</volume><fpage>2023</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.13005/bbra/1870</pub-id></element-citation></ref><ref id="B296-marinedrugs-18-00570"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borquaye</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Darko</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ocansey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ankomah</surname><given-names>E.</given-names></name></person-group><article-title>Antimicrobial and antioxidant properties of the crude peptide extracts of <italic toggle="yes">Galatea paradoxa</italic> and <italic toggle="yes">Patella rustica</italic></article-title><source>SpringerPlus</source><year>2015</year><volume>4</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/s40064-015-1266-2</pub-id><pub-id pub-id-type="pmid">26405620</pub-id><pub-id pub-id-type="pmcid">PMC4574042</pub-id></element-citation></ref><ref id="B297-marinedrugs-18-00570"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Priya</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lavanya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kalpana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karthika</surname><given-names>V.</given-names></name></person-group><article-title>Potential of water and methanol extracts of <italic toggle="yes">Lambis lambis</italic> against fish and human pathogens</article-title><source>Biol. Rhythm Res.</source><year>2012</year><volume>43</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1080/09291016.2010.548923</pub-id></element-citation></ref><ref id="B298-marinedrugs-18-00570"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanchana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vennila</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajesh Kumar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>T.</given-names></name></person-group><article-title>Antagonistic and cyto-toxicity activity of mollusc methanol extracts</article-title><source>J. Biol. Sci.</source><year>2014</year><volume>14</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.3923/jbs.2014.60.66</pub-id></element-citation></ref><ref id="B299-marinedrugs-18-00570"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silveira-Dorta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Padr&#243;n</surname><given-names>J.M.</given-names></name></person-group><article-title>Synthesis and identification of unprecedented selective inhibitors of CK1&#949;</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>96</volume><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.03.046</pub-id><pub-id pub-id-type="pmid">25899335</pub-id></element-citation></ref><ref id="B300-marinedrugs-18-00570"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickler</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.X.</given-names></name><name name-style="western"><surname>Musselli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martino</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Kris</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Brezicka</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>S.C.</given-names></name></person-group><article-title>Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer</article-title><source>Clin. Cancer Res.</source><year>1999</year><volume>5</volume><fpage>2773</fpage><lpage>2779</lpage><pub-id pub-id-type="pmid">10537341</pub-id></element-citation></ref><ref id="B301-marinedrugs-18-00570"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roch&#233;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perren</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Glaspy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dodwell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mayordomo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tres</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer</article-title><source>Oncologist</source><year>2011</year><volume>16</volume><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2010-0307</pub-id><pub-id pub-id-type="pmid">21572124</pub-id><pub-id pub-id-type="pmcid">PMC3228158</pub-id></element-citation></ref><ref id="B302-marinedrugs-18-00570"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hankey</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>D.L.</given-names></name></person-group><article-title>Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy</article-title><source>Cancers</source><year>2011</year><volume>3</volume><fpage>2223</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.3390/cancers3022223</pub-id><pub-id pub-id-type="pmid">24212806</pub-id><pub-id pub-id-type="pmcid">PMC3757414</pub-id></element-citation></ref><ref id="B303-marinedrugs-18-00570"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.-X.</given-names></name></person-group><article-title>Development of peptide mimotopes of lipooligosaccharide from nontypeable <italic toggle="yes">Haemophilus influenzae</italic> as vaccine candidates</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>4373</fpage><lpage>4379</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.8.4373</pub-id><pub-id pub-id-type="pmid">12682274</pub-id></element-citation></ref><ref id="B304-marinedrugs-18-00570"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Jegaskanda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juno</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Esterbauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tilmanis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Yewdell</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem</article-title><source>J. Clin. Investig.</source><year>2019</year><volume>129</volume><fpage>850</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1172/JCI123366</pub-id><pub-id pub-id-type="pmid">30521496</pub-id><pub-id pub-id-type="pmcid">PMC6355240</pub-id></element-citation></ref><ref id="B305-marinedrugs-18-00570"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyd</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bakaletz</surname><given-names>L.O.</given-names></name></person-group><article-title>Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable <italic toggle="yes">Haemophilus influenzae</italic> from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx</article-title><source>Infect Immun.</source><year>2003</year><volume>71</volume><fpage>4691</fpage><lpage>4699</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.8.4691-4699.2003</pub-id><pub-id pub-id-type="pmid">12874350</pub-id><pub-id pub-id-type="pmcid">PMC165997</pub-id></element-citation></ref><ref id="B306-marinedrugs-18-00570"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Synthetic peptides representing epitopes of outer membrane protein F of <italic toggle="yes">Pseudomonas aeruginosa</italic> that elicit antibodies reactive with whole cells of heterologous immunotype strains of <italic toggle="yes">P. aeruginosa</italic></article-title><source>Infect Immun.</source><year>1992</year><volume>60</volume><fpage>3497</fpage><lpage>3503</lpage><pub-id pub-id-type="doi">10.1128/IAI.60.9.3497-3503.1992</pub-id><pub-id pub-id-type="pmid">1379985</pub-id><pub-id pub-id-type="pmcid">PMC257350</pub-id></element-citation></ref><ref id="B307-marinedrugs-18-00570"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Ability of synthetic peptides representing epitopes of outer membrane protein F of <italic toggle="yes">Pseudomonas aeruginosa</italic> to afford protection against <italic toggle="yes">P. aeruginosa</italic> infection in a murine acute pneumonia model</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1750</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00166-X</pub-id><pub-id pub-id-type="pmid">8701588</pub-id></element-citation></ref><ref id="B308-marinedrugs-18-00570"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokol</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kooi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Cachia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>D.E.</given-names></name></person-group><article-title>Immunization with a <italic toggle="yes">Pseudomonas aeruginosa</italic> elastase peptide reduces severity of experimental lung infections due to <italic toggle="yes">P. aeruginosa</italic> or <italic toggle="yes">Burkholderia cepacia</italic></article-title><source>J. Infect Dis.</source><year>2000</year><volume>181</volume><fpage>1682</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1086/315470</pub-id><pub-id pub-id-type="pmid">10823769</pub-id></element-citation></ref><ref id="B309-marinedrugs-18-00570"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Shiloh</surname><given-names>M.U.</given-names></name></person-group><article-title>A baculovirus-conjugated mimotope vaccine targeting <italic toggle="yes">Mycobacterium tuberculosis</italic> lipoarabinomannan</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0185945</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185945</pub-id><pub-id pub-id-type="pmid">28982200</pub-id><pub-id pub-id-type="pmcid">PMC5628901</pub-id></element-citation></ref><ref id="B310-marinedrugs-18-00570"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tebbey</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>G.E.</given-names></name></person-group><article-title>Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus</article-title><source>J. Exp. Med.</source><year>1998</year><volume>188</volume><fpage>1967</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1084/jem.188.10.1967</pub-id><pub-id pub-id-type="pmid">9815273</pub-id><pub-id pub-id-type="pmcid">PMC2212411</pub-id></element-citation></ref><ref id="B311-marinedrugs-18-00570"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Szalai</surname><given-names>K.</given-names></name><name name-style="western"><surname>El-Housseiny</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pali-Sch&#246;ll</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jensen-Jarolim</surname><given-names>E.</given-names></name></person-group><article-title>Mimotope vaccination for therapy of allergic asthma: Anti-inflammatory effects in a mouse model</article-title><source>Clin. Exp. Allergy</source><year>2010</year><volume>40</volume><fpage>650</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2009.03392.x</pub-id><pub-id pub-id-type="pmid">19958367</pub-id><pub-id pub-id-type="pmcid">PMC2999747</pub-id></element-citation></ref><ref id="B312-marinedrugs-18-00570"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demoly</surname><given-names>P.</given-names></name><name name-style="western"><surname>Persi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dhivert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Delire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bousquet</surname><given-names>J.</given-names></name></person-group><article-title>Immunotherapy with keyhole limpet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy</article-title><source>Clin. Exp. Allergy</source><year>2002</year><volume>32</volume><fpage>1071</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2002.01392.x</pub-id><pub-id pub-id-type="pmid">12100056</pub-id></element-citation></ref><ref id="B313-marinedrugs-18-00570"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arancibia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campo</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Nova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.I.</given-names></name></person-group><article-title>Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects</article-title><source>Eur. J. Immunol.</source><year>2012</year><volume>42</volume><fpage>688</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1002/eji.201142011</pub-id><pub-id pub-id-type="pmid">22144228</pub-id></element-citation></ref><ref id="B314-marinedrugs-18-00570"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuyler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Masten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bice</surname><given-names>D.</given-names></name></person-group><article-title>Immunoglobulin response to intrapulmonary immunization of asthmatics</article-title><source>Immunology</source><year>1997</year><volume>91</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.1997.00234.x</pub-id><pub-id pub-id-type="pmid">9227313</pub-id><pub-id pub-id-type="pmcid">PMC1363843</pub-id></element-citation></ref><ref id="B315-marinedrugs-18-00570"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>The</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>de Gast</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Pastoor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Orie</surname><given-names>N.G.</given-names></name></person-group><article-title>The primary immune response of patients with different stages of squamous-cell bronchial carcinoma</article-title><source>Thorax</source><year>1978</year><volume>33</volume><fpage>755</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1136/thx.33.6.755</pub-id><pub-id pub-id-type="pmid">746500</pub-id><pub-id pub-id-type="pmcid">PMC470974</pub-id></element-citation></ref><ref id="B316-marinedrugs-18-00570"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>C.</given-names></name><name name-style="western"><surname>Freireich</surname><given-names>E.J.</given-names></name></person-group><article-title>The human primary immune response to keyhole limpet haemocyanin: Interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation</article-title><source>Clin. Exp. Immunol.</source><year>1970</year><volume>6</volume><fpage>473</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">4320164</pub-id><pub-id pub-id-type="pmcid">PMC1712800</pub-id></element-citation></ref><ref id="B317-marinedrugs-18-00570"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Boverhof</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Woolhiser</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>J.A.</given-names></name></person-group><article-title>Assessment of the respiratory sensitization potential of proteins using an enhanced mouse intranasal test (MINT)</article-title><source>Food Chem. Toxicol.</source><year>2013</year><volume>59</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2013.05.037</pub-id><pub-id pub-id-type="pmid">23747714</pub-id></element-citation></ref><ref id="B318-marinedrugs-18-00570"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riedl</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Landaw</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diaz-Sanchez</surname><given-names>D.</given-names></name></person-group><article-title>Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>7440</fpage><lpage>7445</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.11.7440</pub-id><pub-id pub-id-type="pmid">15905593</pub-id></element-citation></ref><ref id="B319-marinedrugs-18-00570"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Sanchez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jyrala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>A.</given-names></name></person-group><article-title>Nasal challenge with diesel exhaust particles can induce sensitization to a neoallergen in the human mucosa</article-title><source>J. Allergy Clin. Immunol.</source><year>1999</year><volume>104</volume><fpage>1183</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(99)70011-4</pub-id><pub-id pub-id-type="pmid">10588999</pub-id></element-citation></ref><ref id="B320-marinedrugs-18-00570"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Weller</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Kallenberg</surname><given-names>C.G.M.</given-names></name><name name-style="western"><surname>The</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Orie</surname><given-names>N.G.M.</given-names></name></person-group><article-title>Sensitivity to hydrocortisone is a relevant factor in the immunoendocrine relationship. I. The cell-mediated immune response in relation to blood levels and in vitro immunosuppressive effects of hydrocortisone in patients with asthma and healthy control subjects</article-title><source>J. Allergy Clin. Immunol.</source><year>1986</year><volume>78</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">3760402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0091-6749(86)90028-x</pub-id></element-citation></ref><ref id="B321-marinedrugs-18-00570"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Pomin</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>de Barros</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Zaganeli</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pav&#227;o</surname><given-names>M.S.G.</given-names></name></person-group><article-title>Unique extracellular matrix heparan sulfate from the bivalve <italic toggle="yes">Nodipecten nodosus</italic> (Linnaeus, 1758) safely inhibits arterial thrombosis after photochemically induced endothelial lesion</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>7312</fpage><lpage>7323</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.091546</pub-id><pub-id pub-id-type="pmid">20053999</pub-id><pub-id pub-id-type="pmcid">PMC2844179</pub-id></element-citation></ref><ref id="B322-marinedrugs-18-00570"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cragg</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Borris</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Carte</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cordell</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Soejarto</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Iwu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Madulid</surname><given-names>D.A.</given-names></name></person-group><article-title>Interactions with source countries: Guidelines for members of the American Society of Pharmacognosy</article-title><source>J. Nat. Prod.</source><year>1997</year><volume>60</volume><fpage>654</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1021/np970125q</pub-id></element-citation></ref><ref id="B323-marinedrugs-18-00570"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cordell</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Colvard</surname><given-names>M.D.</given-names></name></person-group><article-title>Some thoughts on the future of ethnopharmacology</article-title><source>J. Ethnopharmacol.</source><year>2005</year><volume>100</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2005.05.027</pub-id><pub-id pub-id-type="pmid">16009517</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-18-00570-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Molluscan body parts used to derive extracts/compounds in (<bold>A</bold>) Traditional Chinese Medicines (n = 61 marine remedies; [<xref rid="B104-marinedrugs-18-00570" ref-type="bibr">104</xref>] <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S2</xref>), (<bold>B</bold>) other traditional medicines (n = 39 remedies; <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S1</xref>) (<bold>C</bold>) in vitro, in vivo and clinical biomedical studies (n = 97 articles; <xref rid="marinedrugs-18-00570-t005" ref-type="table">Table 5</xref>, <xref rid="marinedrugs-18-00570-t006" ref-type="table">Table 6</xref>, <xref rid="marinedrugs-18-00570-t007" ref-type="table">Table 7</xref> and <xref rid="marinedrugs-18-00570-t008" ref-type="table">Table 8</xref> and <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S3</xref>; not including studies using Hc as a model antigen <xref ref-type="app" rid="app1-marinedrugs-18-00570">Table S4</xref>). NA: not available, AM: adductor muscle, HBG: hypobranchial gland, DG: digestive gland, SG: salivary gland; shell includes cuttlebone; whole includes those listed as &#8220;whole animal&#8221; or &#8220;body and shell&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="marinedrugs-18-00570-g001.jpg"/></fig><fig id="marinedrugs-18-00570-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Dolastatin-10, kahalalide F, and derivative compounds of molluscan origin showing potent activity against respiratory cancers. Adapted from [<xref rid="B67-marinedrugs-18-00570" ref-type="bibr">67</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="marinedrugs-18-00570-g005.jpg"/></fig></floats-group></article></pmc-articleset>